



# ADRENAL CORTEX

---

*Transactions of the Fifth Conference*  
*November 4, 5 and 6, 1953, Princeton, N J*

*Edited by*  
ELAINE P RALLI, M D  
ASSOCIATE PROFESSOR OF MEDICINE  
NEW YORK UNIVERSITY  
COLLEGE OF MEDICINE  
NEW YORK N Y

*Sponsored by the*  
JOSIAH MACY, JR FOUNDATION  
NEW YORK N Y

*Copyright 1954 by the*  
**JOSIAH MACY JR FOUNDATION**  
*Library of Congress Catalog Card Number A51 4008*  
*Price \$3 75*

*Opinions expressed and any conclusions drawn are those of  
the participants of the conference and are not to be understood  
as necessarily having the endorsement of or representing the  
viewpoints of the Josiah Macy Jr Foundation*

*Printed in the United States of America*  
*By Corlies Macy & Company Inc New York N Y*

# PARTICIPANTS

## *Fifth Conference on Adrenal Cortex\**

---

### MEMBERS

C N HUGH LONG *Chairman*

Department of Physiology Yale University School of Medicine  
New Haven Conn

ELAINE P RALII *Secretary*

Department of Medicine New York University College of Medicine  
New York N Y

EDWIN B ASTWOOD

Department of Medicine Tufts College Medical School  
Boston Mass

WALTER BAUER

Medical Division Massachusetts General Hospital  
Boston Mass

KONRAD BLOCH

Department of Biochemistry and Institute of Radiobiology and Biophysics  
University of Chicago The School of Medicine  
Chicago Ill

JEROME W CONN

Department of Internal Medicine University of Michigan Medical School  
Ann Arbor Mich

ERNEST GELHORN†

Department of Neurophysiology University of Minnesota Medical School  
Minneapolis Minn

DWIGHT J INGLE

Department of Physiology Ben May Laboratory for Cancer Research  
University of Chicago  
Chicago Ill

EDWARD C KENDALL

The James Forrestal Research Center Princeton University  
Princeton N J

CHOH HAO LI

Department of Biochemistry University of California  
Berkeley Calif

ROBERT F LOEB

Department of Practice of Medicine  
Columbia University College of Physicians and Surgeons  
New York N Y

GREGORY PINCUS

Worcester Foundation for Experimental Biology  
Shrewsbury Mass

---

\*This is the final conference

†Absent

**ROBERT F PITTS†**

Department of Physiology Cornell University Medical College  
New York N Y

**GEORGE SAYERS†**

Department of Physiology Western Reserve University School of Medicine  
Cleveland Ohio

**HANS SELYE**

Institute of Experimental Medicine and Surgery University of Montreal  
Montreal Quebec Canada

**GEORGE W THORN**

Department of Medicine Peter Bent Brigham Hospital  
Boston Mass

**ABRAHAM WHITE**

Department of Biochemistry and Biophysics Yeshiva University  
Albert Einstein College of Medicine  
New York N Y

## **GUESTS**

**RALPH I DORFMAN**

Worcester Foundation for Experimental Biology  
Shrewsbury Mass

**T F GALLAGHER**

Departments of Steroid Biochemistry and Metabolism Sloan Kettering Institute  
New York N Y

**H L MASON**

Department of Biochemistry Mayo Clinic  
Rochester Minn

**W W SWINGLE**

Department of Biology Princeton University  
Princeton N J

**FRANK G YOUNG**

Department of Biochemistry University of Cambridge  
Cambridge England

**The Josiah Macy Jr Foundation**

**FRANK FREMONT SMITH** *Medical Director*

**JANET FREED LYNCH** *Assistant for the Conference Program†*





1st Row. Robert F. Loeb W. W. Swingle George W. Thom. Elaine P. Rallh C. N. Hugh Long Edward C. Kendall Frank G. Young  
 Hans Sully Gregory Pincus  
 2nd Row. Peggy Lubbe Konrad Bloch Walter Bauer Choh Hao Lo Dwight J. Ingle Edwin B. Astwood Abraham White Ralph I.  
 Dorfman Jerome W. Conn Ruth E. Rue T. F. Gallagher H. L. Mason

# TABLE OF CONTENTS

## *Fifth Conference on Adrenal Cortex*

---

### The Josiah Macy Jr Foundation Conference Program

<i>Frank Fremont Smith</i> .....	9
----------------------------------	---

### The Salt and Water Factor of the Adrenal Cortex

<i>H L Mason</i> .....	11
------------------------	----

#### Group Interchange

References .....	25
------------------	----

### The Metabolism of Adrenal Steroids *Ralph I Dorfman* .. 27

#### Group Interchange

References .....	93
------------------	----

### ACTH — A Single Substance or a Mixture of Hormones

<i>Frank G Young</i> .....	97
----------------------------	----

#### Group Interchange

References .....	159
------------------	-----

Cumulative Index .....	163
------------------------	-----





## THE JOSIAH MACY, JR FOUNDATION CONFERENCE PROGRAM

WHEN I WAS on a destroyer out at Bikini in 1946 I was fascinated listening to our radio operator as he tested communication equipment. He would ask another ship through his radio "How do you hear me?" and the answer often would come back "I hear you Nine Nine Nine." That meant that everything was satisfactory. Of the three nines one was for intensity one for clarity and one for meaning.

The Josiah Macy, Jr. Foundation has organized and devoted a large portion of its resources to the support of its Conference Program because the officers are cognizant of the fact that there is considerable obstruction to communication and mutual understanding across the disciplines and specialties and that this in fact is one of the major factors delaying scientific advance. We feel that there are psychological as well as semantic factors contributing to the difficulty of communication. People even in arguments with one another are too much inclined to make statements *at* rather than to communicate *with* others. I think that we are inclined to forget though that the real question is are these words and statements those which are likely to convey to the listener the whole or even a small part of what I would like to express.

I have a feeling that we should be very much concerned with the other fellow's receiving set and not only with our own transmitter. If the other person doesn't seem to understand us it may not be enough merely to increase the power of our transmission. We must try to find the obstruction in his receiving set, and see what kind of filters and resistors he uses. So if we call out to the interprofessional No-Man's Land "How do you hear me?" and the reply comes back "I hear you Nine Nine Nine" we have the beginning of communication. What we try to do in these conferences conducted by the Foundation is to set the stage for meaningful communication.

With the accelerating rate at which new knowledge is accumulating and with the increasing recognition that nature is of one piece it becomes evident that the continued isolation of the several branches of science from one another is a serious obstacle to scientific progress. Nowhere in science is the need for combined opera-

tions more evident than in medicine Today to be effective medical research and practice must embrace data from all the disciplines including nuclear physics at one end of the spectrum and cultural anthropology at the other for advances in one field are frequently dependent upon knowledge derived from quite another discipline

Although the fertility of the multidiscipline approach is thus recognized universities and scientific societies and journals which are usually restricted to one small area of a field in their coverage have not yet made adequate provision for channels of interdisciplinary communication We do not wish to compete with the formal scientific meetings or with the scientific journals which have established patterns and formats for the presentation of material Our purpose at the meetings is to keep an informal atmosphere and to encourage the exchange of methods research plans concepts and difficulties which cannot be done if there is formal speech making

The Foundation has endeavored to meet the need for interdisciplinary communication by bringing together for a series of two and a half day annual conferences a small group of investigators representing in so far as possible all the branches of science related to a chosen problem Participants in these informal conferences over a five year period develop a feeling of friendship trust and mutual respect which in turn promotes communication cross fertilization of ideas and cooperation The success of such an endeavor however is dependent upon full participation of all members in the discussion Accordingly attendance at any conference is limited to twenty five

Under the guidance of Dr Willard C Rappleye President of the Foundation since 1942 the Conference Program has been gradually expanded and enlarged until during 1953 it included twelve different groups which meet annually to discuss a wide variety of problems in the field of medicine and the closely related disciplines Our plan is to discontinue the meetings of each group at the end of five years

In order to share with a wider group of investigators and students the essential quality of these conferences and to give others an insight into the functions of the scientific mind the informal nature and tempo of the discussions as far as possible are preserved in the published transactions

FRANK FREMONT SMITH M D  
*Medical Director*

# THE SALT AND WATER FACTOR OF THE ADRENAL CORTEX\*

H L MASON

*Department of Biochemistry  
Mayo Clinic*

YOU ARE ALL I think familiar with the works of Tait Simpson and Grundy (1) and Woodford (2) in England. More recently Reichstein and his associates (3) have announced the isolation of what has tentatively been called "electrocortin". Dr Reichstein has indicated to us that electrocortin is not a satisfactory name but feels that a better name should at least await the determination of the structure.

We were a little behind Reichstein in announcing the crystallization of our compound which appears to be the same one that he and his associates have isolated. A lack of materials on both sides has prevented a comparison of the two preparations. Briefly, our preparation involved column chromatography, first on silica gel columns. We had difficulty in obtaining clean separations of our active material from cortisone, so we turned to acetylation. Perhaps that was a hazardous procedure inasmuch as Grundy *et al* (2) stated that acetylation of their material destroyed its activity. Of course, when one speaks of activity one should indicate the level at which it has been tested; we found a considerable amount after acetylation of a test portion of the material. Therefore, we decided to acetylate it.

Figure 1 summarizes one of our first columns. The fractions containing compounds A and B are indicated, and our activity is bracketed between the two vertical lines which include compound E. In accordance with the findings of Grundy *et al* (2), we also found that the activity traveled with much the same mobility as cortisone (Figure 2). After acetylation, however, we found that the sodium retaining activity was much more mobile than cortisone acetate, and that we could achieve a clean separation of the latter. The zone containing the sodium retaining activity also contained a

---

\*Associates in this work were Drs V. H. Mattox and A. Albert of the Mayo Clinic, Rochester, Minnesota.




FIGURE 1 Fractionation of beef adrenal extract by column chromatography




FIGURE 2 Fractionation of cortisone zone by column chromatography after acetylation

number of other substances some of which were crystalline but the nature of which we do not know.

The acetate in our assay appeared to have about the same activity as desoxycorticosterone acetate (DCA) which of course was not very encouraging but in view of the statement of Grundy *et al* (2) we thought we should hydrolyze it (Figure 3). The acetate




FIGURE 3. Enzymic hydrolysis of diacetate of sodium retaining compound

which we have designated at least tentatively as diacetate was treated with citrus acetylsterase. After paper chromatography of the product of hydrolysis we found there were two substances one of which we called monoacetate and the other the dihydroxy compound. Those designations are tentative but serve to identify the particular fractions.

The monoacetate crystallized first; it had an activity of approximately 25 times that of desoxycorticosterone acetate which was encouraging in view of the low activity of the diacetate. Eventually we crystallized the dihydroxy compound and found it had an activity of 85 or perhaps 100 times that of desoxycorticosterone acetate which is comparable with the compound described by Simpson, Tait, Reichstein *et al* (3). Their compound has been described as having an activity of from 50 to 100 times that of DCA.

Figure 4 is a paper chromatogram showing the mobilities of the three compounds just described: the diacetate, the monoacetate and the free compound.

Figure 5 is a comparison of the free compound and the monoacetate with cortisone and cortisone acetate. You will note that the mobilities of cortisone and of the free compound are very similar whereas the mobilities of the acetates are very different. As to the




FIGURE 4 Paper chromatography of sodium retaining substance and its mono- and diacetate

chemistry of the compound by the use of ultraviolet and infrared spectroscopy we found that there was an alpha beta unsaturated ketone group which was also identified by Reichstein and of course it is the easiest thing to find. In conformity with the known adrenal hormones the obvious thing is to assign the ketone group to the 3 position and the double bond to the 4 5 position in conjugation with it. Also by infrared spectroscopy we have evidence of an alpha ketol side chain that is the spectrum of the acetate is in agreement with the spectra of the 21 acetates of the known steroids with alpha ketol side chains. The substance reduces




FIGURE 11 Paper chromatography of free hormones and acetylated derivatives

tetrazolum promptly. Thus, unless this is an entirely unorthodox steroid, we have placed three oxygen atoms. Lacking an elementary analysis, we do not actually know whether it has four or five oxygen atoms; we have evidence of only four. We have been unable to identify the presence of another ketone group, but cannot be sure that it is not there.

However, we think that another hydroxyl group, in addition to the three already mentioned, would account for the mobility in chromatography. Where it is placed remains to be seen, but we think we have rather definitely eliminated position 16. The compound does not give a Porter-Silber reaction, and we have been



informed by Dr Gordon Farrell of Western Reserve University that 16 $\alpha$  hydroxy 11 desoxycorticosterone does give the Porter Silber reaction. A recent communication by Hirschmann, Hirschmann and Farrell (4) stated that the latter compound does not have the high salt retuning activity of electrocortin. Thus on chemical and biological grounds one may I think eliminate the possibility of its being a 16 $\alpha$  hydroxy 11 desoxy compound. The negative Porter Silber test also pretty well rules out the presence of the 17 hydroxyl group as does the absence of a hydroxyl band in the infrared spectrum of what we have called the diacetate.

We have made the 3 dinitrophenylhydrazones of the diacetate and the 3 dinitrophenylhydrazones of 6  $\alpha$  and 11  $\beta$  hydroxy 11 desoxycorticosterone. When the latter two were heated with perchloric acid and acetic acid the acetic acid was split out, and the absorption maxima shifted from 10 to 15  $\mu$  toward longer wave lengths. In the case of the unknown compound there was no shift in the spectrum under such treatment. Thus we believe there is little possibility that a 6 hydroxyl group is present. We think perhaps this experiment with the dinitrophenylhydrazones would make the presence of a hydroxyl or acetoxy group unlikely at positions 1 and 2. We have no model compounds so we cannot be entirely certain of that. It probably eliminates position 7 also.

Next for consideration is the 11  $\alpha$  position. A hydroxyl group in that place would give the 11 isomer of corticosterone which has also been tested biologically and has been found to have very little if any of the growth promoting activity associated with sodium retuning activity. Because the unplaced hydroxyl group was acetylated under very mild conditions we think the tertiary positions have been ruled out. Remaining then are positions 12 and 15 and the two angular methyl groups 18 and 19.

I stated that we think one more hydroxyl group in the right position combined with the other structural features of desoxycorticosterone would account for the mobility of this material on paper. That conclusion is supported by the fact that 16 $\alpha$  hydroxy 11 desoxycorticosterone moves with about the same mobility as cortisone.

Under conditions which would form the 21 acetate we have prepared a monoacetate which is different from that obtained by enzymatic hydrolysis of the diacetate. When this monoacetate was oxidized with chromic acid the product moved at a rate which would be expected from the conversion of a hydroxyl group to a

ketone group. This result furnishes further evidence that we are dealing with a secondary hydroxyl group.

The physiological properties of this compound are unknown except that it does have a high degree of activity in causing retention of sodium and excretion of potassium. We have necessarily been confined in our physiological studies to an assay method in order to isolate the material.

*Long* Dr. Mason has set before us an extremely interesting and provocative topic. For many years we have suspected that there might be a substance in the adrenal cortex which has an effect on mineral metabolism. It now appears to be a fact. Whatever the structure of the compound may prove to be, we certainly await with a great deal of interest further analyses of its physiological properties.

*Kendall* I should like to congratulate Dr. Mason on a piece of work which is of high order. When one considers the modest amount of material at his disposal, it is evident that it took a great deal of courage to go forward with only 2.98 mg. I think we will all agree that he has uncovered some definite evidence.

I believe the most important aspect of the problem now lies in what else the molecule does physiologically, in addition to the effect on the metabolism of sodium and potassium and the distribution of water. We have associated certain physiological activities with cortisone and hydrocortisone, but the effect produced by those two hormones on mineral metabolism is quite inadequate for us to accept them as the only active agents in the gland.

Finally we come to the mechanism which regulates the amounts of this substance as well as cortisone and hydrocortisone. Apparently the amount of the material is not increased by the administration of ACTH. Is the level of sodium regulated by the activity of the gland which in turn is regulated by the level of sodium, that is, is it like calcium and the parathyroid? The other hormones, cortisone and hydrocortisone, are under the control of ACTH. It would be very interesting to know the entire mechanism for the control of these three hormones, that is, cortisone, hydrocortisone, and the sodium factor, unless we crossed off cortisone and ascribed the effect on organic metabolism to hydrocortisone. That would bring the number of hormones down to two.

*Long* Dr. Kendall showed that the amount of this new substance in the adrenal blood is not increased by ACTH.

*Kendall* It has been known for a long time that after hypophysectomy the animal does not go into too much of a decline from

loss of control of the metabolism of sodium Dr R C de Bodo (5) has done some nice work on the effect of hypophysectomy on the adrenal gland The animal does very well with regard to sodium metabolism

*Long* The situation in the hypophysectomized animal is a relative one I think Gaunt (6) and others have shown it cannot respond to low water and salt in the way a normal animal can it suffers from water intoxication to the same extent as an adrenalectomized animal If this newly isolated substance alone is involved under those conditions one would suspect that there must be an increase Also has it not been shown that in the case of many adrenalectomized humans administration of cortisone or hydrocortisone is all that is required to maintain the mineral as well as the organic metabolism

*Kendall* I think that varies with the individual In some it is certainly true

*Mason* Some patients with Addison's disease do better when they receive both cortisone and desoxycorticosterone

*Kendall* How about the patients who have been adrenalectomized for various reasons? Some I believe get along without desoxycorticosterone Is that right?

*Conn* Yes some of them do but the majority require a small amount of desoxycorticosterone perhaps a milligram a day

*Mason* Didn't Dr Charles Huggins of the Ben May Laboratory for Cancer Research University of Chicago treat all his patients with cortisone alone with one or two exceptions?

*Conn* I think so

*Long* May I ask the method of assay you employed Dr Mason?

*Mason* The assay method is not very different from that of Simpson and Tait (7) except that we used the flame photometer for determination of sodium and potassium rather than radio activity It also differs in some other details Rats of about 150 gm weight were adrenalectomized and kept on an ordinary diet with salt water for drinking Twenty four hours before the assay they were taken off the salt water The test substances were injected and the urine collected over a three hour period

*Rall* Did you hydrate the rats and then administer the test substance?

*Mason* No

*Rall* You simply withheld salt?

*Mason* Yes just overnight

*Ingle* Dr Mason who isolated the 16 $\alpha$  hydroxy compound?

Mason Dr Hans Hirschmann and his associates (4) have synthesized 16 $\alpha$  hydroxy 11 desoxycorticosterone

Ingle Has only the one isomer been prepared?

Mason That is my understanding

Pincus I think we might eliminate position 12 Dr Dorfman didn't you study 12 keto 11 desoxycorticosterone a number of years ago?

Dorfman Yes I studied the substance prepared by Dr R D H Heard of McGill University Montreal and it was active but contained from 1 to 20 per cent of desoxycorticosterone That was reported in one of our early papers (8)

Mason Was it 12 hydroxy?

Dorfman Yes I believe so

Pincus Alpha or beta?

Dorfman The designation I think was not specified at that time It would have to be checked

Pincus We had the 12 ketone from Dr Heard and it had about 1/100th the activity of 11 desoxycorticosterone Thus I should think that unless this is a very unusual compound that requires a hydroxyl function for especially high activity position 12 might very well be eliminated by the same type of reasoning as applies to some of the others I think position 15 should also be excluded because as I remember the work of Simpson and Tait (9) the remaining and unknown hydroxyl is a rather strongly bonded hydroxyl according to the infrared spectrum Isn't that correct?

Mason I was not aware that they had an infrared spectrum

Kendall No I do not think they do They did not even suggest 15

Pincus What does your infrared spectrum show? Isn't it strong? If so position 15 would be unlikely

Mason We actually have not had an infrared spectrum on the compound with the free hydroxyl group in the unknown position

Pincus You have had all the acetate?

Mason All the diacetate Dr Norman Jones took a spectrum for us on the monoacetate which we have assumed has the  $\Delta$  position acetylated and the 21 hydroxyl group free We have no evidence for that so I cannot answer the question

White Did I understand you to say that Dr Hirschmann has made the 16 alpha desoxycorticosterone but that so far as you know the 16 beta has not as yet been made?

Mason That is correct

*Young* Is there any reason to suppose that the 16 beta hydroxyl would give the Porter Silber reaction?

*Mason* I cannot answer that but I think it probably would

*Young* You would eliminate 16 beta on that basis?

*Mason* Tentatively at least I would reason by analogy from the 6 alpha and 6 beta hydroxylated compounds. There is a difference in the yield of the  $\Delta^6$  compound from the two isomers one dehydrates or loses acetic acid more readily than the other. Offhand I do not know any reason why a 16 hydroxyl group should not behave similarly.

*Pincus* The 16 beta would be very labile to acid I should imagine

*Mason* That would certainly give the Porter Silber reaction. We found that compounds with the delta 16 bond gave the Porter Silber reaction so it appears that that reaction involves a dehydration between the 16 and 17 carbon atoms.

*Bloch* If there is a hydroxyl at one of the angular methyl groups one should obtain an aldehyde on oxidation instead of a ketone. Moreover if 15 is eliminated there are really no positions left.

*Mason* The analyses were done on just a few micrograms. We thought the angular methyl groups were probably eliminated by the oxidation procedure. Of course so much of our evidence is tentative that I do not think any chemist would be entirely satisfied with it.

*Long* What is the best estimate of the amount of this corticoid that is present in a kilo of glands? At our conference last year Dr. Martha Vogt (10) gave the estimates of Simpson and Taft. What is your experience as to the quantity present in a kilo of glands compared to the other steroids?

*Mason* I have not actually calculated it. We obtained an amount similar to that of Reichstein who mentions 500 kilos yielding 22 mg. In another place he speaks of 1 100 kilos yielding about the same. I think the latter figure is probably correct. Thus there would be about 2 mg. per 100 kilos.

*Ingle* If this compound is very labile in the fractionation procedures the amount isolated would not necessarily reflect the secretory activity of the gland would it?

*Mason* We have no idea as to what the losses might be during the preparation but of course every effort was made to keep the conditions as mild as possible. For that reason we used partition chromatography rather than adsorption chromatography.

*Young* Do you have any positive evidence that the substance is present in the amorphous fraction? Or do you assume that by exclusion because it is not present in other fractions?

*Mason* Our first experiment was directed toward that very thing. We prepared some amorphous fraction as had been done in the past, and although we could not positively identify the active material at least the mobility on paper appeared to be the same as in the material which we had isolated. We have not actually compared the two since we do not have any more of the amorphous fraction.

*Pincus* Dr. Mason, you said that it was difficult to separate this material from compound E by the usual method. Is cortisone a constituent of the amorphous fraction?

*Mason* Cortisone, compound F, corticosterone, and a dozen other things are present.

*Pincus* The point I am trying to get at is this: cortisone has been separated from adrenal extract with ease. Why do you say that this material is characteristic of the amorphous fraction? Why isn't it one of the things that goes along with cortisone in the usual fractionations for cortisone?

*Mason* I do not know that I can answer that with any authority. We have not tested natural cortisone for this type of activity. Have you, Dr. Kendall?

*Kendall* Prof. W. W. Swingle and his associates have tested cortisone for its ability to retain sodium. It is very weak. The sodium factor does not separate with cortisone and the other crystalline material at all.

*Pincus* It is in the mother liquor?

*Kendall* Yes, all of the sodium retaining material is there.

*White* Dr. Mason, you said did you not that your experience with the dinitrophenylhydrazone behavior indicated that position 8 should be eliminated and you felt that this evidence ruled out positions 1 and 2 and probably 7 as well?

*Mason* I said "possibly."

*White* Some of us have had experience with bioassays of the 2-hydroxy compounds and it can probably be said that the 2-alpha-hydroxy compounds are quite inactive. I do not know whether anyone here has had any experience with the 2-beta-hydroxy compounds.

Another point from the standpoint of chemistry: how would you interpret the structure in terms of the significant degree of destruction of activity on acetylation?

*Mason* That has puzzled me a great deal and I have no constructive suggestion to make about that. It was surprising to find that uncovering just the 21 alcohol group increased the activity about 25 to 30 times.

*White* How is this material administered for bioassay?

*Mason* It is given subcutaneously in a 1:1 mixture of propylene glycol and water.

*Rall* Does the effect occur because the increased rate of urine output increases the excretion of potassium?

*Mason* It occurs because of the amount of sodium and potassium excreted. There is a retention of sodium and a stimulation of potassium excretion. Simpson and Tait (7) used the sodium and potassium ratio and we also found that to be a better index than measuring the sodium retention alone.

*Kendall* Do you always determine both sodium and potassium and use the ratio of sodium to potassium?

*Mason* Yes.

*Dorfman* How about life maintenance? Does it parallel this high activity?

*Mason* We have not done that but people at the Upjohn and Company Laboratories have. Dr. Ingle, do you remember what they said about this effect?

*Ingle* I cannot remember any ratios but I know that this principle was many times as potent as DCA in the life maintenance test and in supporting the growth of the immature adrenalectomized rat.

*Kendall* It was not as much as desoxycorticosterone?

*Mason* Many times more.

*Kendall* Not as much as 80 or 100?

*Mason* No.

*Young* I think I have seen some data recently which suggested that if the urinary sodium/potassium ratio is taken as criterion which is what Simpson and Tait did, the material is approximately 100 times as active as desoxycorticosterone but in the case of life maintenance it may be 30 times as great. If we take sodium retention in the dog it is about 50 times as active.

*Long* Is that about the ratio you found with your old amorphous fraction, Dr. Kendall?

*Kendall* There is a figure of 2 gamma per kilo in an old paper of mine (11).

*Long* Did you use the dog originally maintained on a low potassium high sodium diet?

*Hendall* No not high sodium I think we should recognize the time factor Dr Mason speaks of three hours If one injection or even two are given in a day the animal must be sustained for the entire 24 hours Thus I would not be surprised if this value of 100 were to shrink to 20 or 30 on a life maintenance or growth basis

*Long* There is no evidence at all so far as to whether the material has or has not any effect on carbohydrate or protein metabolism?

*Mason* Not in the case of crystalline material As to the old amorphous fraction I think Dr Ingle could answer the question

*Ingle* It had a greater effect than desoxycorticosterone but much less than cortisone when assayed in the work test

*Long* An amorphous fraction might have contained some cortisone

*Mason* It undoubtedly contains cortisone and also hydrocortisone

*Long* Do the crystals so far as is known possess any activity other than the effect on water and salt metabolism?

*Mason* If so it has not been measured as yet

*Young* Knauff Nielson and Haines (12) say that it has no effect on carbohydrate metabolism but it is rather risky to say that it has no activity without knowing the dose used Do you recall what dose they administered?

*Mason* I am sure I have heard them say but I do not remember exactly

*Pincus* They did not state the dose in their paper Is there any evidence of other electrolyte regulating substances in the amorphous fraction?

*Mason* We have not found appreciable activity in any other fraction but we have not looked very thoroughly We are centering our attention on the fraction that gave us the greatest activity

*Long* I should like to get back to the lack of effect of ACTH Has any other pituitary hormone been tried? I am thinking particularly of what Dr Selye has suggested that there may be another pituitary factor that controls the secretion of the water and salt regulating hormone Has growth hormone been tried?

*Li* Growth hormone has been demonstrated to retain sodium and potassium in both normal and adrenalectomized rats (13)

*Long* That is not quite the same thing as we are talking about here

*Conn* Dr Long the only other suggestion about a relationship is the effect of ACTH on nephrotic patients who are excreting



large amounts of this material. Upon cessation of ACTH this electrolyte active factor disappears from the urine with the diuresis.

*Long* The suggestion is that this condition was stimulated by ACTH?

*Conn* Yes

*Pincus* I believe that in the analysis of adrenal vein blood Dr I. E. Bush (14) found increased amounts of this material after ACTH. We found it in perfusates. I cannot state unequivocally that it is increased after ACTH administration. However I think it must be because the experiments in which it has been shown to be present have all been found in ACTH perfused adrenals.

*Rall* If the material has a water retaining effect one would expect it to increase the reabsorption of water and thus decrease the volume of urine excreted. Did you measure the urine volume?

*Mason* No we have not attempted to do that.

*Pincus* If it acts like DCA in the acute test with the rat there should be a definite decrease of urine volume. That is one of the characteristics at least of desoxycorticosterone. Are the animals given a salt load Dr Mason?

*Mason* Dr A. Albert of the Mayo Clinic has been doing the assays and I cannot speak too authoritatively because the details have been changed from time to time however as I understand it no salt load was given. That was done at first but not later.

*Long* However they drink one per cent sodium chloride to maintain them?

*Mason* Yes

*Long* That is a fair level of salt intake?

*Mason* No it is not very much.

*Long* This compound recalls one of the central questions of adrenal physiology which is the apparent separation of the effects on water and salt metabolism of compounds of this type and the effects of cortisone on the organic metabolism. Nevertheless I understand that cortisone and hydrocortisone when they are employed in sufficient amounts have a complete effect on both the organic metabolism and inorganic metabolism.

*Dorfman* It is a question of what you mean by complete. After all desoxycorticosterone can increase the glycogen level of the fasting animal both in the rat and mouse. It has about one per cent of the activity of hydrocortisone.

*Rall* It might not be due solely to the hydrating effect of DCA on the animal. If the general condition of an animal is improved

by the administration of desoxycorticosterone his capacity to absorb from the intestinal tract may also be improved

Dorfman These are fasted animals

Long And also adrenalectomized?

Dorfman Yes

Long I believe it is a different story in the intact animal in that case have you ever seen any glycogen decomposition from desoxy corticosterone?

Ingle Exacerbation of diabetes will occur if 10 mg of desoxy corticosterone per day is given to the partially depancreatized rat

Long Is this in an adrenalectomized animal?

Ingle The adrenals are intact

White I assume the uncertainty about four versus five oxygen atoms is largely due to inadequate amounts of material for elemental analysis However from the standpoint of its polarity the chances are that it is four

Mason Yes we think four is probable

EDITOR'S NOTE Since this discussion took place Dr Reichstein and his associates (15) have reported the following findings

Chemical degradation of the new crystalline mineralocorticoid provisionally called electrocortin has shown that this compound is 11 $\beta$  21 dihydroxy 3 20 diketone-4 pregnane 18 al In solution this reacts mainly as the 11 hemiacetal We suggest aldosterone as a definitive name for the compound

#### REFERENCES

- 1 TAIT J F SIMPSON S A and GRUNDY H M The effect of adrenal extract on mineral metabolism *Lancet* 1 172 (1952)
- 2 GRUNDY H M SIMPSON S A TAIT J F and WOODFORD M Further studies on the properties of a highly active mineralocorticoid *Acta endocrinol* 11, 199 (1952)
- 3 SIMPSON S A TAIT J F WETTSTEIN A NEHER R VON ELW J and REICHSTEIN T Isolierung eines neuen kristallisierten Hormons aus Nebennieren mit besonders hoher Wirksamkeit auf den Mineralstoffwechsel *Experientia* 9 333 (1953)
- 4 HIRSCHMANN H HIRSCHMANN F B and FARRELL G L Partial synthesis of 16 $\alpha$  21 diacetoxy progesterone *J Am Chem Soc* 75 4817 (1953)
- 5 LANE N and DE BODO R C Generalized adrenocortical atrophy in hypophysectomized dogs and correlated functional studies *Am J Physiol* 168 1 (1952)
- 6 GAUNT R REMINGTON J W and SCHWEIZER M Some effects of intraperitoneal glucose injections and excess water in normal adrenalectomized and hypophysectomized rats *Am J Physiol* 120 53 (1957)

- 7 SIMPSON S A and TAIT J F A quantitative method for the bioassay of the effect of adrenal cortical steroids on mineral metabolism *Endocrinology* 50 150 (1952)
- 8 DORFMAN R I Influence of adrenal cortical steroids and related compounds on sodium metabolism *Proc Soc Exper Biol & Med* 72 395 (1949)
- 9 SIMPSON S A and TAIT J F Physico chemical methods of detection of a previously unidentified adrenal hormone *The Determination of Adrenocortical Steroids and Their Metabolites* P Eckstein and S Zuckerman Editors. Memoirs of the Soc for Endocrinol London Dennis Dobson 1953 (p 9)
- 10 VOGT M Existence nature and site of production of a salt hormone (mineralo corticoid) secreted by the adrenal gland *Adrenal Cortex* E P Ralli Editor Trans Fourth Conf New York Josiah Macy Jr Foundation 1953 (p 101)
- 11 KENDALL E C The adrenal cortex *Arch Path* 32 474 (1941)
- 12 KNAUFF R E NIELSON E D and HAINES W J Studies on a mineralocorticoid from hog adrenal extract *J Am Chem Soc* 75 4868 (1953)
- 13 STEIN J D JR BENNETT L L BATTY A A and LI C H Sodium potassium and chloride retention produced by growth hormone in the absence of the adrenals *Am J Physiol* 171 387 (1952)
- 14 SIMPSON S A TAIT J F and BUSH I E Secretion of a salt retaining hormone by the mammalian adrenal cortex *Lancet* 2 226 (1952)
- 15 SIMPSON S A TAIT J F WETTSTEIN A NEHER R VON EUW J SCHINDLER O and REICHSTEIN T Konstitution des Aldosterons des neuen Mineralcorticoids *Experientia* 10 132 (1954)

# THE METABOLISM OF ADRENAL STEROIDS

RALPH I. DORFMAN

*Worcester Foundation for Experimental Biology*

As you all know, the metabolism of adrenocortical hormones is a complex subject. I shall limit my discussion to the metabolism of adrenocortical steroids in man and present some recent speculations on this problem. Furthermore we shall consider *in vivo* or over all metabolism. This is an important phase of metabolism particularly for clinical medicine. If we could relate the endogenously produced adrenocortical steroids to specific metabolites in the urine and if these metabolites could be quantitatively determined we would then have a rational system for determining the specific status of the adrenal cortex. I shall present for your consideration (a) a summary of the known facts about the relationship between the tissue steroids and the metabolites in the urine (b) a generalization of steroid metabolism which leads to a method for the calculation of quantities of steroids endogenously produced (c) an analysis of the meaning of group steroid reactions as applied to urinary extracts and (d) a working hypothesis concerned with the biochemical defects that lead to various clinical types of adrenocortical hyperactivity.

At the moment we have evidence to indicate that a variety of adrenal steroids are secreted into the blood stream. These substances are metabolized by various peripheral tissues and finally appear in the urine. The greatest amount of work has been concerned with the urinary compounds.

I should like to consider now the reduction of Ring A of the steroid nucleus—a story that will lead us to a working hypothesis. All of the neutral steroid hormones that possess biological activity thus far studied contain in Ring A an  $\alpha\beta$  unsaturated ketone or more specifically  $\Delta^4$  3 ketone. One of the characteristic features in metabolism in the human as well as in the animal is the reduction of the ketone group to a secondary alcohol and the saturation of the 4-5 double bond (1).

I should like to present for discussion the thesis that the type of reduction of the  $\Delta^4$  double bond is regulated by the constituent

groups on the steroid molecule. That is the reduction is oriented either into one or another stereoisomeric form which may be designated as alpha (androstane or allopregnane) or beta (etiocholine or pregnane). In the  $C_{17}$  series (androgens) compounds of the  $5\alpha$  configuration are called the androstane group while those of the  $5\beta$  series are of the etiocholine group. In the  $C_{21}$  series of steroids which include progesterone and adrenocortical hormones  $5\alpha$  will designate the allopregnane series while  $5\beta$  will refer to the pregnane compounds.

We now come back to the general thesis that substituent groups at carbon atoms 11 and 17 influence the way in which the double bond at carbon atoms 4 and 5 are reduced. When  $C_{17}$ ,  $\Delta^4$  3 ketosteroids with a 17 oxygen function either as a hydroxy or a ketone group (such as testosterone or  $\Delta^4$  androstene 3 17 dione) are present in the body these compounds are reduced so that the ratio of the  $5\beta$  to  $5\alpha$  form varies between 0.6 and 3.7 with a mean of about 2.1. If on the other hand we deal with compounds having the same 19 carbon atoms but with an additional oxygen at position 11 such as in adrenosterone the ratio of  $5\beta$  to  $5\alpha$  stereoisomers is something of the order of 0.2 (Table I).

**TABLE I**  
**Metabolism of  $\Delta^4$  3 Keto- $C_{19}$  Steroids to**  
**Saturated  $C_{19}$  Steroids In Vivo\***  
**(Humans)**

Steroid Administered	No of Experiments	Ratio $5\beta/5\alpha$ Mean (Range)
Testosterone	4	1.89 (0.6-3.70)
$\Delta^4$ Androstene 3 17 dione	4	1.92 (1.02-2.23)
Dehydroepiandrosterone	5	1.83 (0.6-4.6)
Adrenosterone	1	0.19

Data of Schull *et al* (2) Dobner (3) Gallagher *et al* (4) Dorfman (5) Ungar and Dorfman (unpublished) Mason and Kepler (6) Miller *et al* (7) Savard *et al* (8)

$5\beta$  = etiocholine 3 $\alpha$  ol 17 one or 11 oxygenated etiocholine 3 $\alpha$  ol 17 one  
 $5\alpha$  = androsterone or 11 oxygenated androsterone

If we have a  $\Delta^4$  3 ketosteroid with a side chain at carbon 17 as in the case of progesterone we find that in metabolism (reduction of  $\Delta^4$  group) there is a preponderance of the  $5\beta$  stereoisomer formed. Actually in the experiments in the literature and our own experience the mean ratio of  $5\beta$  to  $5\alpha$  form is something of the order of 21:1 (Table II). Studies with desoxycorticosterone, 11 dehydrocorticosterone, cortisone and other  $C_{21}$  steroids have yielded Ring A reduced compounds only in the pregnane series (Table II). Some of these steroids contain oxygen functions at 11

TABLE II  
Metabolism of  $\Delta^4$  3 Keto  $C_{21}$  Steroids to  
Saturated  $C_{21}$  Steroids *in Vivo*\*  
(Humans)

Steroid Administered	No of Experiments	Ratio $5\beta/5\alpha$ Mean (Range)
Progesterone	4	21 (7.5-33.0)
Cortisone	2	$\infty$ †
Hydrocortisone	1	$\infty$ †
21 Desoxycortisone	2	$\infty$ †
Desoxycorticosterone	4	$\infty$ †
11 Dehydrocorticosterone	1	$\infty$ †
$\Delta^4$ Dehydroprogesterone	1	$\infty$ †
11 Ketoprogesterone	1	$\infty$ †
Data of Burstein <i>et al</i> (9,10,11) Horwitz <i>et al</i> (12) Ungar <i>et al</i> (13) Dobriner and Lieberman (14) Kyle and Marrian (15) Savard and Dorfman (unpublished) Mason (16)		
†No allopregnane derivative thus far isolated		

Reprinted by permission, from Dorfman, R. I. Neutral steroid hormone metabolites. *Recent Progr. Hormone Research* 9: 5 (1954)

as in cortisone and corticosterone in addition to the presence of a side chain. When both C-11 oxygen and a C-17 side chain are present it appears that the influence of the side chain is more important than the 11 oxygen. This is true since the type of metabolites we obtain in the pregnane series are similar to the type found for  $C_{21}$  compounds with an 11 oxygen substitution.

There is a suggestion that in the metabolism of a compound such as cortisone to 17 ketosteroids two pathways exist. That is one pathway (A) where the formation of a dihydro derivative ( $5\beta$  series) would be produced by two hydrogens saturating the double bond at 4-5 which in turn would be converted to a 17 ketosteroid of the  $5\beta$  form and a second pathway (B) where cortisone would be oxidatively converted to adrenosterone which would be metabolized on both  $5\beta$  and  $5\alpha$  reduced forms. Thus from route (A) we obtain a ratio of  $5\beta$  to  $5\alpha$  forms of about 21:1 and from route (B) a ratio of 1:5. The total products from routes (A) and (B) have been determined to be of the order of 65:1.

Table I presents the *in vivo* metabolism of three  $C_{19}O_2$  steroids and one  $C_{19}O_3$  steroid. Specifically testosterone,  $\Delta^4$  androstene-3,17-dione and dehydroepiandrosterone when administered to the human are metabolized in such a manner that there is a slight preponderance of the  $5\beta$  reduced form. Tables I and II as well as in Table III which is to follow the difference in stereoisomerism at carbon atom 5 is emphasized. When  $C_{19}O_2$  compounds are metabolized the end products are androsterone ( $5\alpha$ ) and etiocholine ( $5\beta$ ). We observe in Table I that the mean ratio of the  $5\beta$  to the  $5\alpha$  isomers was 1.89 and varied from 0.6 to 4.6. In contrast to the  $5\beta$  to  $5\alpha$  ratio 1.89 for the  $C_{19}O_2$  steroids the metabolism or reduction of adrenosterone a  $C_{19}O_3$  compound resulted in a preponderance of the  $5\alpha$  form. Here the  $5\beta$  and  $5\alpha$  isomers refer to the 11 oxygenated derivatives but the type of reduction at carbon 5 is similar to that of the  $C_{19}O_2$  compounds. In Table I therefore we have suggested that the presence of an oxygen function at 11 influences the manner in which the  $\Delta^4$  group is reduced.

Table II deals with the metabolism of the  $\Delta^4$ -3 keto  $C_{19}$  steroids which are reduced to the saturated  $C_{19}$  steroids. Here we have eight different compounds which are known to be reduced in Ring A. Using again the same convention of  $5\beta$  and  $5\alpha$  stereoisomers we find the interesting fact that in all instances the important reduction product quantitatively is the  $5\beta$  form. Actually in the case of progesterone for which the greatest number of experiments were reported the preponderance of  $5\beta$  stereoisomer is indicated by the fact that the mean  $5\beta$  to  $5\alpha$  ratio is somewhere in the neighborhood of 21, varying from 7.5 to 33. Thus the important fact that this table illustrates is that the presence of a side chain at carbon 17 with or without an oxygen function at 11 orients the reduction of the 4-5 double bond to the  $\beta$  form.

*White* How do you bring into harmony the 11 keto progesterone and progesterone?

*Dorfman* The only metabolite of 11 progesterone that I know of is 11 ketopregnandiol which is in the pregnane series. The point is that in each of these instances a pregnane derivative has been isolated.

*White* With DCA then as compared with progesterone is the nature of  $C_{21}$  significant? I am concerned with the fact that you are making a good deal of whether or not there is an 11 oxygen as compared to the nature of the side chain because in DCA and progesterone neither has an 11-oxygen they have side chains which are somewhat similar yet there are marked differences in metabolites.

*Dorfman* The presence of oxygen at 11 changes the ratio in the  $C_{21}$  compounds but when there is a side chain and oxygen at carbon 11 the influence of the side chain seems to dominate the picture. Certain  $C_{21}$  steroids may be metabolized to saturated  $C_{19}$  compounds. These include substances like cortisone, hydrocortisone, 17 $\alpha$ -hydroxydesoxycorticosterone and 17 $\alpha$ -hydroxyprogesterone. All of these compounds have the characteristic feature of oxygen present both at carbon atoms 20 and 17. Such substances when administered to humans produce in part 17 ketosteroid by oxidative removal of the side chain. These results are indicated in Table III. Because the over all metabolism of  $C_{21}$  and  $C_{19}$  steroids is such that a ratio of 5 $\beta$  to 5 $\alpha$  is approximately 9 and because it is known that substances like adrenosterone when metabolized to reduced ketosteroids yield ratios of the 5 $\beta$  to the 5 $\alpha$  isomers of 0.2 it is unlikely that the only mechanism of conversion of  $C_{21}$  to  $C_{19}$  steroids is by removal of the side chain followed by reduction of Ring A. If this were so the administration of cortisone and hydrocortisone would yield ratios of the 5 $\beta$  to 5 $\alpha$  isomers in the neighborhood of 0.2 instead of the experimentally determined value in the order of 9. Further if substances like cortisone and hydrocortisone were fully reduced in Ring A before the side chain was removed one would expect a ratio of the  $C_{19}$  reduced forms derived from the  $C_{21}$  compounds to be present in a ratio of approximately 20. But that is not in agreement with the experimentally determined value of 9. Therefore it is suggested that actually two pathways for the conversion of  $C_{21}$  steroids to  $C_{19}$  steroids exist: the minor pathway would involve the oxidative removal of the side chain with the formation from cortisone of adrenosterone and from



TABLE III

Metabolism of  $\Delta^4$ -3 keto  $C_{21}$  Steroids to Saturated  $C_{21}$  Steroids In Vivo\*  
(Humans)

Steroid Administered	No of Experiments	Ratio 5 $\beta$ /5 $\alpha$ † Mean (Range)
Cortisone	3	65† (43-91)
Hydrocortisone	3	110† (20-244)
21 Desoxycortisone	1	41†
17 $\alpha$ Hydroxydesoxycorticosterone	2	118** (70-165)

Data of Burstin *et al* (9-10-11) Rubin and Dorfman (unpublished)

5 $\beta$  = 11 keto plus 11 $\beta$  hydroxycholesterol 3 $\alpha$  of 17 one

5 $\alpha$  = 11 keto plus 11 $\beta$  hydroxyandrosterone

\* 5 $\beta$  = cholesterol 3 $\alpha$  of 17 one

5 $\alpha$  = androsterone

Reprinted by permission from Dorfman H I Neutral steroid hormone metabolites  
*Recent Progr Hormone Research* 9:5 (1954)

hydrocortisone 11 $\beta$  hydroxy  $\Delta^4$  androstene-3-17 dione. The major but not exclusive pathway would involve the preliminary reduction of the  $\Delta^4$  double bond with the subsequent oxidative removal of the side chain. The  $C_{21}$  metabolites derived from the two pathways one yielding a ratio of 0.2 and the other a ratio of approximately 20 would then make up the specific mixture resulting in a final ratio of 9. It has been estimated that approximately 88 per cent of the hydrocortisone and cortisone to be converted to  $C_{21}$  steroids probably go through the  $C_{21}$  5 $\beta$  intermediate and that the remaining 12 per cent go through the  $\Delta^4$ -3 keto  $C_{21}$  intermediate.

From metabolic studies with various steroids in human subjects we can make an estimate of the percentage of administered steroid that is recovered or determinable in the urine. The percentage of recoveries varies according to the type of compounds that we deal with. For substances possessing the  $\Delta^4$ -3 keto group in the  $C_{21}$  series a total recovery of ketosteroids of approximately 40 per cent may be expected. For a substance such as adrenosterone a repre-

sentative of the  $\Delta^4$ -3 keto group of  $C_{17}O_3$  compounds a recovery of 15 per cent is indicated. In the  $C_{19}$  series compounds of the type of 17 hydroxy 11 desoxycorticosterone appear to be converted to  $C_{19}$  17 ketosteroids to the extent of 5 per cent while hydrocortisone and cortisone are converted to ketosteroids to the extent of 3 per cent. Actually we have used these figures in an attempt to calculate the specific production of individual ketosteroids in the body from data on quantitative excretion of related metabolites in the urine.

Long: That is total metabolite recovery?

Dorfman: No, these are ketosteroids. In each instance there are other metabolites. In the case of cortisone, for example, by far the largest amount by weight would be the tetrahydrocortisone of the  $3\alpha$  hydroxy  $5\beta$  form.

In the case of testosterone and  $\Delta^4$  androstene 3,17 dione there is a figure of 40 per cent; other metabolites are present in minute concentrations which still have the steroid nucleus.

Rall: Were these all administered to normal subjects?

Dorfman: These figures are an average of our experience with various subjects including some rheumatoid arthritics.

Bauer: What percentage were rheumatoid arthritics?

Dorfman: About 40 per cent for the whole experiment.

I should like to go on now to indicate a method for the precise calculation of the origin of the 11-oxygenated  $C_{17}$  17 ketosteroids in normal urine. Of importance in this work is the utilization of a new method for the quantitative determination of six individual 17 ketosteroid components in urine by Rubin *et al.* (17). Once these values are available together with certain preliminary figures on the generalizations which I have already presented it becomes possible to set up mathematical relationships so that the origin of the individual 11 oxygenated  $C_{17}$  ketosteroids may be calculated. The data I shall use for these calculations are derived from analyses of the urine of normal men from 19 to 35 years of age. The mean value for eight such subjects was found to be 1.08 mg per day for the 11 oxygenated compounds of the androstane ( $5\alpha$ ) series and 0.86 mg per day for the 11 oxygenated compounds of the etiocholane ( $5\beta$ ) series. Because we have already determined that cortisone and hydrocortisone can give rise to both  $5\beta$  and  $5\alpha$  11 oxygenated  $C_{17}$  steroids in a ratio of 9:1 and because adrenosterone and related compounds also are metabolized to both  $5\beta$  and  $5\alpha$  forms in a ratio of essentially 1:1 it is possible to set up the following mathematical relationships:

TABLE III

Metabolism of  $\Delta^4$  3 Keto  $C_{21}$  Steroids to Saturated  $C_{17}$  Steroids in *Vivo*\*  
(Humans)

Steroid Administered	No of Experiments	Ratio $5\beta/5\alpha$ Mean (Range)
Cortisone	3	65† (43-91)
Hydrocortisone	3	110† (20-244)
21 Desoxycortisone	1	41†
17 $\alpha$ Hydroxydesoxycorticosterone	2	118** (70-165)

Data of Burstein *et al* (9-10-11) Rubin and Dorfman (unpublished)

$5\beta$  = 11 keto plus 11 $\beta$  hydroxyetiocholan-3 $\alpha$  ol 17 one

$5\alpha$  = 11 keto plus 11 $\beta$  hydroxyandrosterone

\*  $5\beta$  = etiocholan-3 $\alpha$  ol 17 one

$5\alpha$  = androsterone

Reprinted by permission from Dorfman H I Neutral steroid hormone metabolites  
*Recent Progress Hormone Research* 9:5 (1954)

hydrocortisone 11 $\beta$  hydroxy  $\Delta^4$  androstene-3,17-dione. The major but not exclusive pathway would involve the preliminary reduction of the  $\Delta^4$ -double bond with the subsequent oxidative removal of the side chain. The  $C_{17}$  metabolites derived from the two pathways one yielding a ratio of 0.2 and the other a ratio of approximately 20 would then make up the specific mixture resulting in a final ratio of 9. It has been estimated that approximately 88 per cent of the hydrocortisone and cortisone to be converted to  $C_{17}$  steroids probably go through the  $C_{17}$ - $5\beta$  intermediate and that the remaining 12 per cent go through the  $\Delta^4$  3 keto  $C_{17}$  intermediate.

From metabolic studies with various steroids in human subjects we can make an estimate of the percentage of administered steroid that is recovered or determinable in the urine. The percentage of recoveries varies according to the type of compounds that we deal with. For substances possessing the  $\Delta^4$  3 keto group in the  $C_{21}$ ,  $O_2$  series a total recovery of ketosteroids of approximately 40 per cent may be expected. For a substance such as adrenosterone a repre-




FIGURE 6. Reactions that do not appear to occur. Reprinted by permission from Dorfman R I and Ungar F *Metabolism of the Steroid Hormones* Minneapoli: Burgess Publishing Company 1953

Total  $5\alpha$  11 oxygenated  $C_{19}$  steroids = 1.08 mg per day

Total  $5\beta$  11 oxygenated  $C_{19}$  steroids = 0.86 mg per day

Ratio  $\frac{5\beta}{5\alpha}$  (for hydrocortisone and cortisone) =  $\frac{9}{1}$

Ratio  $\frac{5\beta}{5\alpha}$  (for adrenosterone and related steroids) =  $\frac{1}{4}$

Let  $X$  = quantity of  $5\alpha$  from cortisone and hydrocortisone  $Y$  = quantity of  $5\beta$  from cortisone and hydrocortisone

Then

$1.08 - X$  = quantity of  $5\alpha$  from adrenosterone and related steroids

$0.86 - Y$  = quantity of  $5\beta$  from adrenosterone and related steroids

Ratio  $\frac{5\beta}{5\alpha}$  (for hydrocortisone and cortisone) =  $\frac{Y}{X} = \frac{9}{1}$

Ratio  $\frac{5\beta}{5\alpha}$  (for adrenosterone and related steroids) =

$$\frac{0.86 - Y}{1.08 - X} = \frac{1}{4}$$

Solving for  $X$  and  $Y$

$$X = 0.07$$

$$1.08 - X = 1.01$$

$$Y = 0.63$$

$$0.86 - Y = 0.23$$

In a similar manner it should be possible to calculate the origin of androsterone and etiocholanone in normal men

*Thorn* Should we assume that there was no adrenosterone secreted directly as such?

*Dorfman* We cannot assume that. As a matter of fact adrenosterone and/or  $11\beta$  hydroxy  $\Delta^4$  androstene 3,17 dione is secreted.

*Thorn* Am I correct in thinking that it is not necessary to know the total amount of cortisone in order to derive the significance which you attach to this ratio?

*Dorfman* That is right. Rather than show you all the reactions that occur in the organism, I shall discuss the reactions that do not appear to take place. These are illustrated in Figure 6. These facts actually simplify steroid metabolism (*in vivo*) and make it possible to relate urinary steroids to their tissue precursors. Once the double bond at carbon 4 and 5 is saturated, either as the  $5\beta$  or the  $5\alpha$  in both the  $C_{19}$  series or in the  $C_{21}$  series, the  $\Delta^4$  or  $\Delta^5$  group is no longer formed. Specifically, neither androsterone or etiocholanone are transformed to  $\Delta^4$  androstene 3,17 dione.




FIGURE 7 Differential in vivo metabolism of dehydroepiandrosterone and  $\Delta^4$  androstene 3,17 dione

the calculations previously suggested it should be possible to estimate the amounts of these steroids derivable from  $C_{17}$  compounds and those that come from the  $C_{21}$  steroids that we are at present considering. Figure 8 outlines our particular problem. It can be seen that the two steroids 17 $\alpha$  hydroxyprogesterone and 17 $\alpha$  hydroxy 11 desoxycorticosterone may be analyzed as a group by three independent measures: first by using the two 17 keto steroids androsterone and etiocholanolone; second by analysis of pregnane 3 $\alpha$  17 $\alpha$  diol 20 one; and third by analysis of pregnane 3 $\alpha$  17 $\alpha$  21 triol. All three of these measures, it should be pointed out, indicate the combined production of the two  $C_{21}$  steroids. One additional analysis would have to be done in order to measure each of these compounds. The substance pregnane 3 $\alpha$  17 $\alpha$  21 triol 20 one would be a specific measure of 17 $\alpha$  hydroxy 11 desoxycorticosterone.

Further as far as we know and as far as others have observed one needs oxygen at carbon 17 as well as at carbon 20 in order to permit the conversion of a  $C_{21}$  compound to a 17 ketosteroid. This fact also helps to permit the differentiation of 17 20 oxygenated steroids from 20 oxygenated steroids.

Another point is that the presence of oxygen on the ring at carbon 11 does not yield the corresponding desoxysteroid in any appreciable quantity and finally that the  $\Delta^4$ -3 ketone cannot be converted back to the  $\Delta^5$   $3\beta$  hydroxy group. This is particularly fortunate because it affords a method to differentiate and quantitate dehydroepiandrosterone and  $\Delta^4$  androstene 3 17 dione.

I should like now to discuss with you various methods proved or indicated that would lead to a precise analysis of individual endogenous steroids produced by the adrenal cortex. Our first problem consists in the differentiation of dehydroepiandrosterone and  $\Delta^4$  androstene 3 17 dione. Both these substances on the basis of best available evidence are probably produced by the adrenal cortex. Further it is known that part of the dehydroepiandrosterone produced in the organism can in fact be converted to  $\Delta^4$  androstene 3 17 dione. Further both these 17 ketosteroids yield the common metabolites androsterone and etiocholine. It is obvious therefore that some additional means would be needed to differentiate quantitatively between these two substances. Figure 7 is presented to indicate such a possibility. In other words both dehydroepiandrosterone and  $\Delta^4$  androstene-3 17 dione would be expected to yield the two common metabolites androsterone and etiocholine. Because the  $\Delta^4$  3 ketone cannot be transformed in metabolism to the  $\Delta$   $3\beta$  hydroxy group the  $C_{19}$  steroids still possessing this grouping should in fact be derived only from dehydroepiandrosterone. Three such indicators in the urine are available to us for consideration. These are dehydroepiandrosterone  $\Delta^5$  androstene  $3\beta$  17 $\beta$  diol and  $\Delta$  androstene  $3\beta$  16 $\alpha$  17 $\beta$  triol. The quantitative measure of any or all of these constituents would in fact be a measure of the endogenously produced dehydroepiandrosterone. On the other hand the measure of androsterone and etiocholine would also be a measure of dehydroepiandrosterone and  $\Delta^4$  androstene 3 17 dione. By noting the difference it should be possible to evaluate quantitatively both of these  $C_{19}$  O androgens.

A similar problem is found with respect to the two  $C_{21}$  steroids 17 $\alpha$  hydroxyprogesterone and 17 $\alpha$  hydroxy 11 desoxycorticosterone. We know that both these compounds can be converted to saturated  $C_{19}$  17 ketosteroids androsterone and etiocholine. By means of




FIGURE 7 Differential *in vivo* metabolism of dehydroepiandrosterone and  $\Delta$  androstene 3,17-dione

the calculations previously suggested it should be possible to estimate the amounts of these steroids derivable from  $C_{17}$  compounds and those that come from the  $C_{21}$  steroids that we are at present considering. Figure 8 outlines our particular problem. It can be seen that the two steroids 17 $\alpha$  hydroxyprogesterone and 17 $\alpha$  hydroxy 11 desoxycorticosterone may be analyzed as a group by three independent measures: first by using the two 17 keto steroids androsterone and etiocholan; second by analysis of pregnane-3 $\alpha$  17 $\alpha$ -diol 20-one; and third by analysis of pregnane-3 $\alpha$  17 $\alpha$  21 triol. All three of these measures, it should be pointed out, indicate the combined production of the two  $C_{21}$  steroids. One additional analysis would have to be done in order to measure each of these compounds. The substance pregnane-3 $\alpha$  17 $\alpha$  21 triol 20-one would be a specific measure of 17 $\alpha$  hydroxy 11 desoxycorticosterone.







FIGURE 8 Differential in vivo metabolism of 17 $\alpha$ -hydroxyprogesterone and 17 $\alpha$ -hydroxy-11-desoxycorticosterone

This compound has already been shown to be a metabolite of the theoretical intermediate or dihydro form. Once the concentration of 17 $\alpha$ -hydroxy-11-desoxycorticosterone can be calculated from an independent index, the precise production of both constituents could be estimated.

We go on now to consider the metabolism of the 11-oxygenated steroids. In Figure 9 we have represented the metabolism of both adrenosterone and 11 $\beta$ -hydroxy- $\Delta^4$ -androstene-3,17-dione. Both these substances are converted to four 11-oxygenated 17-ketosteroids as indicated. It is not possible at the present time to differentiate between the 11 $\beta$ -hydroxy and the 11-keto forms. However, as indicated earlier, it is possible to calculate the endogenous production of  $\Delta^4$ -3-keto-11-oxygenated  $C_{21}H_{32}O$  compounds on the basis of ratios formed in metabolism.

Figure 10 illustrates the metabolism of cortisone and hydrocortisone, and here we have multiple indicators. First, we may

FIGURE III Metabolism of adrenosterone and 11 $\beta$  hydroxy  $\Delta^4$  androstene 3 17 dione




FIGURE 10 . Metabolism of cortisone and hydrocortisone

mention the four 11-oxygenated 17 ketosteroids which are similar to those derivable from the  $C_{19}O_3$  compounds already discussed. We have also considered the manner in which we can calculate the origin of the 11 oxygenated  $C_{19}O_3$  compounds on the basis of ratio studies. Specific indicators of cortisone and hydrocortisone are the unchanged substances but here again we cannot decide whether the endogenously produced material contains an 11 keto or an 11 hydroxy group because this group is interchangeable in metabolism and no generalization or hypothesis can be made as to the factors which influence the interconversions. The tetrahydro derivatives of both hydrocortisone and cortisone are perhaps the most valuable indicators of endogenously produced cortisone and hydrocortisone. These are excreted in the largest amounts perhaps as high as 6 mg per day in the urine of a normal adult. An additional index of hydrocortisone and cortisone production are probably the 21 desoxytetrahydro derivatives but because their concentration is relatively low and methods for their detection are not established we shall not dwell on this point.

*Long* Dr Dorfman has presented this difficult subject very clearly. May I ask what is the spectrum of biological activity obtained with this variety of compound for instance following the administration of cortisone what type of biological activity would the urinary steroids exhibit?

*Dorfman* Cortisone (or hydrocortisone) is excreted as such and therefore we have adrenocortical activity. The conversion to 11 oxygen androsterone derivatives means that androgens are excreted to a small extent. There might be some inhibitors of adrenocortical hormones in the tetrahydro derivatives of cortisone but that has not been definitely established.

*Long* What I have in mind is whether the administration of any of these steroids actually increased the amount of let us say androgenic material in the urine.

*Dorfman* Cortisone yields some urinary androgens.

*Thorn* We have done the androgen assays on cortisone but not the salt retaining assays.

*Young* Is there any indication that steric hindrance can account for some of these differences particularly between 5- $\alpha$  and 5- $\beta$  substances?

*Dorfman* I believe that the basic question in the 5- $\beta$  to 5- $\alpha$  ratio is the enzyme responsible for each of the reductions.

*Young* I think I am right in my belief that if cholesterol is reduced directly with the double bond in the 5-6 position we

obtain cholestanol which is  $5\alpha$ . If we first oxidize the hydroxyl group to ketone so that the double bond is reduced in the 4,5 position we then obtain coprostanol which is  $5\beta$ . That also seems to occur in the intestine. It appears to be related to the steric hindrance and perhaps also to the type of phenomenon that you are concerned with.

*Gallagher* I think it is a question of the enzyme systems that are present. I believe the reduction of these alpha beta unsaturated ketones is biochemically a rapid and complete reaction. The stereochemistry is a result of the enzyme systems that participate in them. I do not believe the analogy can be extended from a platinum catalyst, a hydride or other chemical reducing agent to the biochemical system.

*Young* However there is a difference with inorganic catalysts between the reduction of delta 4,5 and delta 5,6 substances.

*Bloch* On the other hand biologically  $\Delta^4$  cholestenone is reduced to cholestanol to a significant extent.

*Young* Coprostanol is the predominant steroid excreted in feces.

*Bloch* Yes, but if  $\Delta^4$  cholestenone is administered to rats it can be shown that a high percentage of the reduction product is  $5\alpha$ .

*Rall* Dr. Dorfman is the starting point of the synthesis of all these compounds, cholesterol?

*Dorfman* Cholesterol and acetate appear to be precursors of the neutral steroids.

*Rall* I ask this because Dr. Gallagher mentioned the influence of enzyme systems on these reactions and I was wondering which one he had in mind.

*Gallagher* I had in mind only those enzyme systems responsible for the conversions that Dr. Dorfman has been talking about. I was not concerned with the total synthesis.

*Rall* You mean the enzyme systems concerned particularly with acetate?

*Gallagher* Yes, those concerned with the reduction of alpha beta unsaturated ketones and the oxidation-reduction reactions of the 11 hydroxy group and the side chain.

*Rall* Do you have evidence that some enzymes will influence either the rate or the degree of this synthesis?

*Gallagher* No.

*Dorfman* It seems quite likely that two enzymes are present, one which catalyzes reduction to the  $5\alpha$  form and the other to the  $5\beta$  form. However, at the moment we are doing studies on this.

*in vitro* and I think I should point out that certain serious complications have been encountered such as a discrepancy between the *in vivo* and the *in vitro* metabolism

**Long** Where are these enzymes? Are they liver enzymes?

**Dorfman** Liver is a particularly effective source but the kidney also has some I suspect that we should also find them in other tissues if we were to look for them Certainly the enzyme systems concerned with the oxidation or reduction of the oxygen function at carbon 17 are widely distributed in the organism

**Long** Has it been established that the liver is the main organ in which these changes are taking place? What about the biliary excretion of the metabolites or the hepatic circulation of the steroids if the point of attack is largely in the liver? Do these products appear only in the urine after they have circulated through these organs?

**Dorfman** We really have no data on the fecal excretion of neutral steroids but I think Dr Gallagher does and will probably take up this question We have recently reported that when testosterone was administered to patients with biliary fistulas we were unable to detect either androgenic activity of true 17 ketosteroids in the bile These patients received as much as 900 mg per day

**Gallagher** I think there is a real species difference here Dr Long In the rodent with the radioactive steroids cortisone and testosterone there is a very considerable biliary excretion of either the hormone or the end products The principal route of elimination in the rodent is the gastrointestinal tract and as much as 70 per cent of the metabolites of these hormones are found there

In the human however this does not appear to be the case The principal route of excretion is the urine and in the case of these two substances fecal excretion is approximately 10 per cent of the dose administered over as long a period as seven days Usually it is nearer 5 per cent of the total amount of radioactivity administered

**Long** It is an interesting point that there should be this large difference between the species

**Dorfman** That is why we chose the human

**Gallagher** I do believe in contradiction to Dr Dorfman that some material does get into the bile in the human but it may be to a very considerable extent reabsorbed

**Thorn** Regarding the liver enzymes in some preliminary observations which we carried out two or three years ago large doses of steroid were given in the presence of diffuse acute liver disease such as hepatitis It was of interest to note that the patients

handled their cortisone or compound F about as well during the period of illness as they did later when they appeared to be completely recovered as measured by hepatic functional tests. It thus appeared that either recirculation assisted in the metabolism of the steroids or some other mechanism was responsible for the change — a mechanism which does not seem to be interfered with by the liver despite widespread parenchymatous disturbance.

*Rall:* Hepatitis presents a different problem from the point of view of the functional capacity of the liver, than does chronic liver disease.

*White:* Because Dr. Gallagher has worked with labeled compounds in the human and because we have seen so little of the administered material accounted for in the nonlabeled experiments I wonder whether he could indicate where the rest of this material goes. What is the fate of the labeled material if it does not go into the bile in man and if so little relatively, is found in the urine?

*Gallagher:* I cannot provide any factual information. One thinks immediately, of course, of complete oxidation or total degradation of the steroid nucleus and the incorporation of the label into some other pool such as acetate or  $\text{CO}_2$ . The amount of material we used was so small that it was impossible to measure radioactivity in the expired air.

*Bloch:* Did you ever look into the acidic fractions?

*Gallagher:* Yes, of course. There is some material there but the percentage is not large.

*White:* Has there been any opportunity to examine tissues?

*Gallagher:* Certain of our studies bear on that point as well as the one that Dr. Thorn mentioned a few minutes ago. Cortisone disappeared very rapidly from the synovial fluid; indeed the disappearance of radioactivity was quite comparable to the disappearance of sodium ion in the same patient (Figure 11).

*Bauer:* Was that a normal or an inflamed joint?

*Gallagher:* A massive effusion so that samples of fluid could be withdrawn; it was not an inflamed joint. The sample of joint fluid withdrawn about 25 minutes after the introduction of the labeled cortisone had measurable radioactivity. An isotopic dilution with cortisone was made and less than 5 per cent of the radioactivity was still present as cortisone. Apparently either the enzymes in the synovial fluid or the membranes were able to metabolize that hormone and I suspect that this is also true of other tissues.

*Bauer:* There could be a very fast exit from such an articulation.

*Gallagher:* It was a rapid exit.




FIGURE 11 The disappearance of radiocortisone and radiosodium from the synovial fluid of a human subject Reprinted by permission, from Gallagher T F Biochemical problems of the steroid hormones *Chemical Specificity in Biological Interactions* No 3 Chapt V of Harvard Memours New York Academic Press 1954 (pp 50-64)

*Bauer* How much would be due to excretion, and how much to oxidation?

*Gallagher* Of the material that remained in the joint fluid approximately 0.5 mg was still cortisone. Perhaps that is not a tracer amount in the joint but it is still a small quantity. There are limitations in dilution even with radioactive tracers.

*Pincus* Dr Vogt's (18) work on the fate of the corticosteroid activity coming from the adrenal has shown that there was scarcely a tissue which did not very rapidly "utilize" the activity. I suspect that the joint is merely a happy medium. I think practically all attempts to trace corticosteroid in any tissues you may wish to mention will lead to a picture of very rapid disappearance.



handled their cortisone or compound F about as well during the period of illness as they did later, when they appeared to be completely recovered as measured by hepatic functional tests. It thus appeared that either recirculation assisted in the metabolism of the steroids or some other mechanism was responsible for the change — a mechanism which does not seem to be interfered with by the liver despite widespread parenchymatous disturbance.

*Rall* Hepatitis presents a different problem from the point of view of the functional capacity of the liver than does chronic liver disease.

*White* Because Dr. Gallagher has worked with labeled compounds in the human and because we have seen so little of the administered material accounted for in the nonlabeled experiments I wonder whether he could indicate where the rest of this material goes. What is the fate of the labeled material if it does not go into the bile in man and if so little relatively is found in the urine?

*Gallagher* I cannot provide any factual information. One thinks immediately of course of complete oxidation or total degradation of the steroid nucleus and the incorporation of the label into some other pool such as acetate or CO<sub>2</sub>. The amount of material we used was so small that it was impossible to measure radioactivity in the expired air.

*Blach* Did you ever look into the acidic fractions?

*Gallagher* Yes of course. There is some material there but the percentage is not large.

*White* Has there been any opportunity to examine tissues?

*Gallagher* Certain of our studies bear on that point as well as the one that Dr. Thorn mentioned a few minutes ago. Cortisone disappeared very rapidly from the synovial fluid; indeed the disappearance of radioactivity was quite comparable to the disappearance of sodium ion in the same patient (Figure 11).

*Bauer* Was that a normal or an inflamed joint?

*Gallagher* A massive effusion so that samples of fluid could be withdrawn. It was not an inflamed joint. The sample of joint fluid withdrawn about 25 minutes after the introduction of the labeled cortisone had measurable radioactivity. An isotopic dilution with cortisone was made and less than 5 per cent of the radioactivity was still present as cortisone. Apparently either the enzymes in the synovial fluid or the membranes were able to metabolize that hormone and I suspect that this is also true of other tissues.

*Bauer* There could be a very fast exit from such an articulation.

*Gallagher* It was a rapid exit.

Gallagher \* The following figures will answer the question that was asked about the effect of ACTH on the excretion of these metabolites. The subjects were two normal young university men. The study was done by Dr. Thorn and the urines were provided to Dr. L. Dobriner. I did not have much to do with the experiments except to bring them to completion.

Figure 12 is concerned with Subject C-21. In the control period we may observe the 11-oxygenated steroids. There is also another control period and three periods when 20 mg. of ACTH were given intravenously each day. There is a rise in 11-hydroxy androsterone of I think, very significant degree. There is also a rise in 11-hydroxy etiocholanone. The interesting thing is that there is an increase and quite a marked one in the excretion of 11-desoxy steroids following this course of ACTH. That is quite general and we have a number of instances of that response.

We can contrast the situation after administration of compound E in a dose of 500 mg. per day orally. As Dr. Dorfman has indicated the principal metabolite is a derivative of etiocholanone, 16 mg. a day in the second period. The formation of 11-hydroxy etiocholanone indicates again as Dr. Dorfman has pointed out that there is reduction of the 11-ketone group of cortisone. There was a stepwise diminution of the excretion of 11-desoxy steroids.

Figure 13 is the same type of study on another young man, M-21. In this patient there is not quite so marked an increase in androsterone with ACTH, a process which seems to vary in different subjects. Invariably there is an increase in the etiocholanone and in the 11-oxygenated compounds. The cortisone results are much the same; there is the same stepwise decrease of desoxy steroids and a marked increase in 11-ketoetiocholanone.

Bauer: What about the 11-ketoandrosterone?

Gallagher: We find the compound in small amounts and infrequently. It is not an error in technique. Were it present in any reasonable amount we would find it.

I should like to ask Dr. Dorfman what explanation he offers for the fact that the etiocholanone metabolite of "F" or "L" is excreted largely as the ketone, whereas the androstane metabolite is excreted largely as the 11-hydroxy compound.

Dorfman: Our results have also shown that in the 11-oxygenated etiocholanone series the principal quantity of urinary material is in

\*The following grants are gratefully acknowledged: the American Cancer Society, the Anna Filler Fund, the Lilla Babbitt Hyde Foundation, the Teagle Foundation Grants (C-440) and (C-522) of the National Cancer Institute, National Institutes of Health, and the Damon Runyon Memorial Fund.

*Selye* Is there any difference in the disappearance of steroid between an inflamed and normal joint?

*Gallagher* We did not determine this. We did not think we could withdraw enough fluid for satisfactory measurement from a normal joint that is why we took this very abnormal situation.

*Pincus* We\* have done the same experiment *in vitro* by taking joint fluid and incubating hydrocortisone. What Dr. Gallagher says was borne out very definitely. Within half an hour the amount of hydrocortisone was reduced to a very small fraction of the amount originally incubated.

*Baur* Was the synovial fluid cell count high?

*Pincus* All specimens were cleared of cells by centrifuging.

*White* Have you done any bioassays on such incubates after the hydrocortisone has disappeared?

*Pincus* Only on glycogenetic activity which is very much reduced in this case.

*Rall* In the *in vitro* studies did you incubate with any other substances besides cortisone and the synovial fluid? Would it be possible to step up the oxidation? I am thinking of the influence of the enzyme systems that Dr. Gallagher mentioned.

*Pincus* It was not necessary. Within half an hour less than 5 per cent of the hydrocortisone could be accounted for. All the rest was something else.

*Rall* There is no way of inhibiting it either?

*Pincus* No. We stopped those experiments because we felt we should go to the actual enzymes rather than concern ourselves with miscellaneous fluids. We boil the fluid and then we obtain good recoveries.

*Thorn* What happens in the presence of heat?

*Kendall* Nothing.

*Thorn* Isn't there some degradation with heat? Does the compound still maintain its stability?

*Kendall* Yes.

*Mason* One of the pharmaceutical companies prepares the solution by suspending the material in saline and autoclaving.

*Pincus* We have assayed those solutions and the activity is there. I should like to ask what happens when ACTH is administered. Have you done any calculations on that?

*Dorfman* We do not have suitable data as yet.

*Pincus* If there is a predominance of one steroid type rather than the other it might give us a partial answer.

\*Romanoff, E. H. and Pincus, G. Unpublished data, 1953.




FIGURE 13 The effect of ACTH and cortisone upon the excretion of C19 metabolites of steroid hormones in a normal man




FIGURE 12 The effect of ACTH and cortisone upon the excretion of C 19 metabolites of steroid hormones in a normal man

*Dorfman* Administration of progesterone to the rabbit has been done with the isolation of the  $5\beta$  stereoisomer pregnanediol

*Gallagher* That is still a small amount

*Dorfman* However, comparatively speaking it is not because in the normal human only from 10 to 15 per cent of the administered progesterone is obtained as urinary pregnanediol. In the pregnant woman the conversion goes up as high as 30 per cent

*White* The rabbit is a very good case in point. It is pretty well established from a variety of studies *in vivo* that the liver forms the  $5\beta$  isomer from progesterone. Have you done the counterpart *in vitro* with rabbit liver using progesterone?

*Dorfman* We have not done that yet

*Long* If the kidneys are removed in animals is there any possibility of measuring the rate of accumulation in the blood of these various products?

*Dorfman* I see no reason why it could not be done

*Long* I think you mentioned that the kidney may play an important part in changing these metabolites

*Dorfman* In experiments where both liver and kidney tissues were used certain enzymes have been found in both tissues. Their concentrations appeared to be lower in the kidney than in the liver

*Long* Is it possible to make any estimate of what the half life of cortisone injected into the blood stream is?

*Dorfman* Dr. Gallagher, do you have some time studies on that?

*Gallagher* A short time after tracer amounts of less than a milligram of tritium labeled cortisone were injected intravenously we found a very small amount of radioactivity in the blood. Further studies with hydrocortisone are in progress

*Rull* What would you find in the kidney if you measured the radioactivity?

*Gallagher* The metabolites are rapidly excreted. We have not looked in the kidney but have examined the urine. The results I mention have been obtained with humans

*Loeb* Apropos of Dr. Long's question, what is known of the specificity of the renal clearance of these compounds? I think this would be of importance when dealing with such relatively small amounts as appear in urine. I suppose it would be difficult to determine

*Thorn* We have had experience with the excretion of the tetrahydro compound where we obtained very high yields in the urine. These ratios were compared with those obtained from hydrocorti-

the 11 keto form while in the 11 oxygenated androstane series the 11 hydroxy form is major

**Gallagher** Are you speaking of normal people or after the administration of compounds?

**Dorfman** They are the values found in the urine from normal people. I cannot explain these facts at present. It may be the same sort of thing as the influence of the side chain, and the reduction of the double bond carbons 4 and 5.

I should like to make some remarks with respect to the reduction of the  $C_{21}$   $\Delta^4-3$  ketone by *in vivo* and *in vitro* methods. I think it is well to point out at this time that there is a discrepancy which cannot be explained adequately. If we administer any of the  $C_{21}$   $\Delta^4-3$  keto compounds we obtain reduction products primarily of the  $5\beta$  configuration. However the reduced  $C_{21}$  compounds that have been isolated from tissues such as the adrenal are all of the  $5\alpha$  configuration. If one incubates  $C_{21}$   $\Delta^4-3$  ketosteroids with liver or adrenal tissues the primary and almost exclusive reduction products are in the  $5\alpha$  series. Perfusion of both  $C_{19}$  and  $C_{21}$  steroids through rat and bovine tissues again yield  $5\alpha$  reduced steroids. Thus at the moment we have *in vivo* studies on the human which yield for  $C_{21}$   $\Delta^4-3$  ketones predominately  $5\beta$  stereoisomers whereas *in vitro* and isolation studies indicate mostly  $5\alpha$  reduction products.

**Thorn** Do you have any experiments using the material recovered in the urine in experimental animals?

**Dorfman** The urinary excretion in animals at the moment is poorly characterized as compared to studies in humans. We did some steroid metabolism studies years ago on the guinea pig. We have isolated  $5\alpha$  stereoisomers in the  $C_{19}$  series and  $5\beta$  stereoisomers in the  $C_{21}$  series. These experiments were rather crude and the amounts isolated relatively low. We are now approaching this problem in two ways: (a) by observing *in vitro* steroid changes with tissue preparations and also *in vitro* steroid metabolism in the guinea pig and (b) by doing *in vitro* steroid studies on the human liver.

**Gallagher** With respect to Dr Selye's question we made an attempt to study the nature of the metabolites after administration of testosterone to mice. In both the urine and the feces we were unable to obtain the radioactive metabolites in either soluble form.

**Pincus** There are a lot of data on the administration of progesterone in the rabbit.

tion If they were both short we should anticipate that there would have to be a high rate of ACTH activity which continued for a long time On the other hand if the half life of cortisone were long we would only need to have a brief stimulus with ACTH and the effects from the adrenal hormones would be prolonged

*Astwood* Just because the substance is only there for a minute does not mean that the effect may not last for a long time

*Long* That is true but perhaps we should not speculate too far

*Li* Is it also possible that the hormone when injected into the body appears in a different form? Cortisone itself disappears in one minute yet it might be converted into some other substance and so escape detection

*Long* It should still have biological activity

*Bauer* And also pick up radioactivity

*Long* What I am trying to get at is this has anyone done an experiment of injecting cortisone into the blood and then sampling the blood at various intervals?

*Pincus* I believe the radioactivity experiment is the complete answer If there are any metabolites circulating in the blood radioactivity should be observed even if the metabolites are not identified

*Thorn* Since the conjugated material seems to disappear so rapidly from the blood stream one would anticipate that the biological activity would fall off in a matter of a few minutes

*Rall* If it is true that the biological activity is decreasing so rapidly how do you account for its therapeutic effect?

*Thorn* Probably because the effect it produces metabolically persists after its initiation and requires time to return to the normal or low normal level We know for instance how rapidly a patient may escape from the salt retaining effect of a steroid when it is administered intravenously However if the period of administration has taken place over a period of time and if for instance the patient has accumulated an appreciable positive sodium chloride balance then it will require a number of hours before the kidney effectively excretes the accumulated sodium chloride Thus the patient would not show the signs of the disappearance of the sodium chloride retaining effect until the accumulated salt had been excreted and a negative balance had begun to develop

*Rall* The trouble with that argument is that if what you are saying is true apparently the size of the dose would not affect the rapidity with which it is degraded It is being degraded at a very rapid rate



sone and desoxycorticosterone, endogenous creatinine excretion under fasting conditions forming the basis of reference

Bauer Leaf\* has some data on humans but unfortunately it was obtained from individuals suffering from diabetic acidosis and extensive hemorrhage with reduction of renal function. However apropos of Dr Long's question it would be of interest to do the same type of experiment on a heart lung kidney preparation it would not make it any easier to localize the site of action but it would provide a simpler system for study.

Gallagher It seems to me with respect to the kidney threshold that for the hormones themselves this barrier must be appreciable. There is little unaltered hormone in the urine. On the contrary the kidney threshold for conjugated metabolites must be very nearly nonexistent because they are at such a low level in the blood stream and yet appear in the urine.

Selye In connection with the question of the half life of corticoids and the much discussed problem of their possible "utilization" while they perform their antiphlogistic effects it is perhaps relevant to mention a few recent experiments performed with the "granuloma pouch" technique which I outlined last year at our meeting.

You will remember that in this procedure a definite cavity is formed under the skin by the injection of air and into this an irritant is introduced so as to produce inflammation. We have now found that there is a definite critical period during which inflammation can best be prevented by a minimum amount of cortisone or hydrocortisone (19). Under our experimental conditions this critical period happened to occur 72 hours after introduction of the irritant. It is well to emphasize that if the antiphlogistic hormone (e.g. cortisone) and the irritant are introduced simultaneously there is very little inhibition. Similarly the injection of such hormones into the granuloma pouch after five or six days of exposure to croton oil is also quite ineffective in preventing inflammatory changes.

I wondered whether the chemists of our group could not make use of this technique for the study of cortisone utilization. It would be interesting to determine whether the disappearance and destruction of the hormone are actually greater during the critical period when it does some good than at other times when it fails to elicit any demonstrable actions.

Long We know that ACTH has a half life in the circulation of only a minute or two. Is the half life of cortisone equally short? If so it bears upon the entire problem of the rate of adrenal secre-

\*Leaf A Massachusetts General Hospital Boston Unpublished data

tion If they were both short we should anticipate that there would have to be a high rate of ACTH activity which continued for a long time On the other hand if the half life of cortisone were long we would only need to have a brief stimulus with ACTH and the effects from the adrenal hormones would be prolonged

*Astwood* Just because the substance is only there for a minute does not mean that the effect may not last for a long time

*Long* That is true but perhaps we should not speculate too far

*L<sub>1</sub>* Is it also possible that the hormone when injected into the body appears in a different form? Cortisone itself disappears in one minute yet it might be converted into some other substance and so escape detection

*Long* It should still have biological activity

*Bauer* And also pick up radioactivity

*Long* What I am trying to get at is this has anyone done an experiment of injecting cortisone into the blood and then sampling the blood at various intervals?

*Pincus* I believe the radioactivity experiment is the complete answer If there are any metabolites circulating in the blood radioactivity should be observed even if the metabolites are not identified

*Thorn* Since the conjugated material seems to disappear so rapidly from the blood stream one would anticipate that the biological activity would fall off in a matter of a few minutes

*Rall* If it is true that the biological activity is decreasing so rapidly how do you account for its therapeutic effect?

*Thorn* Probably because the effect it produces metabolically persists after its initiation and requires time to return to the normal or low normal level We know for instance how rapidly a patient may escape from the salt retaining effect of a steroid when it is administered intravenously However if the period of administration has taken place over a period of time and if for instance the patient has accumulated an appreciable positive sodium chloride balance then it will require a number of hours before the kidney effectively excretes the accumulated sodium chloride Thus the patient would not show the signs of the disappearance of the sodium chloride retaining effect until the accumulated salt had been excreted and a negative balance had begun to develop

*Rall* The trouble with that argument is that if what you are saying is true apparently the size of the dose would not affect the rapidity with which it is degraded It is being degraded at a very rapid rate

*Thorn* I believe that is true over quite a wide range of dose schedules. If steroid is given as a single rapid intravenous administration in general a prolonged effect of the hormone will not be obtained unless of course a massive amount of material is infused whereas giving the same amount of material intramuscularly where it is absorbed more slowly, produces quite a marked prolongation of the physiological effect.

*Long* In this connection there is one interesting experiment by Love (20) who injected epinephrine and immediately removed the adrenals just as fast as he could take them out and then followed the fall in the eosinophils. He found he could not take the adrenals out fast enough to prevent the fall in the eosinophils once the gland had been stimulated. This must have been due to the adrenocortical hormone put into the blood stream between the injection and adrenalectomy.

*Selye* Do I understand correctly that Dr. Gallagher feels the destruction of the corticoid is so rapid that such comparisons cannot be readily made?

*Gallagher* I did not use the term destruction. I said disappearance. It may be metabolized and excreted during that time.

*Selye* What I mean is this: in a granuloma pouch there is a closed cavity in which the lining is inflamed. If hormone is injected into it during the critical period the inflammation will be inhibited but if it is injected at any other period the inflammation will not be inhibited. I wonder whether the long debated question concerning the utilization of hormones for the performance of their activity could be successfully analyzed with this technique by comparing the rate of destruction during a given time interval for example at the critical period when the hormone is effective and at another time when the hormone is not effective.

*Bauer* The physiological state is quite different in the two types of experiments that you relate. In your initial experiment in which the two agents are injected simultaneously there is good lymphatic drainage whereas once inflammation is induced there is some obstruction of lymphatics. If they leave by way of the lymphatic rather than the vascular system it would not tell you very much. It might be another way of measuring lymphatic drainage.

*Selye* I do not think this is very likely because we are giving hydrocortisone acetate in the form of crystals and the crystals remain there for days; they may be seen by simple inspection.

*Bauer* However, your fluid exchange in these experiments is dependent in part upon the potency of the lymphatics in the one

instance they would be relatively normal in the other there might be considerable blockage of the lymphatics

*Pincus* One of the interpretations is that a proinflammatory substance is brought in early by the blood stream. With the blockade of that area or of the lymphatics the hydrocortisone is present in relatively excessive amounts during the critical seventy two hour period. I do not know what might happen after that period.

*Thorn* May I go back to Dr. Rall's original problem. If a free form of the hormone is injected intravenously there are not many physiological mechanisms which are sensitive enough to be measured significantly by hourly titration. One of these however would be the renal excretion of electrolytes. We know that within two hours one notes a reduction in the level of sodium excretion with a constant infusion of sodium and of hormone. One must use a constant infusion of sodium or else it is difficult to interpret the falling off of sodium excretion if hormone is given intravenously without additional sodium chloride. However with the constant infusion of sodium and hormone and the considerable retention of sodium one ultimately builds up a pressure head in which one observes an increasing escape from the effect of a constant level of hormone as measured by a gradual rise in sodium excretion. On the other hand the moment one discontinues the hormone infusion there is a much more rapid rate of escape and an increased excretion of accumulated sodium.

*Rall* If you were going to study renal clearances that would be the ideal way to do it. At the time you were infusing a constant amount of the hormone simultaneous clearances could be done for the hormone as well as for sodium chloride.

*Selye* In connection with the remarks of Drs. Bauer and Pincus I should like to repeat that in my opinion it is very unlikely that lymphatic blockade would be responsible for the observed effect. Hydrocortisone proves to be most effective during the critical period even when it is administered systemically at a distance from the pouch so that there can be no question of it being "trapped" at the site of inoculation in the pouch.

*Bauer* When it is given parenterally during the first 72 hours the entrance into the pouch will be more rapid than it will be later because any acute inflammation permits a more rapid rate of entrance. In the early stage of inflammation there may be no lymphatic blockage.

I am speaking of the articular cavity we have had a limited experience with artificial cavities of the type you mention.

*Long* What is known of the fixation of the corticosteroids by the tissues?

*Gallagher* We have attempted to study the question in mice (21) We came to the conclusion that the time cortisone resides in tissues in measurable amount must be a matter of minutes We did indeed find a slightly different tissue distribution within the first three minutes or as soon as we could kill the animals after intravenous infusion There appeared to be more radioactivity in the skin and the carcass than ten minutes after the administration of the hormone Certainly after an hour we do not find any localization in any organs except the liver and the gastrointestinal tract

*Thorn* Probably the most sensitive indicator in man is the Addisonian patient who has had no cortisone for several days prior to the study If under these circumstances a small constant infusion of cortisone is given over a 48 or 72 hour period one observes that equilibrium or at least a constant rate of excretion of hormone is not attained in the first 24 hour period This suggests that in the Addisonian receiving minimal doses of cortisone there is a pool which needs to be filled in the tissues before equilibrium of excretion is attained In normal subjects with intact adrenals given 100 mg of hormone intravenously one does not attain equilibrium by the end of an 8 hour period of infusion of hormone at the rate of 12.5 mg per hour

*Gallagher* The metabolites of hormones are rapidly eliminated as evidenced in Figure 14 Perhaps you will question the amounts we have given and I should not disagree with you During zero to five hours 16 mg of labeled testosterone are infused (22) That may be too large an amount possibly it is However while the infusion is in process more than a third of the material infused is in the urine in the form of definite and recognized metabolites

*Thorn* Is this instantaneous administration?

*Gallagher* No the hormone is given as evenly as possible over a period of four hours

*Pincus* Dr Gallagher I think the problem may be something like this there is a certain retention of radioactivity so over a period of days a tiny amount of material begins to come out What is it and where does it go? Is that the only really active material and is the remainder of little significance?

*Gallagher* I shall debate it but I do not know the answer 16 mg may be too much to give in that period of time The reason we chose that dose was to compare it with other experiments and permit the use of both  $C^{14}$  and deuterium as tracers We have since




FIGURE 14 Excretion of androsterone and etiocholanolone in the urine of a man (Subject F) at intervals after a single injection of 16 mg of testosterone-d 4 C<sup>14</sup>. Reprinted by permission from Gallagher T F Bradlow H I Fukushima D K Beer C Kritchewsky T H Stokem M Edinoff M L Hellman L and Dobriner J Studies of the metabolites of isotopic steroid hormones in man Recent Progr Hormone Research 9 411 (1954) (Academic Press)

repeated the studies with tracer doses but have not finished the work as yet

Pincus The only clue we have for this sort of thing is in immunization or local application experiments such as in anti-inflammatory test in the mouse and according to Dougherty (23) hydrocortisone would be active locally in a very small fraction of the microgram Is that correct?

White Yes

Bauer That is not surprising if one consider it in terms of molecules instead of milligrams

Pincus I do not think it is surprising The point I am trying to make is that perhaps the active material which is localized is so small that ordinarily we cannot measure it I think that may be the answer to Dr Gallagher's experiment After all there is a limit to the amount of radioactivity that can be measured in tissues

Long Dr Gallagher if you could do the experiment again would it be worth trying something similar to what Stadie (24) has

*Long* What is known of the fixation of the corticosteroids by the tissues?

*Gallagher* We have attempted to study the question in mice (21) We came to the conclusion that the time cortisone resides in tissues in measurable amount must be a matter of minutes We did indeed find a slightly different tissue distribution within the first three minutes or as soon as we could kill the animals after intravenous infusion There appeared to be more radioactivity in the skin and the carcass than ten minutes after the administration of the hormone Certainly after an hour we do not find any localization in any organs except the liver and the gastrointestinal tract

*Thorn* Probably the most sensitive indicator in man is the Addisonian patient who has had no cortisone for several days prior to the study If under these circumstances a small constant infusion of cortisone is given over a 48 or 72 hour period one observes that equilibrium or at least a constant rate of excretion of hormone is not attained in the first 24 hour period This suggests that in the Addisonian receiving minimal doses of cortisone there is a pool which needs to be filled in the tissues before equilibrium of excretion is attained In normal subjects with intact adrenals given 100 mg of hormone intravenously one does not attain equilibrium by the end of an 8-hour period of infusion of hormone at the rate of 12.5 mg per hour

*Gallagher* The metabolites of hormones are rapidly eliminated as evidenced in Figure 14 Perhaps you will question the amounts we have given and I should not disagree with you During zero to five hours 16 mg of labeled testosterone are infused (22) That may be too large an amount possibly it is However while the infusion is in process more than a third of the material infused is in the urine in the form of definite and recognized metabolites

*Thorn* Is this instantaneous administration?

*Gallagher* No the hormone is given as evenly as possible over a period of four hours

*Pincus* Dr Gallagher I think the problem may be something like this there is a certain retention of radioactivity so over a period of days a tiny amount of material begins to come out What is it and where does it go? Is that the only really active material and is the remainder of little significance?

*Gallagher* I shall debate it but I do not know the answer 16 mg may be too much to give in that period of time The reason we chose that dose was to compare it with other experiments and permit the use of both  $C^{14}$  and deuterium as tracers We have since

*Roll:* Very large doses were given so that there would be enough material to analyze. You also speak about the infinitely small amount that is needed to start these reactions. When you give large doses are you measuring what goes on under normal circumstances?

*Dorfman:* To answer that partially I should say that although we have worked with doses of hormones from 50 to 500 mg. we have not as yet seen any qualitative differences in urinary products. Actually in many instances we have even observed comparable quantitative figures for individual constituents.

*Long:* Can you make a kind of rough calculation on what these small amounts are? I think you gave us a figure this morning for cortisone or hydrocortisone production of around 20 mg. a day as being necessary to maintain an adrenalectomized individual. That is a rate of secretion of about 1 milligram an hour and if that is put into 50 kilos of body water obviously the effect of concentration any time during the hour is very low. Assuming equal distribution when 500 mg. is given it is at least 25 times the effective blood concentration since the quantity in the blood at any one time of a normal individual under ordinary circumstances is very low indeed. A rate of production of about a milligram an hour is sufficient to maintain that quantity.

*Thorn:* There are two comments I might make. First, there is considerable evidence that the normal individual does not secrete hormone at the rate of 1 milligram per hour throughout the hours. The active period of secretion appears to be concentrated quite heavily in the 12 hours of the day. Secondly, if one gives an Addisonian patient a milligram per hour of hormone around the clock the physiological reaction is very intense and quite different from that following the single administration of 25 mg. once a day.

*Gallagher:* If I understand what you say you believe that the 20 mg. per day estimate of production is a high value. Do you believe that it is smaller than that amount?

*Thorn:* I would assume that the gland puts out at least 20 mg. or more of hormone per day but that the secretion of this material is concentrated in a very short period of the day and therefore the physiological effect is appreciably less than if the material were secreted evenly throughout the 24 hour period. This emphasizes the point that it is not enough to know the total secretion of the gland in order to estimate its physiological effect; one must also know the time during which that secretion has occurred because that also has a very important effect on the total physiological action. The ratios which Drs. Jenkins and Laird in our laboratory



recently done with the isolated diaphragm where it is immersed in the solution for a short period of time and then washed free of all materials attached to it so that the amount of these materials can be determined? Stadie used this very successfully in the demonstration of the fixation of insulin

*Thorn* We thought that with the radioactive compound F one might study in adrenalectomized patient or animal given a very minute quantity of the substance so that one might analyze return blood flow from various organs and areas of the body in an attempt to trace the fixation or localization of the initial dose of hormone

*Bloch* From the fact that the 9 chloro compounds are 3-4 times more active than E or F could one not argue that conversion to more active forms occur?

*Gallagher* That can be interpreted otherwise of course I should suspect that the chloro compounds are more active because they are less readily metabolized

*White* In a local area where a good measurement of F or E like activity can be obtained it ought to be possible with micro-techniques of identification of E or F to ascertain whether there is histological evidence of persistence of activity at a time when there is no microchemical evidence of the existence of either E or F

*Pincus* We touched upon that earlier in discussing the disappearance of F *in vitro* from joint fluid It would not answer the question we are discussing because what is active is a very small amount of material and what one measures may be the excess It is a very difficult problem I think the Stadie technique is very much more definite

*Rall* In Figures 12 and 13 I think Dr Gallagher presented the injection of substances in normal human subjects I notice cortisone was given and the effect of ACTH on the secretion of certain substances was compared to that of cortisone You gave 500 mg of cortisone a day to these normal subjects?

*Gallagher* Dr Thorn did

*Rall* That is a rather large dose is it not?

*Thorn* Yes I should say so

*Dorfman* It was because of Dr Thorn's experiments that we were able to do most of our early studies on cortisone

*Thorn* The dose was calculated from the chemists' expectations of the amount of material which might be recovered based on the known small proportion of material which would be likely to be excreted

be adequate for this purpose. Of course one does not like to give a larger dose because then the continued action would carry over to the next day's study. From our study on the Addisonian patient under constant hydrocortisone infusion we conclude that the diurnal variation which we observe in normal individuals is probably the result of alteration in secretory activity of the gland rather than a constant 24 hour secretory activity with alteration in metabolic function, let us say in the liver and kidney.

**Bauer:** You therefore conclude that diurnal variations require adrenal glands?

**Thorn:** Yes, we believe that the diurnal variation requires a marked change in secretory activity of the gland. We are particularly interested in the fact that although this variation is very sensitive and we are able to pick it up easily with our present methods of study, this contrasts with the remarks I made a year or two ago when we pointed out that rather severe stresses do not produce a marked change in the secretory activity of the gland as measured by our methods. Thus it is interesting to speculate on the magnitude of the diurnal variation and its sensitivity throughout the 24 hour period and yet its resistance is to a large extent to externally imposed stress during the 24 hour period.

**Bauer:** How much variation do you find in the secretion of the Addisonian patient or an adrenalectomized individual?

**Thorn:** We give our hormone cyclically and of course the individual eats cyclically. Both of these factors would tend to establish some rhythm in the Addisonian patient under ordinary treatment. We are at present trying to establish the level of hydrocorticosteroid excretion in an Addisonian patient maintained on a more constant regimen throughout the entire 24 hour period.

**Astwood:** I think Dr. J. D. Rosenbaum (25) demonstrated that there was a diurnal variation in water and salt excretion?

**Bauer:** Would the diurnal variation in the Addisonian patient be the same as in the normal person?

**Thorn:** One might anticipate a diurnal variation in water and salt excretion in adrenalectomized patients or patients with Addison's disease who are untreated since there are other known factors which modify the excretion of salt and water and which presumably would be functioning under these circumstances.

**Rall:** I wondered whether Dr. Pincus had any data on the diurnal variation in the mentally disturbed or agitated patient.

**Pincus:** We published something on that several years ago. It is quite different from the normal but there are individual variations.

have obtained would indicate that in general three times as much hormone may be secreted during the period of 7 00 a m to 1 00 p m and from 1 00 p m to 5 00 7 00 p m as occurs overnight

Ingle Dr Thorn, may I ask a question that is a bit off the subject? There are cyclic changes in the level of eosinophils throughout the day that have been attributed to cyclic changes in the release of hormones by the adrenal cortices. Have you done the experiment of giving adrenalectomized or Addisonian patients a constant intake of steroid by continuous injection and then following the eosinophils to determine whether that cycle is abolished?

Thorn I am not as certain about the eosinophil cycle in the Addisonian patient as I am about the excretion of steroid in the urine. With respect to the latter we know that the diurnal variation of hormone excretion is minimal when a constant infusion of cortisone or hydrocortisone is given intravenously over a 48 or 72 hour period in an Addisonian patient. We also know that the eosinophil fluctuations are much less in the Addisonian than in the normal person. We do not as yet have adequate data on whether or not a constant infusion of cortisone completely stabilizes the eosinophil level throughout the 24 hour period in an Addisonian patient.

Loeb When you say diurnal variation in excretion of material which material do you have in mind?

Thorn Total 17 hydroxycorticoid and 17 ketosteroid as well

Bauer Do you observe a diurnal variation when you have given a constant infusion for 24 hours?

Thorn The normal pattern is one of high secretion from 7 00 a m to 7 00 p m and of low secretion from 7 00 p m to 7 00 a m. The cut off points do not correspond to these hours but these 12 hour periods show the major day to night variation. We are interested in investigating people who are working at night to see whether the diurnal variation is altered by this type of activity. ACTH administered in the evening will increase the night secretion and excretion of hormone and can reverse the day to night ratio. The constant infusions to which I referred were constant infusions of hydrocortisone in an Addisonian patient where one can eliminate spontaneous variations in endogenous secretion from the adrenal.

Bauer The patient is on constant infusion?

Thorn No the 3:1 ratio day to night preponderance is a phenomenon which we observed in normal individuals. It can be altered under severe psychological stress. It is not affected appreciably by a 24 hour starvation period but can as I said be modified by the administration of ACTH. Four or five units of the ACTH gel may

be adequate for this purpose. Of course one does not like to give a larger dose because then the continued action would carry over to the next day's study. From our study on the Addisonian patient under constant hydrocortisone infusion we conclude that the diurnal variation which we observe in normal individuals is probably the result of alteration in secretory activity of the gland rather than a constant 24 hour secretory activity with alteration in metabolic function let us say in the liver and kidney.

*Bauer* You therefore conclude that diurnal variations require adrenal glands?

*Thorn* Yes we believe that the diurnal variation requires a marked change in secretory activity of the gland. We are particularly interested in the fact that although this variation is very sensitive and we are able to pick it up easily with our present methods of study this contrasts with the remarks I made a year or two ago when we pointed out that rather severe stresses do not produce a marked change in the secretory activity of the gland as measured by our methods. Thus it is interesting to speculate on the magnitude of the diurnal variation and its sensitivity throughout the 24 hour period and yet its resistance is to a large extent to externally imposed stress during the 24 hour period.

*Bauer* How much variation do you find in the secretion of the Addisonian patient or in adrenalectomized individual?

*Thorn* We give our hormone cyclically and of course the individuals cyclically. Both of these factors would tend to establish some rhythm in the Addisonian patient under ordinary treatment. We are at present trying to establish the level of hydroxysteroid excretion in an Addisonian patient maintained on a more constant regimen throughout the entire 24 hour period.

*Astwood* I think Dr J D Rosenbloom (25) demonstrated that there was a diurnal variation in water and salt excretion?

*Bauer* Would the diurnal variation in the Addisonian patient be the same as in the normal person?

*Thorn* One might anticipate a diurnal variation in water and salt excretion in adrenalectomized patients or patients with Addison's disease who are untreated since there are other known factors which modify the excretion of salt and water and which presumably would be functioning under these circumstances.

*Rall* I wondered whether Dr Pincus had any data on the diurnal variation in the mentally disturbed or agitated patient.

*Pincus* We published something on that several years ago. It is quite different from the normal but there are individual variations.

There are some individuals who show good diurnal rhythms and others who show very poor ones. Among psychoneurotics particularly, there are individuals who show no diurnal changes. They go right along as if they were secreting at the same rate morning and night.

*Bauer* Even though they sleep well?

*Pincus* Yes. The psychiatrists suggest that these are people who have rather interesting dreams.

*Thorn* Dr. Dorfman in view of what you said earlier one might anticipate that in emaciated patients a low 17 hydroxysteroid excretion and a low 17 ketosteroid excretion could be easily explained. Recently however we encountered a patient who had a high 17 ketosteroid excretion and a low total 17 hydroxysteroid excretion by the method which we employ. However when given ACTH this patient showed a completely normal response in terms of a marked increase in 17 hydroxysteroid and 17 ketosteroid excretions and furthermore, when given a known quantity of hydrocortisone the anticipated excretion of 17 hydroxysteroids in the urine occurred. I wonder what your explanation might be for this unusual picture of high 17 ketosteroids and low 17 hydroxysteroids in a female patient.

*Dorfman* If you had some of those extracts it would be very interesting to study the difference in this particular patient between 11 oxygenated and the 11 desoxyketosteroid. That would be an important fact to establish. Did she have any signs of hirsutism or masculinization?

*Thorn* No.

*Dorfman* The fact that 17 hydroxysteroids are decreased would indicate that the hydrocortisone production should be decreased which would mean in turn that the 11 oxygenated compounds of etiocholane type coming from the  $C_{21}$  compounds should also be reduced. Thus this would suggest that the precursors which would be increased in this particular individual would be the  $C_{19}O$  ( $\Delta^4$  androstene 3,17 dione) or  $C_{19}O_2$  (adrenosterone) type. An analysis of the individual constituents would give us a more precise understanding of the problem.

*Thorn* That is interesting because given a test dose of F this patient excreted the predicted ratio of 17 keto to 17 hydroxy so it did not seem to be primarily a shift in the metabolism. I was wondering what your thought was on the secretion of the adrenal at that time.

*Gallagher* May I ask why you measured ketosteroids in this woman?

*Thorn* Yes This was a long term study of a patient whose physical appearance was normal but who was psychologically disturbed and we were interested in observing the reaction of her adrenals at that time Later on it was of interest to note that she spontaneously reverted to the more normally expected 17 hydroxy 17 keto ratio in the urine

*Pincus* What were the ovaries like?

*Thorn* We do not know because no operation was performed We saw the reverse of this situation in other severely stressed individuals in conjunction with the studies of Dr Francis D Moore\* of the Peter Bent Brigham Hospital Boston on patients after serious burns or major surgery In these cases we observed a maintenance at a high level of 17 hydroxysteroids with an initial rise in 17 ketosteroids and a subsequent reduction in 17 ketosteroid excretion to normal or low normal levels with a persistent high level of 17 hydroxy secretion This is the first time that we have observed a reversal in the opposite direction and a spontaneous recovery

*Rall* Dr Pincus have you determined these substances in the disturbed individual before and after electroshock therapy which can arrest the agitation and return the patient within 48 hours to a completely relaxed state?

*Pincus* We have not studied that in detail

*Dorfman* Within 24 hours after electroshock we have seen increases in both 17 ketosteroids and corticoids determined by the formaldehydogenic method

*Rall* When the patient comes into the quiescent phase what happens?

*Dorfman* We have never studied them at that time All we know is that therapeutic shock certainly calls forth definitive increases within a 24 hour period

*Rall* As compared to excretion during the control period before therapy?

*Dorfman* That is right

*Thorn* Since this patient showed the normal anticipated response

---

Moore F D Steenburg R W Ball M H Wilson C M and Myrden J A Studies in surgical endocrinology I The urinary excretion of 17 hydroxycorticoids and associated metabolic changes in cases of soft tissue trauma of varying severity and in bone trauma (In preparation)

to the administration of cortisone and hydrocortisone, it is difficult to assume that there was a metabolic aberration at this time accounting for an altered metabolism of the steroids once secreted. Since she showed the normal response in 17 hydroxy and 17 ketosteroid values following ACTH the gland was able to respond normally to exogenous ACTH. That was why I was interested in Dr Dorfman's explanation of the physiological significance of the altered ratio.

*Dorfman* I cannot explain the ACTH stimulation data in this patient unless the amount of ACTH she secreted was at a minimum level—enough for certain reactions to proceed but not others. When ACTH is administered essentially all the necessary enzymes are brought into play.

*Thorn* You suggest that a qualitative difference in the ratio of 17 hydroxy and 17 ketosteroid in the urine might be due to a quantitative difference in the level of ACTH secretion.

*Dorfman* That is right.

*Long* When large quantities of these steroids are administered do any appear in the spinal fluid?

*Dorfman* I do not know of any evidence for or against that.

*Thorn* I believe studies have been made on this point although we have not done any of them. We were interested in the problem however during our experiments on the effect of ACTH and cortisone in patients with long standing multiple sclerosis.

*Pincus* In regard to our problem Dr Oscar Hechter has some data which may be pertinent\*. He has been giving rabbits ACTH and then sampling the adrenal vein blood. A rabbit is an animal which if you just take it as it comes secretes mostly compound B corticosterone and after the initial ACTH administration there is an increase in B output. However after a matter of weeks of administration compound B practically disappears and only compound F is found. Thus I think there is a possibility that a qualitative change may occur under such circumstances. However this is an extreme instance.

*Thorn* If you believe that the low dosage of ACTH gives rise to this abnormal ratio are you able to account for the fact that patients with inanition who have low 17 hydroxysteroids also have low 17 ketosteroids?

*Dorfman* In inanition as I recall the evidence tends to indicate a normal corticoid excretion by the older methods is compared to the 17 ketosteroid which does significantly decrease.

\*Kass E, Hechter O, Macchi I A and Ascock H. Unpublished data 1959.

Actually it would be a reverse picture of this. After a relatively intense stress such as a severe burn the corticoids stay up for about five days while the 17 ketosteroids go up immediately and are below normal within one to two days. The latter do not return to normal for about 10 to 12 days. We observed that in our early studies with burned and infected patients in collaboration with Dr Shipley (26) This was a period when many investigators showed this type of diagram and we obtained it too. However after that we ran a number of these experiments and did not always see it and I think I should agree with Dr Gallagher that it is not an invariable pattern. Perhaps it depends on the type of stress, duration and other circumstances so it warrants further study I think.

*Conn:* We have been interested too in the stress pattern and generally have obtained the elevation of both types of steroids initially. This is followed by a decrease in the 17 ketosteroids with the 17 hydroxycorticoids remaining elevated for the longer period of time. An interesting thing happens in patients with chronic liver disease. Administration of steroidal compounds that increase 17 ketosteroid excretion in normal people fails to increase significantly the 17 ketosteroid excretion in patients with this disease. We had an opportunity to study urinary steroidal excretions in a patient with severe liver disease on whom major surgery was performed. The operation resulted in no increase at all of urinary 17 ketosteroids but we observed the highest values for formaldehydrogenic steroids which we have ever obtained in our laboratory. This suggests that much of the increase of urinary 17 ketosteroids observed after severe stress is derived from 17 hydroxycorticoids and that this conversion is a function of the liver.

This again brings up the point regarding some of the enzymatic activities of the liver versus the kidney in this respect. In the case cited the liver was abnormal the kidneys were presumably capable of making the transformations but did not. Also we may have a partial answer to the question Dr White brought up with respect to diurnal variation in the eosinophils in Addisonian patients receiving a fairly constant amount of cortisone. We did not administer the cortisone intravenously as Dr Thorn did but we gave 5 mg orally every four hours throughout the 24 hour period and found no diurnal variation in eosinophils under those circumstances. In addition we applied the stress of exercise in an effort to see whether exercise superimposed on those circumstances might induce eosinopenia. However it failed to occur under those circumstances.



to the administration of cortisone and hydrocortisone it is difficult to assume that there was a metabolic aberration at this time accounting for an altered metabolism of the steroids once secreted. Since she showed the normal response in 17 hydroxy and 17 ketosteroid values following ACTH the gland was able to respond normally to exogenous ACTH. That was why I was interested in Dr. Dorfman's explanation of the physiological significance of the altered ratio.

*Dorfman:* I cannot explain the ACTH stimulation data in this patient unless the amount of ACTH she secreted was at a minimum level—enough for certain reactions to proceed but not others. When ACTH is administered essentially all the necessary enzymes are brought into play.

*Thorn:* You suggest that a qualitative difference in the ratio of 17 hydroxy and 17 ketosteroid in the urine might be due to a quantitative difference in the level of ACTH secretion.

*Dorfman:* That is right.

*Long:* When large quantities of these steroids are administered do any appear in the spinal fluid?

*Dorfman:* I do not know of any evidence for or against that.

*Thorn:* I believe studies have been made on this point although we have not done any of them. We were interested in the problem however during our experiments on the effect of ACTH and cortisone in patients with long standing multiple sclerosis.

*Pincus:* In regard to our problem Dr. Oscar Hechter has some data which may be pertinent.\* He has been giving rabbits ACTH and then sampling the adrenal vein blood. A rabbit is an animal which if you just take it as it comes secretes mostly compound B corticosterone and after the initial ACTH administration there is an increase in B output. However after a matter of weeks of administration compound B practically disappears and only compound F is found. Thus I think there is a possibility that a qualitative change may occur under such circumstances. However this is an extreme instance.

*Thorn:* If you believe that the low dosage of ACTH gives rise to this abnormal ratio are you able to account for the fact that patients with inanition who have low 17 hydroxysteroids also have low 17 ketosteroids?

*Dorfman:* In inanition as I recall the evidence tends to indicate a normal corticoid excretion by the older methods as compared to the 17 ketosteroid which do significantly decrease.

\*Kass, E., Hechter, O., Macchi, I. A. and Aylcock, H. Unpublished data, 1953.

of this disease by saying that these individuals do not have a demonstrable adrenal cancer nor do they show significant masculinization. We shall consider the overt signs of overproduction of androgenic substances and the absence of any significant amount of metabolic disease due to overdosage of hydrocortisone. Finally, our classification of adrenal hyperplasia (adrenogenital syndrome) will refer to those patients who show typical masculinization but are free of cancer and who do not reveal the metabolic effects of excessive amounts of hydrocortisone and cortisone.

*Thorn:* For purposes of clarification would you be willing to change your classification and make Cushing's syndrome represent bilateral hyperplasia so that we do not have both clinical syndromes and anatomical characterizations as the basis for your classification? This might be quite confusing in our subsequent discussion.

*Dorfman:* Let me present them as I have it and then you will tell me where corrections are necessary.

*Loeb:* I think most of us would call the "adrenogenital syndrome" your final item?

*Dorfman:* Yes "adrenogenital syndrome" would be a better term than "adrenal hyperplasia."

As a background for our consideration of the biochemical differentiation between the different types of adrenal hyperactivity it may be profitable first to consider the normal adrenocortical hormone production. The events on the basis of the best available information plus of course some speculation are listed in Figure 15. The thicknesses of arrows indicated in this figure should serve as guides for the following three figures numbered from 16 to 18 in which changes or modifications in amounts of hormones at various points are indicated. Although the relative thickness of these lines are not considered to be absolute they are indicative of the relative amounts of steroids produced at any given level.

Starting with the pituitary control of the adrenocortical hormone production we consider ACTH as a crucial stimulus acting upon the adrenal cortex in two distinct manners. ACTH (either one or more principles) is responsible for the growth and maintenance of the adrenal cortex and also is concerned with the transformation of cholesterol and smaller particles to the steroids which are eventually converted to adrenocortical hormones ( $C_{21}$ ) and androgenic hormones ( $C_{19}$ ).  $\Delta^4$ -Pregnene 3 $\beta$  or 20 one (pregnenolone) and dehydroepiandrosterone are considered to be these "first" sub

*Thorn* However I believe that you might have obtained it if the stress had been severe enough. We have seen eosinopenia develop in patients with Addison's disease when there had been acute serious illness prior to the administration of cortisone.

*Conn* Yes, but under those conditions the eosinopenia may have nothing to do with the presence or absence of cortical hormone.

*Thorn* That is right. We did some experiments on a telephone operator who did not show the expected reversal and rhythm. He was on the schedule six nights per week, with one night off. However the night telephone operators' activities decrease after 1 00 or 2 00 a.m. so perhaps this particular individual would not give us the greatest difference in day to night activity. This subject must be investigated with further studies.

*Pincus* We have published some reports on the 17 ketosteroid rhythms of people working in a factory at night. Under these circumstances the excretions were reversed. Their 17 ketosteroids were maximum whenever they awoke. Whether it was half an hour before they went to the job or several hours before. I personally went through a period of insomnia. During the first night I did not show much change but during the second I did.

*Thorn* The point I wish to make is that the rhythm is not easily interfered with and it certainly is not altered by the first night one remains up all night. Thus the diurnal variation does not appear to be directly related to general activity or change in food habit but undoubtedly it can be reversed over a more prolonged period of alteration in the character of day to night activities. This point however certainly needs clarification.

*Long* We shall continue the discussion by asking Dr Dorfman to give us his ideas on the metabolism of adrenal steroids in certain pathological conditions.

*Dorfman* I should like to present at this time working hypotheses for the study of the biochemical defects that are associated with various types of adrenocortical hyperactivity. We shall consider the clinical entities of Cushing's syndrome, adrenal cancer and the adrenal hyperplasia (adrenogenital syndrome). Since many mixed types of these diseases are known it is obvious that our speculations will not pertain to all the possible variations. However it may be profitable to consider these three classes of adrenal hyperactivity individually to indicate biochemical defects. By Cushing's syndrome we mean that type of adrenal hyperactivity which is characterized by the metabolic changes arising from overdosage of hydrocortisone and/or cortisone. We shall further limit our discussion

stances which result from the precursors cholesterol and/or smaller particles as a result of ACTH action

It is suggested that there are two principal pathways of steroidogenesis in the adrenal gland one concerned with the  $C_{11}$  compounds and the other with the  $C_{19}$  steroids. The possibility of movement directly from the  $C_{19}$  to the  $C_{11}$  and back is indicated by arrows in Figure 15 with question marks. This interrelationship although possible does not appear to be important. Once a substance such as pregnenolone in the  $C_{19}$  series is produced it is subjected to the enzyme ( $3\beta$  dehydrogenase) which has the ability to oxidize the  $\Delta^5$   $3\beta$  hydroxy group to the  $\Delta^4$ -3 ketone thus forming progesterone. A similar reaction occurs in the  $C_{19}$  series when dehydroepiandrosterone is oxidized to  $\Delta^4$  androstene-3,17 dione. The next reactions in the biosynthetic sequence are those of hydroxylation. In the  $C_{19}$  series the only hydroxylation reaction that we shall consider is  $11\beta$  hydroxylation and the product formed from  $\Delta^4$  androstene-3,17 dione is  $11\beta$  hydroxy  $\Delta^4$  androstene-3,17 dione which in peripheral metabolism is converted to a variety of 11 oxygenated 17 ketosteroids and has already been discussed. In the  $C_{21}$  series hydroxylation of progesterone can yield six different types of hydroxylated products. Not all of these possibilities are listed in Figure 15. Actually, hydrocortisone in the human accounts for the principal biological activity (carbohydrate protein stress etc.) and it is probably this substance which exerts the principal inhibitory influence on the anterior pituitary. The production of hydrocortisone from progesterone involves three types of hydroxylation namely  $11\beta$ ,  $17\alpha$  and 21. The combination of  $11\beta$  and 21 hydroxylations on progesterone result in the formation of corticosterone. The 21 hydroxylation of progesterone results in the production of desoxycorticosterone which is not listed in Figure 16. Other compounds are possible such as the  $\Delta^4$  pregnene  $11\beta$ ,  $17\alpha$  diol-3,20 dione appearing in Figure 16 which actually represents a 21 desoxyhydrocortisone but of great importance is the eventual formation of hydrocortisone resulting from the hydroxylation at all three positions in progesterone.

The control or level of activity of the pituitary-adrenal system is in effect controlled by the amounts of ACTH produced by the anterior pituitary and the amount of hydrocortisone acting back on the anterior pituitary to control the ACTH production. This suggested scheme has a very important implication—a direct mutual control between the anterior pituitary and the formation of hydrocortisone and substances possessing adrenocortical hormone activity.




FIGURE 15 Adrenocortical steroid production by the normal gland

but an indirect control of the androgen production. In other words androgen production is dependent upon the quantity of ACTH produced by the anterior pituitary and the amount of hydrocortisone that eventually is produced as a result of the ACTH stimulation. This point is of great importance as will be noted later in our discussions on adrenal hyperplasia (adrenogenital syndrome).

*White:* You are disinclined at this stage to draw a line between the two extremes from pregnenolone on down?

*Dorfman:* Yes, between the  $C_{19}$  steroids and  $C_{21}$  steroids. I am suggesting two pathways.

*White:* You are still supporting the idea you had in the past that these are two separate pathways rather than a single common route of metabolism?

*Dorfman:* Yes. I believe in the relative independence of the two pathways. If this scheme presents the true picture, a unique situation arises. The androgenic production by the adrenal is controlled only indirectly and is dependent upon the relationship between hydrocortisone and ACTH production by the pituitary gland. I think that leads up to our basic story.

*Gallagher:* Do you believe that corticosterone does not influence the pituitary?

*Dorfman:* Both hydrocortisone and corticosterone (and other steroids) probably influence the anterior pituitary, but the relative pituitary inhibitory activity is such that normally the concentration of hydrocortisone determines the issue.

I should like to continue now with a consideration of the steroidogenesis in the condition of pure Cushing's syndrome. The events are depicted in Figure 16 with the thickness of the arrows essentially indicating the relative concentration of hormones produced at various steps. In Cushing's syndrome it is suggested that there is an increase in ACTH causing a greater stimulation of the adrenal cortex to produce a larger quantity of  $C_{21}$  steroids than of  $C_{19}$  steroids. Thus, as a result of the increased quantity of ACTH, a greater amount of pregnenolone is produced and in turn converted to an abnormally high amount of progesterone which is efficiently and in high yield converted to hydrocortisone and probably other hydroxylated steroids. The important point, however, is the fact that the hydrocortisone production is significantly higher and is responsible for the symptoms of the disease. Why then does this increased amount of hydrocortisone not inhibit the production of ACTH by the anterior pituitary? This question cannot be answered with certainty at this time, but the indications are that the anterior




FIGURE 16 Adrenocortical production by the gland in patients with pure Cushing's syndrome. Compound names: 1 = cholesterol; 2 =  $\Delta^4$  androstene-3,17-dione; 5 = 11 $\beta$  hydroxy  $\Delta^4$  androstene-3,17-dione; 7 = hydrocortisone; 26 = corticosterone; 28 = progesterone; 39 =  $\Delta^4$  pregnene-3 $\beta$ ,20-one; 40 =  $\Delta^4$  pregnene-11 $\beta$ ,17 $\alpha$ -diol-3,20-dione.

diminished inhibition of the anterior lobe what is the evidence for that?

*Dorfman* I do not have it, I suggested a possible explanation. However there is some evidence that there is probably an increase in ACTH production.

*Thorn* I should like to modify a statement I made before. If a patient with Cushing's syndrome is given ACTH we may over a period of 48 hours obtain levels as high as 70, 80 or 90 mg of total 17 hydroxysteroid excretion in the urine. We cannot say from our data that the increase in 17 ketosteroid is necessarily greater than we should obtain if the same excess of compound F as measured by the urinary total 17 hydroxysteroid excretion were to be administered. Thus I do not believe we have evidence of an increase in 17 ketosteroid fraction by this technique in certain patients which would be consistent with the remarks which Dr Dorfman has made.

*Gallagher* Our results with patients who have classical Cushing's syndrome are in agreement with these results. There is a slight increase in the usual 17 ketosteroids but in addition to that there are a considerable number of other compounds present. With many of these we have not been able to make a quantitative measurement; the substances are seldom seen in appreciable amounts in normal urine.

*Long* When you say Cushing's syndrome do you mean adrenal hyperplasia with no adrenal or pituitary tumor?

*Dorfman* Adrenal hyperplasia may or may not occur. I really do not know whether all of those people have demonstrable changes in the adrenal but they could still have the Cushing syndrome. There is no definable tumor. What is seen is only the metabolic effects of high amounts of hydrocortisone.

*Thorn* It is a picture of excess ACTH.

*Dorfman* Yes.

*Long* However these people would have the so called Crooke's changes in the pituitary?

*Loeb* I think that is a perfectly safe statement.

*Mason* You mentioned a case which we studied some time ago. The patient was a boy with Cushing's syndrome who was excreting large amounts of formaldehydogenic steroids and about 80 mg a day of 17 ketosteroids. These are the urinary steroids which we succeeded in isolating.

In Table IV you will note that there is a rather large amount of dehydroisandrosterone, a small amount of etiocholanone one 11



pituitary in Cushing's disease has lost its sensitivity to the inhibitory action of hydrocortisone or the metabolic products which normally produce this effect

A second question that must be answered with respect to Cushing's syndrome is the differentiation between the production of  $C_{21}$  and  $C_{19}$  steroids. Since we have adopted as our primary thesis that these two channels are essentially unrelated it must follow that in Cushing's disease the stimulation of ACTH must result in a relatively lower  $C_{19}$  than  $C_{21}$  steroid production. Thus in the "pure" Cushing's syndrome we conceive of the following biochemical defects: (a) an increment in ACTH production, (b) a relatively large increase in  $C_{21}$  steroid production as compared to the  $C_{19}$  steroid production, and (c) a relative pituitary refractoriness to hydrocortisone.

**Thorn:** Do you believe that the  $C_{19}$  compounds are actually increased or could the larger quantity be accounted for by the increase in the derivatives coming from the other steroids?

**Dorfman:** They may be accounted for on the basis of the increased amount of metabolites coming from hydrocortisone. We are anxious of course to accumulate as many patients as we can to define this as precisely as possible.

**White:** Does the *in vitro* stimulation of the gland with ACTH throw any light on this question? If these compounds are arising indirectly, then *in vitro* we should expect very little of the lower line compounds to appear, but if they are coming directly, then possibly ACTH *in vitro* might increase both lines.

**Thorn:** The 17 ketosteroids are often fairly normal with a very high F output.

**Dorfman:** In such a case I would suggest that the bulk of the 17 ketosteroids would be of the 11 oxygenated etiocholanone type.

**Bauer:** Would the situation alter if ACTH were given to such patients?

**Thorn:** If ACTH is given to a patient with classical Cushing's syndrome, there is a tremendous rise in both the 17 ketosteroids and the 17 hydroxysteroids.

One would have to study a patient with Cushing's syndrome who had a high level of 17 ketosteroids not derived from cortisone or hydrocortisone in order to settle this point. It would probably require relatively large doses of hydrocortisone to suppress the 17 ketosteroid derivation from non-17 hydroxysteroids.

**Long:** You indicated that under these circumstances there is




FIGURE 17 Adrenocortical steroid production by the gland from patients with adrenal cancer. Compound names: 1 = dehydroepiandrosterone; 2 =  $\Delta^5$  androstene 317 dione; 5 =  $11\beta$  hydroxy  $\Delta^5$  androstene 317 dione; 7 = hydrocortisone; 23 = progesterone; 39 =  $\Delta^5$  pregnene 320 one; 40 =  $\Delta^5$  pregnene-11 $\beta$  17 $\alpha$  diol 320 dione.

TABLE IV

Compounds Isolated from the Urine in Cushing's Syndrome  
With Diabetes During 25 Days

Compound	Weight mg
Dehydroisoandrosterone	130
Etiocholane 3( $\alpha$ ) ol 17 one	8
Etiocholane 3( $\alpha$ ) 11( $\beta$ ) diol 17 one	33
Pregnane-3( $\alpha$ ) 20( $\alpha$ ) diol	172
Pregnane-3( $\alpha$ ) 17( $\alpha$ ) 20( $\alpha$ ) triol	35
17 Hydroxycorticosterone	191

oxygenated 17 ketosteroid (etiocholane-3 $\alpha$  11 $\beta$  diol 17 one) considerable pregnanediol and some pregnetriol

Dorfman Androsterone is missing

Mason It may have been there in small amounts but not very much I am sure

Astwood There was no tumor in this case?

Mason No

Long May I come back to these Crooke's changes because of this factor you have introduced of diminished inhibition of the pituitary? I just consulted my colleague Dr Thorn and our understanding is that when Crooke's changes occur in the pituitary they represent pituitary inhibition since they are produced by giving excessive cortisone to animals

Conn Crooke's changes have been produced in man with therapeutic doses of cortisone (27)

Dorfman We shall continue now with a consideration of the defects that are consistent with the condition of adrenal hyperactivity known as adrenal cancer. We are choosing individuals as mentioned earlier who do not reveal the metabolic effects of excessive doses of hydrocortisone and who show only moderate to severe masculinization as a result of increased androgen production. The stimulation by the anterior pituitary of the adrenal cancer is open

one  $\Delta$  pregnene 3 $\beta$  16 $\alpha$  diol 20 one and  $\Delta^4$  pregnene 3 $\beta$  16 $\alpha$  20 $\alpha$  triol

That portion of pregnenolone which is converted to progesterone however can be effectively hydroxylated at positions 11 17 and 21 and hydrocortisone is produced usually in sufficient quantity to maintain the individual. Other hydroxylated compounds such as corticosterone and desoxycorticosterone (not shown in Figure 17) can be effectively produced. Irrespective of the concentration of hydrocortisone the production of the steroids at the adrenocortical level continue at the same increased rate since essentially the adrenal cortex has an autonomy and the action of hydrocortisone on the anterior pituitary is of little consequence. Thus the biochemical defects in adrenal cancer appear to be (a) the autonomous production of steroids with a preponderance of the formation of C<sub>19</sub> steroids and (b) a relative lack in that enzyme (3 $\beta$  dehydrogenase) which normally converts the  $\Delta^4$  3 $\beta$  hydroxy group to the  $\Delta^4$  3 ketone leading to the accumulation of dehydroepiandrosterone and other  $\Delta^4$  3 $\beta$  hydroxy steroids.

Thorn: The theory is sound regarding ACTH but one must keep this fact in mind. Patients with cancer of the adrenal and with inhibition of remaining adrenal cortical tissue may respond to ACTH if it is given in large doses over a continued period of time. Under these circumstances one might anticipate a slow gradual rise in the secretion of steroid from the atrophic adrenocortical tissue in contrast to the very rapid and large rise which one would anticipate in a patient with bilateral hyperplasia of the adrenals receiving a similar quantity of ACTH. Thus in cancer of the adrenal one could not exclude a normal adrenocortical response if adequate ACTH were administered.

Rall: If the malignant tumor is removed from these patients — and presumably it attacks only one adrenal — does the other adrenal function normally?

Dorfman: In most of the patients we have studied the steroid excretion will stay down for a few months after removal of the primary tumor.


Conn: I should like to ask Dr Dorfman what kinds of adrenal cancer he is referring to. One adrenal cancer may produce a picture that looks like Cushing's syndrome others may be masculinizing or feminizing. From what kinds of cancer patients are these data derived?

Dorfman: This would be a condition where the patient shows a minimum of or no metabolic changes attributable to high concen

to question. It is most likely that although ACTH may be produced and circulating it is of little consequence with respect to the production of steroids by this cancerous adrenal. In other words we are saying that the adrenal bearing this cancer has now achieved a certain autonomy of hormone production.

The cancerous adrenal tissue produces increased amounts of both  $C_{21}$  and  $C_{19}$  steroids (Figure 17) with perhaps the usual pattern showing the preponderance of  $C_{19}$  steroids. This point will not be decided with certainty until adequate methods are available for precise quantitation of total  $C_{19}$  and  $C_{21}$  steroids. Under these conditions there could be and usually is a large increase in the production of dehydroepiandrosterone as one of the first products from either the cholesterol or acetate. It will also be noted that the transformation of dehydroepiandrosterone to  $\Delta^4$  androstene-3,17-dione is represented by an arrow thinner than that indicating the production of dehydroepiandrosterone. An important factor in the disease seems to be that although the tissue can produce relatively enormous amounts of dehydroepiandrosterone there appears to be a relative lack of the  $3\beta$  dehydrogenase which oxidizes the  $\Delta^3$ - $3\beta$  hydroxy group to the  $\Delta^4$ -3 ketone. Thus only a portion of the dehydroepiandrosterone can be converted to the Ring A oxidized form. That part which is converted to  $\Delta^4$  androstene-3,17-dione however can be  $11\beta$  hydroxylated and on the basis of our preliminary analysis of individual components of the  $C_{19}$  series it is evident that there is a preponderant increase in urinary products derivable from  $\Delta^4$  androstene-3,17-dione and  $11\beta$  hydroxy  $\Delta^4$  androstene-3,17-dione. However the accumulation of dehydroepiandrosterone is the most striking part of the urinary steroid pattern. Since the  $11\beta$  hydroxylase does not efficiently operate on compounds having the  $\Delta^3$ - $3\beta$  hydroxy group the presence of the  $11\beta$  hydroxy derivative of dehydroepiandrosterone is probably formed only in minute amounts and has as yet not been isolated. Instead some of the dehydroepiandrosterone appears to be efficiently converted to various other derivatives such as  $\Delta^4$  androstene-3 $\beta$ ,17 $\beta$ -diol and  $\Delta^4$  androstene-3 $\beta$ ,16 $\alpha$ ,17 $\beta$ -triol.

With regard to the  $C_{21}$  steroids it is found that a relative increase in pregnenolone would be consistent with our thesis and that a good portion but not all of this substance would be converted to progesterone. The accumulation again of the  $\Delta^3$ - $3\beta$  hydroxy group compound is seen from the fact that in adrenal cancer there is excreted in increased quantity of the following  $\Delta^3$ - $3\beta$  hydroxy compounds:  $\Delta^5$  pregnene-3 $\beta$ ,20 $\alpha$ -diol,  $\Delta^5$  pregnene-3 $\beta$ ,17 $\alpha$ -diol, 20

[illegible]

trations of hydrocortisone certainly not the massive disease that is seen in Cushing's syndrome

*Ingle* Is there evidence that metastases of adrenal tumors can secrete hormones?

*Dorfman* I am fairly sure they do because when metastases are present the steroid production increases significantly

*Long* There are a good many examples of that from the cases of the Mayo Clinic collected by Dr E J Keppler where the tumor was removed and later metastases in the liver appeared with a recurrence of Cushing's syndrome

*Dorfman* I should like to consider the biochemical defects in the adrenogenital syndrome patient. These events are depicted in Figure 18 in which it will be noticed that the representation includes the fact that increased amounts of ACTH are produced by the anterior pituitary

Experimental proof for this fact has been made available by the direct analysis of the blood ACTH in children by Sydnor (28). Thus increased ACTH production by the anterior pituitary results in an increased formation of both  $C_{11}$  and  $C_{21}$  steroids. In other words both dehydroepiandrosterone and pregnenolone are produced in increased quantities and each of these substances is efficiently transformed to the  $\Delta^4$  3 keto compound. In the  $C_{21}$  series we should therefore feature an efficient production of progesterone which can now be hydroxylated. In the  $C_{19}$  series an increase in the amount of  $\Delta^4$  androstene 3 17 dione is present and this compound in turn is hydroxylated at position 11 to form increased amounts of 11 $\beta$  hydroxy  $\Delta^4$  androstene 3 17 dione. The fact that this 11 hydroxylated androgen is present in increased amounts (29) is evident from the fact that in patients of this type there is an enormous increase in 11 oxygenated androsterone. Thus at this point we can say that without question there is not a decreased amount of 11 $\beta$  hydroxylase in these adrenals but rather that the concentration of this particular enzyme is actually increased in total and perhaps in enzyme units/gm per gram of tissue.

Coming back to our consideration of the increased production of progesterone we find from the evidence of urinary studies that both pregnane 3 $\alpha$ ,20 $\alpha$  diol and pregnane 3 $\alpha$ ,17 $\alpha$ ,20 $\alpha$  triol are increased enormously in this syndrome. The pregnane 3 $\alpha$ ,20 $\alpha$  diol would be a reflection of the increased progesterone production but the presence of increased amounts of pregnane-3 $\alpha$ ,17 $\alpha$ ,20 $\alpha$  triol indicates to us that 17 hydroxylation has efficiently taken place and in fact at an increased rate. Thus we may say that of the three

*Dorfman* Also although not shown in Figure 18 there should be a relative lack of desoxycorticosterone because that too would require efficient 21 hydroxylation

*Pincus* Dr *Thorn* I believe you once supplied us with urine from a patient getting large doses of adrenosterone and as I remember there was a definite inhibition there of pituitary activity Is that right?

*Dorfman* When large doses of adrenosterone were administered we had somewhat of a decrease in the products normally derived from  $\Delta^4$  androstene-3 17 dione

*Long* However if the patient has large amounts of corticosterone why should he run into salt deficiency?

*Dorfman* He cannot have corticosterone in large amounts because the 21 hydroxylation reaction is deficient This would cause a relative deficiency in cortisone hydrocortisone desoxycorticosterone and possibly electrocortin

*White* There is the example of the young patient with adrenal hyperplasia who shows an inability to retain salt and in whom the administration of DCA is quite ineffective because there appears to be in this instance not only an inability to make DCA but the production of something which may be anti DCA Does such an individual respond quite well to exogenous DCA?

*Conn* They respond to DCA but the administration of ACTH may intensify the salt loss

*Thorn* Although I think one might predict Addison's disease on the basis of refractory renal tubules without evidence of over all kidney damage we have never observed the patient with intact renal function by other measurements who did not respond to desoxycorticosterone with sodium chloride retention It is only in total renal failure that we have detected the rare cases of salt losing nephritis which are completely refractory to desoxycorticosterone

*Conn* I think there is one other point which fits in very well and that is the occasional case of adrenogenital syndrome that develops hypoglycemia We have followed one such case Each time the patient had an infection hypoglycemia resulted from that stress I believe Wilkins (30 31) has two cases showing the same phenomenon

*Dorfman* If these ideas are correct we should be able to find relative differences in concentration of certain enzymes such as those responsible for 11 $\beta$  17 $\alpha$  and 2 hydroxylation as well as the enzyme which converts the  $\Delta^3$  3 $\beta$  hydroxyl to the  $\Delta^4$  3 ketone



hydroxylation enzymes that are necessary to produce hydrocortisone from progesterone two are actually increased these being the  $11\beta$  and  $17\alpha$  hydroxylase. However there is a proportionately decreased amount of  $21$  hydroxylase as evidenced by the fact that the amounts of hydrocortisone and corticosterone produced are relatively low. Thus it appears that since the hydrocortisone content is kept relatively low, insufficient hydrocortisone would be available to inhibit efficiently, the anterior pituitary the latter gland would therefore continue to produce its increased amount of ACTH. Thus we may say that there is one cardinal defect in this system that is a relative lack of  $21$  hydroxylase, which causes an insufficient quantity of hydrocortisone to be produced which in turn leads to increased ACTH production and finally an increased production of steroids by the adrenal. As has already been mentioned when we discussed the normal steroidogenesis by the adrenal of particular importance in this scheme is the fact that the androgen production is dependent upon the relationship between the quantity of hydrocortisone produced and the amount of ACTH produced. Thus in this syndrome the lack of  $21$  hydroxylase leads to an increased production of androgens which in turn are responsible for the clinical syndrome. Recent clinical work by Wilkins and co workers (30) indicates that the symptoms of the patients suffering from this disease may be promptly corrected by the administration of hydrocortisone or cortisone. This is consistent with the scheme presented since the additional amounts of hydrocortisone would effectively cause inhibition of the anterior pituitary and the direct result would be decreased production of the androgenic hormones which are the offending steroids in the adrenogenital syndrome.

*Thorn* Would you say that the large arrow in Figure 18 which indicates coming from the pituitary may not necessarily be the initiating factor but rather a secondary factor and that the increased secretion of ACTH is the result of the process rather than a cause of the syndrome?

*Dorfman* I think that is probably so.

*Thorn* We have had one patient with this syndrome who showed a good eosinophil fall with ACTH which we interpreted as representing the secretion of some  $17$  hydroxysteroids but who subsequently died of salt retaining hormone deficiency. We are impressed that salt deficiency is one of the most characteristic clinical aspects of patients with this syndrome.

some people fortunately produce enough enzymes to balance the effect of increased ACTH production

**Dorfman** That is right it may be a question of enzymes. In other words what I say is that people probably vary in the amount of ACTH they produce but if there are proportionate amounts of enzymes the hydrocortisone production is adequate to prevent the ACTH production from increasing to the point of producing excessive amounts of androgens

**Loeb** I believe what Jaier has been hoping for is that someone would find a very large adrenal in one of these people which might be removed and perfused

**Dorfman** We have perfused some of these glands from patients with the adrenogenital syndrome but have learned little

**Rall** If we were to isolate or identify the principal enzymes involved is there any reason to think that the information might be a clue to the situation?

**Dorfman** Are you suggesting that enzymes should be administered?

**Rall** Yes

**Pincus** I believe it may not be the enzyme at all but some necessary cofactor of the enzyme. For example according to Bush (32) the rat adrenal produces mostly corticosterone which is a 17 desoxycorticosteroid. This has been confirmed by other people. Nevertheless Heard (33) and Hofman and Davison (34) have both incubated the rat adrenal *in vitro* and obtained 17 oxygenated steroid from it. So the *in vitro* picture is not the same as the *in vivo* picture

What is the explanation? I suggest that the enzyme system is there all right but that *in vivo* there is either an inhibitor preventing it from acting or a cofactor which is absorbed so fast by the adrenal tissue that it cannot be used whereas in the *in vitro* experiment there is either a storage of the cofactor or the inhibitor is destroyed. I think it is probably a cofactor

**Rall** A cofactor which might be the coenzyme

**Pincus** Another reason why I think it is a cofactor particularly in this adrenogenital syndrome is that it is corrected by giving steroid and testing the pituitary inhibition

**Dorfman** Yes we give them the product which they cannot make to bridge that step

**Pincus** I believe that Wilkins (30) finds that the recovery is then complete or practically complete

*Thorn* I wonder whether we should postulate an increase in the total metabolic pool of steroids within the adrenal as a part of this syndrome. It would seem that many of the cases that are seen might be explained on a shift in the distribution of the steroid rather than in alteration of the total quantity.

*Conn* Assuming the validity of Dr Dorfman's thesis, should we not regard the adrenal hyperplasia as compensatory, the primary defect being of adrenal origin, and increased ACTH production representing the normal response of the normal pituitary to such circumstances? That is, the initial defect is one which does not allow enough 21 hydroxylation; serum F falls, ACTH increases in an effort to raise serum F, and secondary hyperplasia occurs whether or not the functional compensation has been accomplished. This would mean then, from a therapeutic point of view, that if something other than F or an F-like compound should be discovered which could inhibit ACTH activity or production, it would be the wrong thing to use in these cases, since it would precipitate adrenocortical insufficiency.

*Dorfman* An interesting point is that there may be a number of people leading a normal life with a relatively high level of ACTH activity, but they are fortunate in having the compensation of adequate enzymes to carry on with so that ACTH level does not get out of bounds; consequently, the production of androgens does not become high enough to produce clinical symptoms.

*Conn* That again brings up the matter which Dr Thorn raised earlier regarding his patient with high 17 ketosteroid and low 17 hydroxycorticoid excretions.

*Thorn* Which compounds have you studied in the first step to demonstrate the failure of oxidation at carbon 21?

*Loeb* Dr J. W. Jailer\* has given 17 hydroxy progesterone to these people and has found no increase in 11 oxysteroids, which is what one would expect.

*Gallagher* Even if a very large amount were given, I should suspect a very tiny amount would go through the adrenal and the rest would be metabolized. Only a small portion would be subjected to hydroxylation at C 11.

*Ralli* Could you look at this from another point of view? There may be some interference in the enzyme system and this may be the initial step in disordering the mechanism and perhaps stimulating an oversecretion of the hormone. In other words, you say that

\*Personal communication

correctly that was hyalinization of the pituitary beta cells Is that correct?

*Dorfman* Yes

*Young* That would indicate a dysfunction of the secretory function of ACTH would it not?

*Thorn* Yes that is correct It is probable that the Crookes changes may represent the long continued effect of excessive adrenal steroid level and are not the initiating cause of the Cushing's syndrome

*Astwood* It may be like Graves disease where there is no evidence for an increased production of thyrotropin it is as though something else were wrong with the thyroid and the normal amount of thyrotropin would make it work too much Perhaps that is the way it is in Cushing's syndrome

*Thorn* The best example of that is to give a small increment of ACTH to a patient with Cushing's disease and measure what happens or give a standard dose of ACTH to a normal individual whose adrenals have been activated a bit The physiological effect of the hormone is intensified tremendously

*Rall* Dr Astwood are you suggesting that the cellular situation of the adrenocortical cells would be the determining factor as to the direction in which the reaction would go when the pituitary stimulus came through?

*Astwood* No I was thinking that in the primary overactivity of an endocrine gland such as the adrenal in Cushing's syndrome and the thyroid in Graves disease the fundamental defect is not excess of the tropic hormone but something else at present unknown

*Rall* It might be some enzymatic change within the cell?

*Astwood* It is probably something more complicated than that because the entire gland is involved

*Rall* If the rat is any index of what may happen a deficiency of pantothenic acid will seriously affect the integrity of the adrenal cells and under these circumstances if the animal is stressed the adrenal enlarges

*Thorn* In regard to secretory activity it is quite possible that if we put out the ordinary amount of ACTH over a 24 hour period rather than over the 12 hour period as our data suggest we might all be suffering from Cushing's syndrome

*Pincus* With a chronic insomnia?

*Thorn* It is possible in certain instances that patients with thyrotoxicosis and Cushing's syndrome are merely individuals who

*Thorn* As a matter for the record has anyone ever demonstrated by direct measurement that cortisone inhibits ACTH in the adrenogenital syndrome?

*Dorfman* If we add the fact that we obtain a decrease in the steroid production by cortisone or hydrocortisone administration to what has already been reported in the literature that there is initially an increase of ACTH in the blood I think it gives a good working point

*Thorn* However an increase in blood level could be explained by an alteration in the rate of destruction or fixation of the hormone as well as on the basis of increased secretion. One could assume that the adrenal cortex itself might be very susceptible to cortisone action and certainly these experiments do not exclude a direct action of cortisone on the adrenal cortex.

*Pincus* You may be perfectly right. We can now say more definitely that if we perfuse the steer adrenal we obtain very little F but a good deal of B. This difference between steer and cow adrenals may be the result of castration. It may be that the gonad hormones have a direct rather than an indirect effect.

*Thorn* It is entirely possible that the adrenal cortex itself may be very sensitive to high or low levels of hydrocortisone.

*Dorfman* Was Juler's work on a hypophysectomized person with adrenogenital syndrome?

*Loeb* No it was adrenal carcinoma.

*Thorn* I do not think it changes your theory.

*Ingle* Has Wilkins given ACTH to these patients and shown that the adrenogenital syndrome is aggravated?

*Dorfman* I believe that this has been done.

*Young* Mason and Morris (35) did that. They tested a girl with congenital adrenal hyperplasia who ultimately died of adrenal insufficiency in spite of cortisone treatment. What evidence is there to preclude the possibility that the enzyme dysfunction is not in the adrenal but in the systems wherever they are in the body that dispose of F and B so that they are being degraded more rapidly than normally and therefore not available for ordinary purposes? If F and B were lacking the pituitary would not be inhibited. ACTH would be produced in excess and C<sub>19</sub> steroids such as dehydroepiandrosterone would appear.

*Ralli* Does the cholesterol level in the blood change in patients with this disease?

*Dorfman* I do not know.

*Young* May I ask about the Crooke changes? If I remember

correctly that was hyalinization of the pituitary beta cells. Is that correct?

Dorfman: Yes.

Young: That would indicate a dysfunction of the secretory function of ACTH. Would it not?

Thorn: Yes, that is correct. It is probable that the Crooke's changes may represent the long continued effect of excessive adrenal steroid level and are not the initiating cause of the Cushing's syndrome.

Astwood: It may be like Graves disease where there is no evidence for an increased production of thyrotropin; it is as though something else were wrong with the thyroid and the normal amount of thyrotropin would make it work too much. Perhaps that is the way it is in Cushing's syndrome.

Thorn: The best example of that is to give a small increment of ACTH to a patient with Cushing's disease and measure what happens or give a standard dose of ACTH to a normal individual whose adrenals have been activated a bit. The physiological effect of the hormone is intensified tremendously.

Rall: Dr. Astwood, are you suggesting that the cellular situation of the adrenocortical cells would be the determining factor as to the direction in which the reaction would go when the pituitary stimulus came through?

Astwood: No. I was thinking that in the primary overactivity of an endocrine gland, such as the adrenal in Cushing's syndrome and the thyroid in Graves disease, the fundamental defect is not excess of the tropic hormone but something else, at present unknown.

Rall: It might be some enzymatic change within the cell?

Astwood: It is probably something more complicated than that because the entire gland is involved.

Rall: If the rat is any index of what may happen, a deficiency of pantothenic acid will seriously affect the integrity of the adrenal cells and under these circumstances if the animal is stressed, the adrenal enlarges.

Thorn: In regard to secretory activity, it is quite possible that if we put out the ordinary amount of ACTH over a 24 hour period rather than over the 12 hour period as our data suggest, we might all be suffering from Cushing's syndrome.

Pincus: With a chronic insomnia?

Thorn: It is possible in certain instances that patients with thyrotoxicosis and Cushing's syndrome are merely individuals who

*Thorn* As a matter for the record has anyone ever demonstrated by direct measurement that cortisone inhibits ACTH in the adrenogenital syndrome?

*Dorfman* If we add the fact that we obtain a decrease in the steroid production by cortisone or hydrocortisone administration to what has already been reported in the literature that there is initially an increase of ACTH in the blood I think it gives a good working point

*Thorn* However an increase in blood level could be explained by an alteration in the rate of destruction or fixation of the hormone as well as on the basis of increased secretion One could assume that the adrenal cortex itself might be very susceptible to cortisone action and certainly these experiments do not exclude a direct action of cortisone on the adrenal cortex

*Pincus* You may be perfectly right We can now say more definitely that if we perfuse the steer adrenal we obtain very little F but a good deal of B This difference between steer and cow adrenals may be the result of castration It may be that the gonad hormones have a direct rather than an indirect effect

*Thorn* It is entirely possible that the adrenal cortex itself may be very sensitive to high or low levels of hydrocortisone

*Dorfman* Was Jailer's work on a hypophysectomized person with adrenogenital syndrome?

*Loeb* No it was adrenal carcinoma

*Thorn* I do not think it changes your theory

*Ingle* Has Wilkins given ACTH to these patients and shown that the adrenogenital syndrome is aggravated?

*Dorfman* I believe that this has been done

*Young* Mason and Morris (35) did that They tested a girl with congenital adrenal hyperplasia who ultimately died of adrenal insufficiency in spite of cortisone treatment What evidence is there to preclude the possibility that the enzyme dysfunction is not in the adrenal but in the systems wherever they are in the body that dispose of F and B so that they are being degraded more rapidly than normally and therefore not available for ordinary purposes? If F and B were lacking the pituitary would not be inhibited ACTH would be produced in excess and  $C_{17}$  steroids such as dehydroepiandrosterone would appear

*Rall* Does the cholesterol level in the blood change in patients with this disease?

*Dorfman* I do not know

*Young* May I ask about the Crooke changes? If I remember

*Dorfman* The bulk of the androgenicity in the adrenogenital syndrome comes from the  $C_{17}$  11 oxygenated compounds I believe that  $11\beta$  hydroxy  $\Delta^4$  androstene-3 17 dione together with some  $\Delta^4$  androstene-3 17 dione are the responsible compounds

*White* How high is the androgenic activity of  $11 = \beta$  hydroxy androstenedione?

*Dorfman* We cannot assess the androgenic activity in humans. We have only rough measures at the moment in chicks probably of the order of one third as active as  $\Delta^4$  androstene-3 17 dione

*Gallagher* It is androgenic?

*Dorfman* Yes

*Gallagher* Salamon and Dobriner (36) isolated  $11\beta$  hydroxy  $\Delta^4$  androstene-3 17 dione from the urine of patients treated intensively with ACTH. It seems reasonable to believe that ACTH exaggerates the normal adrenal secretion and thus their finding would support the view that  $11\beta$  hydroxy  $\Delta^4$  androstene-3 17 dione is normally secreted in small amounts by the adrenal gland. This compound therefore may be one of the adrenal androgens. Some of the metabolites found in the urine during ACTH stimulation may well be derived from this precursor

*Thorn* In so far as excretion products can be interpreted as reflecting original androgen activity of the steroid we know that removal of the adrenal glands in a castrate male gives a marked reduction in biological androgen activity. These studies have been carried out by Dr Paul Munson of the Harvard School of Dental Medicine (37). In other words the material in the urine is biologically androgenic as measured by a technique which one accepts as measuring androgenic activity

*White* Was this assay in the chick or the rat?

*Long* In the chick. If we restore the 17 ketosteroid level with cortisone or compound F in the patient without adrenals the androgenic activity of the 17 ketosteroid fraction in the urine is entirely different than it is in the individual who let us say had a daily excretion 5 mg of 17 ketosteroid from his own gland

*Dorfman* It is lower?

*Long* Much lower in fact it is almost nonexistent until the amount of cortisone is increased to 100 mg

*White* Delta 4 androstenedione is a potent androgen in the chick. It is weakly androgenic in man it has been given to women with no striking development of masculinization. I am still curious to know what the biological activity in urine is when assayed in the chick in relation to the masculinization which we see in man



have a normal total 24 hour secretion of TSH (thyroid stimulating hormone) or ACTH, with no diurnal variation

*Ingle* Dr Dorfman do you believe that the normal adrenal cortex secretes physiologically significant amounts of androgen?

*Dorfman* Yes I do I believe the adrenal cortex directly produces  $C_{19}$  compounds Dehydroepiandrosterone has not been isolated from the tissue but on the basis of all the evidence it appears to be secreted by the gland  $\Delta^4$  Androstene-3,17 dione is also produced by the gland together with  $11\beta$  hydroxy  $\Delta^4$  androstene-3,17 dione and both are secreted into the blood stream Analysis of adrenal perfusates adrenal venous blood and metabolic considerations all point to an actual production and secretion of the  $C_{19}$  androgens

*Loeb* For years I have been impressed by the lack of overt and significant clinical manifestations of any loss of androgenic material in the Addisonian patient I should like to ask what the experience is in totally adrenalectomized individuals so long as one provides say salt and water hormone and cortisone what evidence is there of a significant physiological deficit in androgenic steroids?

*Long* There have been several series of experiments in which the testes have been removed from an animal let us say a male rat or mouse In that case there is marked atrophy of the prostate and seminal vesicles The administration of ACTH in any amount one wishes to give brings about no repair of the prostate or seminal vesicle I believe that your laboratory did some of these experiments Dr Li

*Li* Yes We recently used hypophysectomized castrated male rats to investigate the influence of ACTH on the secondary sex organs ACTH was administered with either gelatin or beeswax as injection media producing an adrenal 8 to 10 times the size of the controls There is no evidence whatsoever of androgen secretion from the adrenal

*White* We first used the word androgen as a blanket term for  $C_{19}$  compounds but now we are shifting our interest to biological activity

*Loeb* The question was about biological activity

*Li* Dr Loeb is right we were measuring the androgenic activity

*White* In that connection I was going to ask whether the adrenal does not produce testosterone I gather that there is no evidence of where the androgenicity that one sees in the adrenogenital syndrome stems from

tion were to diminish for any reason in conjunction with adrenocortical insufficiency the reduced estrogen secreted by the ovary and the reduced androgen secreted by the adrenal might possibly balance each other to some extent with respect to physiological activity. The evidence however is meager for this point with one exception and that is in patients with genetic predisposition for hirsutism. Under these circumstances ACTH treatment in young women can result in a marked change in hair growth. This may become a serious social problem for these patients whereas in other individuals who do not have this inherent capacity of increased hirsutism ACTH treatment may be tolerated quite well. The same comments are applicable with respect to the development of acne.

**Dorfman:** How high were these doses of  $\Delta^4$  androstene 317 dione that were administered to women in whom you did not see the masculinization?

**White:** Two hundred milligrams a day. There were no data as to the extent to which it was absorbed.

**Gallagher:** From isotopic experiments we know the compound is readily absorbed. It surprises me to hear that it is not androgenic. Judged by the capons comb response the compound is a good androgen.

**Ingle:** Dr. Dorfman, do you think that the adrenals and gonads are the only tissues of the human that can secrete steroid?

**Dorfman:** Even after the removal of both the gonads and adrenals of male and female monkeys we still found small amounts of androgens by a chick comb test.

**Ingle:** In your studies on monkeys did you exclude food as a possible source?

**Dorfman:** No extensive studies on food were done.

**Mason:** Didn't you maintain those animals on cortical extract at one time?

**Dorfman:** During the critical test periods many of them were maintained only with salt.

**Rall:** We repeated some of the work that Dr. Pitts (42) reported at these meetings in 1951. You remember that he observed in the adrenalectomized rat that the capacity to handle an acid load was considerably impaired. We were interested in seeing whether this test would serve as a measure of the effect of certain nutritional substances in adrenalectomized rats. Male and female intact and adrenalectomized rats were studied. In the adrenalectomized rats an acid load was given five to seven days following the removal of the adrenal and the ammonia and titratable acid excretion were

and whether we have any indication of what compound is responsible for the masculinization?

*Dorfman* It would be surprising if there were not a dose that would produce a true androgenic effect in man but the relative amount of  $\Delta^4$  androstene 3 17 dione that would be needed might be enormous

*Long* Dr Dorfman has ACTH been given to test this point as to whether sufficient androgen will be produced to correct the hypogonadism?

*Dorfman* I do not know of any studies of that sort

*Long* From the evidence before us it would appear that the rodent adrenal is different from the human but here would be an opportunity to prove it, if people were available

*Dorfman* In 1936 Moon (38) reported the fact that with crude ACTH preparations in a gonadectomized animal he was able to obtain androgenic stimulation of the prostate

*Li* With the crude extract which Dr Moon used we did obtain some suggestive stimulation in castrated hypophysectomized male rats However highly purified ACTH preparations cause greatly hypertrophied adrenals but no increase in ventral prostate weight The only effect in the latter direction is produced with the crude extract We have been wondering whether this might be another pituitary factor

*Astwood* Dr W P Van der Lian (39) has studied that also, and has shown a direct effect of pituitary extracts on the male genital tract in the absence of testes and adrenals

*Pincus* We may extract 11 beta hydroxyandrostenedione from adrenal vein blood (40) and Dr Eli Romanoff (41) has isolated it from human vein blood However as far as I know it has not yet been found in the rat blood and we do not thus far understand its biological effects

*Dorfman* We have tested it on the mammalian indicators have we not?

*Pincus* It is active but the question is how active is it in the human? Dr Thorn do you have any data on adrenosterone in terms of androgenic effect?

*Thorn* We had a small quantity available which we administered over a short period of time In a matter of a few days one would not expect to observe any androgenic effect Returning to Dr Loeb's question we should keep in mind that the lack of androgen in a female patient with Addison's disease would have to be considered with respect to the level of ovarian function Thus if ovarian func




FIGURE 10 The comparison of the specific activity of cholesterol and urinary steroids after a single dose of acetate  $1\text{ C}$  in a patient with an adrenal tumor. Reprinted by permission from Gallagher F F Biochemical problems of the steroid hormones *Chemical Specificity in Biological Interactions* No 3 Chapt. V New York Academic Press 1954 (pp 50-61)

androsterone and etiocholane obtained from a single day's collection from this patient was insufficient to purify without the addition of carrier material. The procedure we adopted with these two substances was similar to that described in an earlier report at the Laurentian Hormone Conference (4). The alpha ketosteroids were separated by chromatography, the infrared spectra of the separated fractions were examined and what was believed to be essentially pure androsterone and etiocholane were separately sublimed in high vacuum; the amount present was determined from the weight of the sublimate and the quantitative Zimmermann reaction. A known amount of carrier was then added and the products were recrystallized to radiochemical purity. It was not

determined over a four hour period. An interesting difference was noted between the female and male adrenalectomized rats: the former had a greater capacity to handle the acid load than did the latter. The female adrenalectomized rats excreted about 28 mEq of ammonia per hour per 100 gm of weight compared to 22 mEq for the male adrenalectomized rats. The female animals excreted about 3.5 mEq of titratable acid as compared to 2.5 mEq for the males. These values may be compared to the average excretion of ammonia of 56 mEq per hour per 100 gm of weight for the intact female and 48 mEq for the intact males. The average intact female excreted about 11 mEq per hour of titratable acid compared to 7.5 mEq for the intact males. After adrenalectomy plus gonadectomy, the excretion of ammonia by the female animals was greater than that of the males (7.5 mEq per hour for the females, 4.9 mEq for the males). There is no significant difference in the excretion of titratable acid after adrenalectomy plus gonadectomy (3.5 mEq per hour per 100 gm of weight for the females and 3.2 mEq for the males).

*Gallagher:* I have a figure to present which may be of interest; it deals with a portion of Dr Dorfman's diagram. Figure 19 is a study of a man with a massive adrenal tumor who excreted very large amounts of dehydroisoandrosterone. Enough was found in a single day's excretion of urine to isolate and carefully purify this and other substances. At the same time we studied the total plasma and fecal cholesterol. We compared the relative specific activities of these products a short time after the feeding of a single dose of carbon labeled acetate.

On the first day, the specific activity of the two metabolites was somewhat higher than either the plasma or the fecal cholesterol. This can be interpreted as indicative of possible independent synthesis on the first day as well as conversion of cholesterol into these substances. As the experiment progressed — and I draw attention to the fifteenth day — the specific activity of the steroid metabolites was somewhat lower than the specific activity of the plasma cholesterol, suggesting perhaps another path of synthesis than that through cholesterol. The experiment, I believe, indicates that both cholesterol and acetate may serve as precursors for these urinary steroid metabolites.

*Dorfman:* Dr Gallagher, where is the androsterone in the figure?

*Gallagher:* The specific activity of the androsterone was nearly identical with that of the etiocholanone. It was not included on the figure in order to simplify the presentation. The amount of

an indication that an adrenal tumor has the ability to synthesize cholesterol of higher specific activity than that which is circulating in the plasma at the same time. We do not have many experiments of that type because such tumors are fortunately rare. When we are concerned about individual organ pools as well as whole body pools we really are on very perilous ground. For that reason I think I should prefer not to speculate. I would repeat however that the results demonstrate that these steroid hormone metabolites can be synthesized from cholesterol and suggest that there is an independent synthesis from another precursor possibly acetate.

**Dorfman:** We did a similar study as you know in which we administered acetate  $C^{14}$  to an adrenal cancer patient who was excreting something of the order of 380 mg of 17 ketosteroids per day and it is interesting that the specific activity of the dehydroepiandrosterone, the etiocholanone 3 $\alpha$  of 17 one and the androsterone isolated from the urine were within 15 per cent of each other and the specific activities of androsterone and etiocholanone isolated in this particular case were equal.

**Pincus:** I think Dr. David Stone and Dr. Oscar Hechter have more direct evidence which should appear shortly in which they perfused  $C^{14}$  labeled acetate and cholesterol in the absence and in the presence of ACTH. There is a 17 fold increase in total radioactivity of the recovered F and II from cholesterol after ACTH and only a 2.5 fold increase after acetate. That would suggest very clearly a pathway independent of ACTH.

**Rall:** Does the concentration of cholesterol in the adrenal bear any relation to its ability to produce a given quantity of these steroids?

**Pincus:** That was a question which we were unable to answer with the bovine adrenals because the concentration was so low that we could not relate it.

**Long:** In rats that are seriously burned or subjected to a severe hemorrhage the concentration of adrenal cholesterol falls 24 hours later to approximately 10 per cent or less. That would be the time we should expect the adrenocortical hormone content in the urine to have risen. Therefore we may argue that the human adrenal at that time would be very low in lipid as well as in cholesterol. I expect that it is.

#### REFERENCES

1. DORFMAN, R. I. and UNGAR, F. *Metabolism of the Steroid Hormones*. Minneapolis: Burgess Publishing Co. 1953.

necessary to add carrier material to the dehydroisoandrosterone and for this reason the specific activity of that compound was the most accurate of the three metabolites examined. At this stage of the disease large amounts of androsterone and etiocholanone were not present in the urine. The specific activity of the androsterone and the etiocholanone were in each period lower than the specific activity of the dehydroisoandrosterone.

*Dorfman* The etiocholanone appears not to be arising solely from the dehydroepiandrosterone in this case, but rather part arises from the 17 hydroxy 11 desoxycorticosterone and/or 17 hydroxyprogesterone. Is the difference in specific activity between dehydroepiandrosterone and etiocholanone 3 $\alpha$  or 17 one significant?

*Gallagher* Very probably although one cannot say so very emphatically. It seems significant that the specific activity was lower in each interval examined but particularly toward the end of the experiment the errors in counting these low specific activities were appreciable.

*Bloch* These differences are very great.

*Gallagher* The difference on the first day between the plasma cholesterol and the isolated urinary steroids is significant. However one must remember that the plasma cholesterol specific activity represents a point in the day whereas the urinary specific activity represents the composite of the whole 24 hours.

*Bloch* I doubt whether this is an argument in favor of independent synthesis. You would by the same token have to conclude that the fecal cholesterol was synthesized independently from the plasma cholesterol.

*Gallagher* We know that the fecal cholesterol is continually diluted by the dietary cholesterol. The specific activities indicate a precursor-product relationship since the only source of radioactivity is in the administered acetate.

*Bloch* How do you explain the differences between dehydroepiandrosterone and etiocholanone? Would you have to postulate three independent pathways, one for cholesterol, another for the C<sub>21</sub> compounds, and a third for the C<sub>19</sub> steroids?

*Dorfman* We do not like the idea.

*Bloch* I think it probably can be explained on the basis of different pools.

*Gallagher* This is one of the knotty problems in the interpretation of these results. We know little about the pool from which these metabolites are derived; we do not know the specific activity of the adrenal tumor cholesterol. From other experiments we have

- 20 LOVE W D Failure of adrenalectomy immediately following stress to prevent eosinopenia in rats *Proc Soc Exper Biol & Med* 75 639 (1950)
- 21 BRADLOW H L DOBRINER K and GALLAGHER T F The fate of cortisone T in mice *Endocrinology* 54 343 (1954)
- 22 FUKUSHIMA, D K BRADLOW H L DOBRINER K and GALLAGHER T F The fate of testosterone infused intravenously in man *J Biol Chem* 206 563 (1954)
- 23 DOUGHERTY T F Studies of the antiphlogestic and antibody suppressing functions of the pituitary adrenocortical secretions *Recent Progr Hormone Research* 7 307 (1952)
- 24 STADIE W C HAUGAARD N HILLS A G and MARSH J B Hormonal influences on chemical combination of insulin with rat muscle (diaphragm) *Am J M Sc* 218 275 (1949)
- 25 ROSENBAUM J D FERGUSON B C DAVIS R K and ROSS MEISL E C The influence of cortisone upon the diurnal rhythm of renal excretory function *J Clin Investigation* 31 507 (1952)
- 26 SHIPLEY R A DORFMAN R I BUCHWALD E and ROSS E The effect of infection and trauma on the excretion of urinary cortin *J Clin Investigation* 25 673 (1946)
- 27 LAQUEUR G L Human hypophysis in diseases of adrenal cortex *Stanford M Bull* 9 75 (1951)
- 28 SYDNOR K L KELLEY V C RAILE R B ELY R S and SAYERS G Blood adrenocorticotrophin in children with congenital adrenal hyperplasia *Proc Soc Exper Biol & Med* 82 695 (1953)
- 29 RUBIN B L DORFMAN R I and PINCUS G Quantitative determination of seven urinary 17 ketosteroids *Recent Progr Hormone Research* 9 213 (1954)
- 30 WILKINS L LEWIS R A KLEIN H GARDNER L I CRIGLER J F ROSENBERG E and MIGEON C J Treatment of congenital adrenal hyperplasia with cortisone *J Clin Investigation* 11 1 (1951)
- 31 WILKINS L CRIGLER J F JR SILVERMAN S H GARDNER, L I and MIGEON C J Further studies of the treatment of congenital adrenal hyperplasia with cortisone III The control of hypertension with cortisone with a discussion of variations in the type of congenital adrenal hyperplasia and report of a case with probable defect of carbohydrate regulating hormones *J Clin Endocrinol* 12 1015 (1952)
- 32 BUSH I L Species differences and other factors influencing adrenocortical secretion *Synthesis and Metabolism of Adrenocortical Steroids* Ciba Foundation Colloquia on Endocrinology Vol VII London J & A Churchill Ltd 1953 (p 210)
- 33 HEARD R D H JACOBS R O'DONNELL V PERON F G SAFFRAN J C SOLOMON S S THOMPSON L M WILL OUGHBY H and YATES C H The application of C<sup>14</sup> to the study of the metabolism of the sterols and steroids hormones *Recent Progr Hormone Research* 9 383 (1954)



- 2 SCHILLER S DORFMAN R I and MILLER M Metabolism of steroid hormones the metabolism of testosterone in normal women *Endocrinology* 36 355 (1945)
- 3 DOBRINER K Adrenal function and steroid excretion in disease *Symposium on Steroids in Experimental and Clinical Practice* A White Editor Philadelphia Blakiston Co 1951
- 4 GALLAGHER T F, FUKUSHIMA D K BARRY M C and DOBRINER K Studies with isotopic steroid hormones *Recent Progr Hormone Research* 6 131 (1951)
- 5 DORFMAN R I Biochemistry of androgens *The Hormones* Vol I G Pincus and K V Thumann Editors New York Academic Press Inc 1948 (p 467)
- 6 MASON H L and KEPLER E J Isolation of androsterone etiocholan 3( $\alpha$ ) ol 17 one and  $\Delta^5$  androstene 3( $\beta$ ) 17( $\alpha$ ) diol from the urine after administration of dehydroisoandrosterone to man *J Biol Chem* 160 255 (1945)
- 7 MILLER A M DORFMAN R I and MILLER M Metabolism of steroid hormones metabolism of dehydroisoandrosterone *Endocrinology* 46 105 (1950)
- 8 SAVARD K BURSTEIN S ROSENKRANTZ H and DORFMAN R I The metabolism of adrenosterone in vivo *J Biol Chem* 202 717 (1953)
- 9 BURSTEIN S SAVARD K and DORFMAN R I The in vivo metabolism of hydrocortisone *Endocrinology* 53 88 (1953)
- 10 ——— The in vivo metabolism of cortisone *ibid* 52 448 (1953)
- 11 ——— The in vivo metabolism of 21 desoxycortisone *ibid* 53 267 (1953)
- 12 HORWITT B N DORFMAN R I SHIPLEY R A and FISH W R Metabolism of steroid hormones conversion of desoxy corticosterone to pregnanediol 3( $\alpha$ ) 20( $\alpha$ ) in man and in the chimpanzee *J Biol Chem* 155 213 (1944)
- 13 UNGAR F DORFMAN R I STECHER R M and VIGNOS P JR Metabolism of steroid hormones metabolism of progesterone and related steroids *Endocrinology* 49 440 (1951)
- 14 DOBRINER K and LIEBERMAN S The metabolism of steroid hormones in humans *Steroid Metabolism and Estimation* Ciba Foundation Colloquia on Endocrinology Vol II London J & A Churchill Ltd 1951 (p 381)
- 15 KYLE T I and MARRIAN G F Allopregnane 3 $\alpha$  20 $\alpha$  diol in the urine of pregnant women *Biochem J* 49 80 (1951)
- 16 MASON H L Metabolites of 11 dehydrocorticosterone pregnane 3( $\alpha$ ) 20 diol 11 one *J Biol Chem* 172 783 (1948)
- 17 RUBIN H L DORFMAN R I and PINCUS G A method for the quantitative analysis of 17 ketosteroid mixtures *J Biol Chem* 203 629 (1953)
- 18 VOLT M Output of cortical hormone by mammalian suprarenal *J Physiol* 102 341 (1943)
- 19 SELYE H The critical period in the development of inflammation *Acta physiol lat amer* (In press)

# ACTH — A SINGLE SUBSTANCE OR A MIXTURE OF HORMONES\*

FRANK G. YOUNG

*Department of Biochemistry  
University of Cambridge  
Cambridge, England*

IN 1951 we advanced the view that there might be a separate factor acting on the adrenal gland other than what is ordinarily called ACTH (1). However before I discuss our own researches I should like to touch on the lines of thought which seem to indicate that ACTH may in fact contain more than one separable factor. The first suggestion of this sort that I am aware of was in 1951 when Talbot and his colleagues (2) observed that the administration of ACTH causes a simultaneous increase in both urinary 11-17 oxycorticosteroids and 17-ketosteroids in humans, but in stress presumably under the influence of endogenous ACTH from the subject's own pituitary gland the 17-ketosteroid excretion diminishes while that of the 11-17 oxycorticosteroids rises. Therefore Talbot and his colleagues inferred that the human pituitary gland secretes two ACTHs, one concerned with 11-17 corticosteroid secretion and the other with 17-ketosteroid formation.

First a word about terminology. I like to use the term ACTH as one which covers any substance present in the pituitary gland that influences the adrenal gland. I think there may be some controversy on that topic and the question of corticotropin or corticotrophin is a matter that sometimes comes up for consideration. I shall use the term "ACTH" as a general one to cover any pituitary substance acting on the adrenal gland in any respect and whether or not it brings about increased nourishment as occurs in the case of corticotrophin.

It is obvious that there are many alternative interpretations to these experimental findings, some of which were touched upon earlier, but it is interesting in view of the more recent experiments of Winter, Hollings and Stebbins (3) to find that simultaneous

---

\*The research on which the following discussion is based was carried out in great part by Mr M. P. Stack Dunne and Mr H. B. F. Dixon. On the histological aspect of the work we are grateful for the collaboration of Dr D. M. Cater.

- 34 HOFMAN F G and DAVISON C Observations on *in vitro* adrenal steroid synthesis in the rat *Endocrinology* 54 580 (1954)
- 35 MASON A S and MORRIS C J O R Congenital adreno cortical hyperplasia a metabolic study *Lancet* 1, 116 (1953)
- 36 SALAMON I I and DOBRINER K Studies in steroid metabolism XVI Isolation of  $11\beta$  hydroxy  $\Delta^4$  androstene 3 17 dione *J Biol Chem* 204 487 (1953)
- 37 MUNSON P L GOETZ F C LAIDLAW J C HARRISON J H and THORN G W Effect of adrenocortical steroids on androgen excretion by adrenalectomized orchidectomized men *J Clin Endocrinol* 14 495 (1954)
- 38 DAVIDSON C S and MOON H D Effect of adrenocortico tropic extracts on accessory reproductive organs of castrate rats *Proc Soc Exper Biol & Med* 35, 281 (1936)
- 39 VAN DER LAAN, W P Direct effects of the anterior pituitary on the ventral prostate in rats *J Clin Investigation* 32 609 (1953)
- 40 PINCUS G The biosynthesis of adrenal steroids *Progr Allergy* (In press)
- 41 ROMANOFF E B HUDSON P and PINCUS G Isolation of hydrocortisone and corticosterone from human adrenal vein blood *J Clin Endocrinol* 13 1546 (1953)
- 42 PITTS R F Effects of adrenal cortical hormones on renal function *Adrenal Cortex* E P Ralli Editor Trans Third Conf New York Josiah Macy Jr Foundation 1952 (p 11)

for the ascorbic acid reducing test and melanophore expanding effects. However this does not preclude the possibility that the substance effective in the Sayers test for ascorbic acid reducing activity does possess a small intrinsic melanophore expanding activity. The loss of this on heat treatment might be relatively small and might be obscured by potentiation of the type I have just mentioned. An overlap of properties such as might occur between ACTH active in the Sayers test and intermedin would perhaps be comparable with that already observed by du Vigneaud and his colleagues (9) to hold for vasopressin which possesses intrinsic oxytocic action in addition to its pressor and antidiuretic activities in contrast to purified oxytocin which does not appear to possess pressor or antidiuretic activity.

The possibility of an overlap of properties of that sort between various factors can be an extremely complicating one in the efforts to separate hormones and it is not one that tends to be observed at the early stages of the work. But it is one that we cannot neglect at the present time.

The possibility that pigmentation in Addison's disease and under other conditions might be related to these activities is something that I am not particularly competent to discuss but it is of some interest if ACTH has intrinsic action of the melanophore expanding type and is also concerned with the development of melanin pigmentation.

Sulman (10) has suggested that ACTH is a complex consisting of three factors: one active in the Sayers test, the second in an adrenal weight increasing test, and the third a substance which he calls the chromatophore hormone (intermedin). However I think the evidence available suggests that the ascorbic acid reducing activity and the adrenal weight increasing activity of the alkali treated intermedin are not very substantial.

More recently Johnsson and Hogberg (11) in agreement with some earlier observations of Hungerford, Reinhardt and Li (12) found that alkali heated ACTH does possess some eosinophil reducing activity. Johnsson and Hogberg state that alkali heated ACTH also induces an increased urinary excretion of potassium and of dehydroepiandrosterone in the human being while leaving the total 17 ketosteroid excretion unchanged. They make no comment about the implications of this finding but they leave open the possibility that after alkali treatment there is some physiologically significant action other than that of melanophore expanding activity.

administration of androgen, methylandrostenediol, and cortisone can induce repair of the adrenal glands in hypophysectomized rats although in these experiments neither steroid alone produced such complete repair. Some comparable observations have been made by Zizine (4).

According to Winter and his colleagues the adrenal cortices of hypophysectomized rats given androgen, methylandrostenediol and cortisone appear to be essentially normal as far as histology is concerned. Thus one may consider the possibility that the extent of adrenal repair induced by ACTH may depend in part upon the rate at which the secretion of androgen is stimulated as compared with the stimulation and secretion of adrenal steroids of the C<sub>1</sub> type. Whether such variations if they do occur would be associated with intrinsic variabilities in the enzyme pattern of the adrenal cortex or with the presence of different fractions in ACTH one of which is particularly potent in stimulating the secretion of androgens of the adrenal cortex is a problem which I do not wish to discuss at the present time. I feel that perhaps the simplest interpretation is that there is variability in the adrenal cortex and that there is no clear evidence from these observations that there is more than one ACTH. I am not inclined to accept the view that the endogenous ACTH in man is different from that which is administered as conventional ACTH.

The second matter which I wish to touch on is the possible relationship of ACTH and intermedin with which we ourselves have not been directly concerned in recent years. We were interested in the question of intermedin a good many years ago and Dr. Collip (5) first made suggestions about the relationship of intermedin with metabolism stimulating pituitary factor but the recent suggestions by Johansson and Hogberg (6) and also by Sulman (7b) that there is a relationship between ACTH and intermedin certainly comes under the scope of the present discussion.

I think it is to be accepted that the purest preparations of ACTH so far obtained do possess some melanophore expanding activity. However it is also true that when such preparations are heated in 0.1 normal NaOH for from 5 to 10 minutes at 100° C. there is an almost complete loss of ascorbic acid reducing activity with a small loss of melanophore expanding activity. Furthermore in some crude preparations of pituitary extracts one finds that heating in alkali appears to potentiate the melanophore expanding action.

I think it is clear from the experiments on heating in NaOH that there can be no simple identity between active structures responsible

pH 8.5 in the cold room and we usually Seitz filter the extracts and keep them in a sterile condition at pH 8 to 8.5. This extract contains substantial growth promoting activity. Tested in the hypophysectomized rat it contains thyrotropic and gonadotropic activity but in the Sayers test it is virtually devoid of action. We find in fact, calculating from the average of a large number of estimates made on material of this sort that about 70 gm. of the material in this extract contains one International unit of ACTH as measured in the Sayers test and I do not think that can be regarded as significant that effect can be obtained only by giving very large doses intravenously in the Sayers test.

**Rall:** May I ask if you assayed this in hypophysectomized albino rats?

**Young:** Yes for the most part however we did not always use albino rats.

**Rall:** We found that in the two weeks following hypophysectomy in young black rats (14) there was an increased deposition of pigment in the hair apparatus of the animals as the adrenal atrophied. This was similar but not as intense as that observed when we removed the adrenals from black rats (15).

**Young:** Was this in entirely black rats?

**Rall:** Yes it is easier to observe in black rats.

**Young:** The two types we have used are Norwegian and hooded rats black and white or all white. We have not noticed any changes in the hair.

**Rall:** The pigment changes are not discernible in the black and white or all white rats but a change should be observed in the hair growth (16, 17).

**Young:** We certainly have not looked for that particular point. As I say it is not at all clear as to why this crude alkaline extract is so deficient in activity in the Sayers test because one can show by extraction with acid acetone for instance that the ox. anterior pituitary tissue that we have used has a reasonable amount of ACTH activity as measured in the Sayers test. We found it to be rather less than pig gland but it is a substantial amount and yet in this alkaline extract there is virtually none at all. It is to be assumed that enzyme action of some sort has occurred under these conditions which has resulted in destruction particularly of the material active in the Sayers test but although we have done a few preliminary experiments on this point we have no clear evidence on the nature of the enzymes.

*Pincus* May I interrupt at this point and ask about the dehydroepiandrosterone? Is this determined chemically or purely on the basis of a color reaction?

*Young* It is on the basis of color reaction

*Pincus* I should like to point out that the color reaction may not be specific

*Young* Yes I think, as Dr Vogt (13) has pointed out one has to be extremely careful about basing any estimation with respect to eosinopenic activity on nonspecific proteins. It seems that nonspecific protein substances are capable of reducing eosinophils and it appears improbable that the alkali heated intermedin does possess physiologically significant activity with respect to eosinophil reducing activity or any other type of action. I do think it is of interest however, that Collip (5) in his early work on ACTH assayed by adrenal weight maintaining activity in hypophysectomized rats and observed that the preparations he had available were remarkably stable to heating in alkali even at pH 10 or 11. We have the intention which we have not yet been able to carry out of going over those earlier findings of Collip and assaying ACTH by adrenal weight increasing activity as he himself did.

Our own interest in adrenal weight increasing activity of ACTH preparations began when we found that the activity of some relatively purified ACTH preparations that is purified on the basis of the Sayers test was relatively poor and that conversely the adrenal weight increasing activity of some other extracts that we were able to prepare which had minimal activity in the Sayers test was substantial (1). In our test for adrenal weight increasing activity we hypophysectomized rats and left them for a couple of weeks or so for the adrenal glands to atrophy and then administered material three times a day for three days interperitoneally, the animals being killed on the fourth day and the adrenal glands being weighed. We regarded that as a pretty rigorous test for adrenal weight increase activity since the atrophy occurring during the two weeks after hypophysectomy was quite substantial.

*Long* Did you test the ascorbic acid depletion of rats two weeks or two or three days after hypophysectomy?

*Young* We did the conventional Sayers test. In these experiments we found that a crude alkaline extract of ox anterior pituitary gland which we had used in other work on diabetogenic action among other things was remarkably ineffective in the Sayers test and we are still not clear why this is so. This extract is prepared from fresh ox anterior pituitary tissue by grinding with saline at

find some differences between the AA and AW tests of the histological activity of what I might call conventional ACTH

*Pincus* I do not understand your ratios in Table V how do you obtain them?

*Young* An Armour preparation 84/85 U was taken as a standard in the AA and AW tests (actually it was 25 International units per mg) and we compared the other substances in terms of that standard. That process is open to a great deal of criticism but if one is comparing activities in different types of response of this sort I do not think the ratios can mean anything quantitatively precise except that they were so large that they did indicate there was a qualitative difference between the types of extract.

In a histological assessment of the adrenal glands we thought we might find some difference between the material that was active in the AA and AW tests. However when we treated the hypophysectomized rat with an AW preparation (growth hormone in this case) the adrenal gland was found to be much more normal than when larger doses of conventional AA active ACTH were administered. That has been a pretty consistent finding. If we give a large dose of AA material we find a distribution of lipid reminiscent of that which is seen in the intact animal under conditions of stress and which we do not obtain with FCS the crude preparation growth hormone or other AW active materials.

*Pincus* Is this done by intravenous administration?

*Young* No these tests are all carried out by intraperitoneal administration.

*Rall* Did you say that the adrenal weight anterior pituitary factor had some growth hormone in it?

*Young* Yes it did. We have in fact used growth hormone as an AW preparation. We also found there was a difference between the two types of active material with respect to stimulation of mitotic activity.

When we examined the number of mitotic figures in an arbitrary area of adrenal gland of a normal hypophysectomized rat treated with a dose of adrenal ascorbic acid reducing material and also of one treated with growth hormone we found there was no significant change in the size of the cells (16). The FCS material or growth hormone would bring back the mitotic activity appearance of the adrenal cortex to something approaching normal which we were unable to do with any reasonable dose of ascorbic acid reducing active material (Figure 20). In fact if we gave any large dose of the ascorbic acid reducing material we always obtained abnormal



TABLE V

Relative Activities of Pituitary Preparations in Terms of the Activity of Preparation 84/85 U

Fraction	Total dose (mg)	Equivalent to standard in		Ratio of AW to AA activity
		AA test	AW test	
FGS A	90	0.0005	2.6	5200/1
FGS B	180	0.0012	2.9	2400/1
Growth hormone	22	0.0024	2.0	830/1
84/85 U	5	5.0	5.0	1/1
84/85 H	15	20.5	2.0	1/8

The crude alkaline extract that I have been referring to is called FGS in Table V. In the first paper we published on this (1) we calculated a ratio of activity in the ascorbic acid reducing (AA) test as compared with activity in the adrenal weight increasing activity (AW) test that we had utilized. These figures show that the adrenal weight increasing activity is significant without there being anything that can be regarded as comparable ascorbic acid reducing activity.

This particular crude extract the FGS was quite rich in growth promoting activity. In the early stages of our work we had used it for the preparation of growth hormone. We therefore were led to test growth hormone for an action in the adrenal weight increasing test particularly since there had been suggestions by Dr Selye and others that it might have some action of a mineralo cortico tropic type. We found that it was indeed active in adrenal weight increasing tests although most of the preparations of growth hormone that we had were rather more active in the Sayers test than the crude FGS extract had been. We found in general weight for weight that the growth hormone we were utilizing was about five times as active in the Sayers test that is about 14 gm of the material was equivalent to one International unit of ACTH in the Sayers assay. Whether that figure is significant or not I should not like to say. I think it probably is not.

We have attempted to investigate the type of action on the adrenal cortex of these various preparations the FGS and the growth hormone because in the early stages of this work we did

distribution of lipid which we did not find with the adrenal weight increasing preparations

*Selye* Did you obtain an actual increase above normal in lipids with the adrenal weight factor?

*Young* We have done very little in the way of chemical estimation of lipids

*Long* Have you determined the adrenal cholesterol and was it normal in the glands treated with the AWF factor?

*Young* Again we have done very little on that but in a few estimations in the early stages we found an essentially normal cholesterol. When the adrenal weight increasing material and the ascorbic acid reducing activity were given simultaneously there was certainly some evidence of summation of effects with respect to adrenal weight increasing activity but none with respect to mitotic stimulating activity that is the latter seemed to be more clearly associated with the factor that was not effective in the Sayers test

It is true that large adrenal glands may be produced by giving large doses of corticotropin but in our studies the histological picture of these glands was quite dissimilar to that seen after the administration of adrenal weight increasing preparations and in any case as I already emphasized the adrenal ascorbic acid reducing activity of our preparations was so small as to be virtually negligible

We have not gone very far with the fractionation of material that is active in the adrenal weight increase test since a good part of our energy has been expended in the direction of the ascorbic acid reducing factor and we have not progressed very satisfactorily with that either. However in the experiments on the fractionation of ascorbic acid reducing activity with ion exchange resin particularly amberlite IRC 50 which Dr. Stanford Moore (19) has used so successfully we found that fractions which ran fast on a column of amberlite IRC 50 produced very large adrenal glands in the AWF test although they showed only slight AA activity (20)

When any crude preparation of ACTH is fractionated on a column of amberlite IRC 50 at pH 6.7 by the method which I need not describe in detail the adrenal weight increasing material is less retarded through the column than is ascorbic acid reducing activity. That has been a reasonably consistent finding in fractionation on the amberlite IRC 50 (Figure 21)

We have not obtained complete separation of AA and AWF activities by using methods of this sort and it is conceivable if two separable substances overlap in activities that we shall never do so




FIGURE 20 Mitotic figures counted in  $1 \text{ mm}^2$  of adrenal cortex. The two lower figures give results for hypophysectomized rats treated with AA preparation 84/85 H (0.5 mg totally equivalent to 1.7 International units) or with growth hormone (20 mg totally). The hormones were given in divided doses three daily for three days intraperitoneally. Reprinted by permission from Cater D B and Stack Dunne M P. The histological changes in the adrenal of the hypophysectomized rat after treatment with pituitary preparations. *J Path & Bact* 66: 119 (1953).

However there were possible alternatives in interpretation that had to be considered. It might be suspected that AA active fractions would be more effective in the AW test when mixed with protein or other material which would be present in fractions coming through the column early. These materials might delay absorption through the peritoneum and might therefore enhance the activity of the material in the AW test or perhaps protect it from extravascular inactivation because when prepared by different methods there appear to be very different susceptibilities of materials to extravascular inactivation.

Thus in many of our experiments we have attempted to slow down to a very substantial extent the rate of absorption of these materials in the AW test by mixing them with various types of material. We have used inert protein (serum albumin or casein) precipitated by tannic acid and in some cases the *beeswax* Arachis method introduced by Bruce and Parkes (21). In all cases we find that the difference between the peak of AA and AW activities in these experiments is still maintained that is one cannot by slowing the absorption alter the apparent peak of AW activity. We are disinclined to believe on the basis of that evidence that these effects are merely due to differences in the rate of absorption of material. Certainly we still find the differences for instance when the absolute value of activity may be increased by as much as twentyfold by mixing with various inert substances designed to delay absorption. The fractionation procedures that we have carried out so far have been inadequate to differentiate between growth hormone and the AW active material.

I should like to refer to some experiments of Rinfret (22) and Forsham (23) that have been published within the last year which may be relevant to our own findings. They report that an extract of horse pituitary glands which is poor in ascorbic acid reducing activity (although they do not give precise figures) will nevertheless maintain the adrenal glands of the hypophysectomized rat. The intravenous administration of this extract in man in contrast to that of conventional ACTH leads to almost no immediate increase in adrenal steroid secretion as estimated by urinary 17 hydroxycorticosteroid and 17 ketosteroid excretion and induces no change in circulating eosinophils.

When a human subject was treated with this adrenal weight increasing preparation for five successive days the subsequent injection of AA preparations (conventional ACTH) led to an increase in the urinary excretion of 17 hydroxycorticosteroids and 17 keto




FIGURE 21 Chromatogram of crude corticotropin on amberlite IRC 50 (200-400 mesh) in 0.2M sodium phosphate buffer pH 6.69 containing 0.2 per cent phenol and 0.5 per cent thiodiglycol. 475 mg of crude corticotropin was extracted with 95 ml of the buffer and 11 ml of the solution put on a 2 cm x 29 cm column. Weight of untreated adrenals was 90 mg. The erect hatched areas represent AA activity. The dependent hatched areas represent AW activity. Reprinted by permission from Dixon H B, Stack Dunne M P, Young F G and Cater D B. Influence of adrenotropic hormone fractions on adrenal repair and on adrenal ascorbic acid. *Nature* 168: 1094 (1951).

*Young* We have not studied that but we should have noticed it in some experiments in which they have been given simultaneously

*Conn* Have you compared mitotic activity in any other organ with that in the adrenal under the same circumstances?

*Young* We have not done any consistent survey in this connection but we have observed in other aspects of our work with growth hormone and with crude FGS that there is certainly mitotic activity in other glands. Certainly one sees it in the islands of Langerhans of the pancreas and also in the pituitary gland in normal animals

*Astwood* Do you find an increase in thyroid and gonad weight under these same conditions?

*Young* We do find consistently an increase in gonad weight which has rather disturbed us because there is no evidence that our growth hormone is free from follicular stimulating hormone (FSH). We find an unimpaired effect on the adrenal weight in castrated rats and it appears as far as we can tell to eliminate the possibility that the adrenal weight increasing action is mediated by the secretion of androgens by the testes

*Astwood* You interpret this increase in gonad weight as being due to an effect of growth hormone or to a hitherto unrecognized gonadotropin?

*Young* We should have performed the experiment of testing for action on the gonads in the absence of the adrenals because of the possibility that androgen production by the adrenals may have been stimulated under these conditions. However this has not been done as yet and until it has we shall have to accept the simple interpretation of our findings which is that the growth hormone is probably contaminated with FSH

*Astwood* Do you have evidence that the adrenal weight factor is indeed not growth hormone?

*Young* My own feeling is that it is not but we have no evidence that it is not or that it is

*Long* I assume that you have not fractionated growth hormone on amberlite columns to see whether you would obtain the type of separation that occurs with ACTH?

*Young* We have tried preliminary experiments of that sort but we have not been very successful so far in finding the conditions that would be appropriate

*Long* Dr Li what was the effect of the highly purified growth hormones on the adrenals in the long term experiments?

steroids which was two to three times those consistently observed in the same subjects before treatment with AW preparations. Purified conventional ACTH and growth hormone in their hands both failed to induce an effect comparable with that of their AW preparation. What the relation of their observation is to ours I am not certain although they may conceivably be related.

Bush (24) has carried out some experiments with some of our preparations intravenously administered to the hypophysectomized rat and has found that the administration of the AA preparations increases the amount of corticosterone in the adrenal venous blood and that the administration of AW preparations under these conditions causes no increase. He has observed that this is true whether the material is administered intravenously or whether it is given some days previously by subcutaneous or intraperitoneal routes. These findings could conceivably be related to those of Rinfret and others although unfortunately we have not been able to follow them up.

Pincus: As I remember Bush found that he did not obtain the same effect when he followed the AW with the conventional AA preparation, and that there was no indication of an enhancement of corticoid secretion. Is that so?

Young: I believe he found no enhancement under those conditions.

Ingle: How much increase in adrenal weight did you find after the injection of the adrenal weight factor for four days?

Young: There is a return to the normal weight of the adrenals. Under some conditions however that is the exception rather than the rule. The adrenals usually weigh up to 18 or 19 mg. in the size of rats we have been using with the controls weighing about 10 to 12 mg.

Li: What happens to the thymus weight?

Young: We have not done a great deal on thymus weight but there is no significant change in these AW tests. I should have emphasized that we have used rather older animals and perhaps we could miss changes in thymus weight that might be more obvious in young animals.

Long: Is there any effect on eosinophils of those preparations?

Young: We have not looked into that.

Selye: When you give the two hormones ACTH and growth hormone simultaneously do you obtain an inhibition of the ACTH involution by your AW factor?

Dr Li very kindly sent us a small sample of his purified growth hormone and this gave us the best peak fraction of any material we handled however it still contained a small amount of material which could be removed by the countercurrent distribution and it makes one extremely hesitant about assuming that growth hormone is pure. The type of evidence that would be useful to us at any rate with regard to the presence or absence of adrenal weight increasing activity and growth promoting activity would be of the types we have been pursuing for some time in respect to diabetogenic activity. If we could find that under all conditions of partial inactivation by various treatments that any disappearance of adrenal weight increasing activity was associated with a comparable disappearance of growth promoting activity we might feel that there was an association between the two if we could separate them completely we might feel there was no association. However at the moment we are lacking in any evidence on this point and therefore I should prefer to await further evidence as to whether growth hormone is or is not a responsible agent.

Loeb: Dr Young was the material you used beef in origin?

Young: Yes.

Loeb: Dr Li did you also use beef?

Li: Yes. Dr Young what system do you use for the countercurrent distribution?

Young: *p*-toluenesulfonic acid and 2 butanol.

Pincus: May I ask whether a similar administration of a highly purified ACTH gave you very different results? In other words in hypophysectomized animals do you observe the growth of the adrenal?

Li: Oh yes it was very marked with almost any purified preparation although the injection vehicle makes a difference in result. When the injection is administered in saline solution there is no gain in adrenal weight or only a very slight gain. However when the preparation is suspended in beeswax pernut oil according to the method of Bruce Parkes and Perry (27) there is a very marked increase. As a matter of fact in collaboration with Dr W. R. Lyons (28) we have obtained evidence of progestogen secretion in these greatly hypertrophied adrenals. When the injection vehicles which result in delayed absorption are used an adrenal weight of about twenty or even forty times the size of the controls may be obtained.

Young: I would not disagree with that. Substantial enlargement of the adrenal glands may be produced with what we may call



**L1** In 1951 we summarized our data accumulated over a period of 12 years on the relationship of growth hormone to adrenal weight changes in hypophysectomized rats (25). We found no evidence that the adrenal cortex is stimulated by growth hormone. It is true that the size of the adrenal increased somewhat in some cases but this increase in adrenal weight seems to be almost solely due to the enlargement of the adrenal medulla. In an experiment in which growth hormone in a total dose of 555 mg was injected for a period of more than a year to young hypophysectomized rats the body grew to about ten times the original size but the adrenal weight when calculated in proportion to body weight decreased 31 per cent as compared with the controls. We have been following Dr. Young's work with keen interest with respect to the possibility of some association between the AW factor and growth hormone and we have tried to fractionate growth hormone as far as we could. So far we have been unable to find that there is any substance which can be fractionated from growth hormone that has any effect on the adrenal. Hence we feel very strongly that the growth hormone prepared in our laboratory does not contain an adrenal weight factor and any changes in adrenal weight produced by it must be due to contamination by an adrenal stimulating substance and not primarily to growth hormone.

**Young** Have you observed mitotic activity in the adrenal glands?

**L1** We have seen no evidence of mitotic changes comparable to yours.

**Young** I am sorry that the work on mitotic activity has not yet been published.

In relation to diabetogenic activity of growth hormone so far we have been unable to differentiate it from growth promoting activity. In regard to the action on the adrenals we have no evidence one way or the other to say that the two go together or that they differ. All we know at the moment is that all the preparations of growth hormone which we have handled do have mitotic stimulating activity and adrenal weight increasing activity.

I should be very apprehensive about saying that any preparations of growth hormone are pure. During the last year Dr. J. G. Pierce of the University of Cambridge (26) has developed a counter-current distribution system for the purification of growth hormone and has managed to remove from all the preparations of growth hormone we have had some small amount of material which is not in the main growth promoting fraction. This small fraction has not yet been tested for biological activity of various types.

TABLE VI

Effect of Acid Hydrolysis on ACTH Activities by  
Two Methods of Assay

Preparation	Ascorbic Acid Depleting Activity		Adrenal Weight Activity*			
	Intravenous injection with saline	Subcutaneous injection with gelatin	Dose†	No of rats	Adrenal**	Thymus**
	USP units per mg	USP units per mg	Mg		Mg	Mg
Untreated	42	43	0.1	19	28	75
Acid hydrolysate	38	53	0.1	10	16	218
			0.0	25	11	228

\*Injected into male rats hypophysectomized at 40 days of age once daily over a four day period beginning four days postoperatively  
†Injection solvent 5 per cent beeswax in peanut oil  
\*\*Control: adrenal 11 mg thymus 228

of adrenal weight from 11 to 16 mg produced by the hydrolyzed material but with the untreated material there is an increase which may reach 28 mg during the four day period

**Young:** We have results which are quite in agreement with that. We compared preparations before and after a partial acid hydrolysis and found as Dr Li has also that there was a diminution in the effect of these materials on the adrenal weight activity. However I am disinclined to quote that as evidence in support of the general view that there might be more than one factor because in this case we are arguing on a quantitative difference and the question of rate of absorption might conceivably be a factor which would be more difficult to control there than in the other preparations that we have had in which there were extreme differences in activity.

**Dr Li:** Have you ever tested a crude alkaline extract of beef pituitary for adrenal weight increasing activity?

**Li:** Yes we have tested some but the adrenal weight increase is not impressive.

**Young:** What about the ascorbic acid reducing activity?

**Li:** We do not have very extensive data concerning the ascorbic acid depleting activity of this particular extract but it is my impression that it was very low.

ascorbic acid reducing factors. Whether the histological picture there is comparable to that seen in animals treated with AW preparations is I think a matter for discussion. The point I wish to emphasize is that we do obtain a very substantial effect on the adrenal weight with material which is virtually lacking in ascorbic acid reducing action. I do not think that the question of rate of absorption or any other factor is likely to account for the findings. If we could obtain material that is completely lacking in any action in the Sayers test that would be more satisfactory, but when we administer very large doses of any preparation of growth hormone we often get a very small effect in the Sayers test which I am inclined to think is not significant. It is so small that it probably does not account for the substantial adrenal weight increasing effect of these preparations.

*L:* In one of our experiments a female rat was hypophysectomized at 27 days of age. Three days later injections of 30  $\mu$ g of  $\alpha$ -corticotropin were begun which continued daily for nine days. At the end of that time the adrenal weighed 22 mg and when compared with that of a hypophysectomized control animal it appeared hypertrophied and overstimulated. The adrenal from the hypophysectomized control animal was injected with beeswax peanut oil and weighed 4 mg.

When purified ACTH is hydrolyzed with 0.2 M hydrochloric acid in a 0.1 per cent solution and refluxed for three hours some hydrolysis takes place. This preparation apparently retains its ascorbic acid depleting activity but the adrenal weight increasing activity is greatly reduced even when it is injected in a beeswax peanut oil suspension.

*Young:* Did I understand you to say the ascorbic acid reducing activity was the same after hydrolysis? I thought you said previously that it was increased.

*L:* It was hydrolyzed much less. In this case the hydrolysis was carried out with refluxing for three hours. The same thing occurs whether the refluxing is for 40 minutes or for one hour.

*White:* Have you given this acid hydrolyzed preparation by continuous intravenous drip in your rats to see whether you can really get the adrenals to grow?

*L:* Not in the experiment I have been citing. Table VI gives the assay data for the acid hydrolyzate which was obtained under the conditions just described. We observed that the untreated material reduced the thymus weight markedly but that the hydrolyzed material had scarcely any effect. There is a slight increase

hours before removal of the adrenal for ascorbic acid determinations were also used in our experiments

*Astwood* I do not think that the three hour subcutaneous method agrees quite as well with clinical effectiveness as has been suggested

*Long* I wonder whether there are any conventional ACTH preparations that are not rapidly inactivated in the blood stream following injection We are interested in this problem for a good many reasons not entirely related to their chemistry Recently one of my colleagues Mr A Brodich devised a method of cross circulating rats so that as much as 100 ml of blood was exchanged in an hour The purpose of this was to obtain some measure of the output of ACTH under various conditions

*Pincus* Do you mean of the normal pituitary?

*Long* Yes If a normal rat is put in cross circulation with a hypophysectomized animal the fall in the adrenal ascorbic acid of the latter is a measure of the amount of ACTH that has been liberated from the pituitary of the normal animal One complication is the question as to how much and how rapid is the inactivation of ACTH that is released since it would appear that this can occur with great rapidity Such rapid inactivation would obviously give too low values when judged by the depletion of adrenal ascorbic acid in the hypophysectomized animal We have attempted to assess this by establishing cross circulation between two hypophysectomized rats and giving ACTH to one The depletion of the adrenal ascorbic acid of both animals is then determined and it is easy to see that when small amounts of ACTH of the order of 5  $\mu$ g are administered that considerable inactivation of ACTH occurs during the period of cross circulation Whether this is also true for the naturally secreted ACTH cannot be answered at present

*Thorn* The ACTH in those experiments was given intravenously?

*Long* Yes

*Pincus* Dr Li in the experiments on the thymus weight was the material given subcutaneously in gelatin?

*Li* No it was given in beeswax peanut oil suspension We found it more effective than the 16 per cent gelatin medium

*Pincus* The rate of movement of the material out of the beeswax and into the blood would be an unknown factor

*Li* The process would be very slow

*Pincus* Thus the degree of inactivation which you speak of would be purely a function of how much actually gets in?

*Young* Dr Li was the material in your crude alkaline sterile extract?

*Pincus* In Table VI, the data on adrenal weight and thymus weight, show that the untreated material increases adrenal weight and that it is quite thymolytic in its activity. By these criteria the acid hydrolyzate is just an ineffective preparation. The acid hydrolyzate is administered over a period of four days as compared with just a few hours for the ascorbic acid test. Therefore, perhaps it is inactivated. You have shown that ACTH preparations may be inactivated by a number of tissues and we have found such inactivation in blood (29) but what I am wondering is whether the hydrolysis simply does not prepare a substance for the inactivating enzymes?

*Li* Dr. White pointed that out.

*Pincus* The other question I should like to ask is do you have preparations which are differentially inactivated? You did some studies on inactivation by tissues. Do you have one ACTH which is very rapidly inactivated by tissue and another which is very slowly inactivated?

*Li* There is some indication to that effect but it is not very clear cut.

*Dorfman* How many animals were used in those ascorbic acid depleting activity tests?

*Li* For the ascorbic acid test there were at least 7 animals per group with two or three dose levels and sometimes as many as 33 animals in one level.

*Astwood* In line with Dr. Pincus' suggestion Drs. Forsham, Renold, and Frawley (30) in 1951 showed that some preparations suffered local inactivation and that others did not. More recently Forsham and co-workers (31) have shown that whereas corticotropin A type preparation which has not been subject to hydrolysis is not inactivated subcutaneously treatment with pepsin to yield what Merck calls corticotropin B type preparation makes the material very ineffectual subcutaneously suggesting that it is rapidly inactivated at the subcutaneous site whereas it maintains its activity in the Sayers test.

*Young* Have you yourself any evidence on that point?

*Astwood* No, we have not.

*Young* Has anybody ever confirmed that view of Forsham's?

*Astwood* Corticotropin assays in rats using subcutaneous injections of gelatin and adrenal ascorbic acid depletion in three hours are in agreement with that view.

*Li* Subcutaneous injections of 16 per cent gelatin injected three

weight protein At the time we did the experiment we did not have the ascorbic acid depletion test I remember that Dr White went to great pains to calculate it in terms of body weight at a dose level of 20  $\mu$ g per day we were able to obtain a fair adrenal weight increase I think Dr White and Dr Long will remember that We are not able to obtain an adrenal weight increase with our most highly purified ACTH preparation which assays 200 IU per mg according to the ascorbic acid depletion assay without using delayed absorption

White This is the partially hydrolyzed product?

Li It is unhydrolyzed but it has been submitted to the oxycelulose adsorption procedure

Long Dr Astwood summed that situation up very well a year or two ago at this conference He said that all we isolated was ballast protein with the ascorbic acid depleting factor attached or words to that effect

Young Dr Li if you mix the purified ACTH with what Dr Long has called "ballast protein" do you in fact increase its AW activity?

Li No if you mix it with growth hormone FSH or pituitary extract you do not obtain the adrenal weight increase

Young In general we find that the adrenal weight increasing effectiveness of our preparations is obtained by mixing them with an inert protein particularly if we make the materials relatively insoluble

Li It is a very soluble protein it does not seem to me to be a matter of solubility

Young I think it is perfectly reasonable to suppose that the adrenal weight increasing activity of these materials will be increased if there is slower absorption over a period of time and that in fact is what we find It is conceivable that the adrenal weight increasing activity of the protein hormone may have been due to the fact that there is 1 per cent ascorbic acid reducing material and 99 per cent protein Dr Li you do not find that your more recent experiments agree with that?

Li No

Long I should like to admit to heresy here for the sake of argument It seems to me that one of the main points of this discussion rests on the comparison of ascorbic acid depletion assigned to a certain activity of the gland against adrenal weight Are we so sure that the ascorbic acid depletion method is the infallible test under all circumstances? Actually how much do we know about

*Li* No We used an alkaline solution at around pH 11 which might be different from an extract made at pH 5

*Young* There may be something peculiar about this crude alkaline extract which we prepared We used it as a standard for a good many years in the early work on diabetogenic activity and found that it was essential to maintain approximately sterile conditions from the early stages so that we could obtain diabetogenic activity We Seitz filtered the material for storage purposes if we did not do that we lost diabetogenic activity It is that material which we used subsequently for our AW test

There is a recently published paper by Winter Brink and Folkers (32) in which they failed to find good adrenal weight increasing activity in a crude alkaline extract They say that their material had less than one unit of ascorbic acid reducing activity per milligram I had the opportunity of discussing this point with Dr Winter the other day but he was not very clear as to just what the activity had been I do not think they assayed it very closely for AA activity and they had had trouble apparently with toxicity of this material which we certainly do not have with our crude extract Thus I wonder whether the whole question of sterility and bacterial action may not be of very much greater significance with these crude extracts than we have thought in the past Dr Astwood you have not used crude extracts of this type have you?

*Astwood* We have not studied the AW phenomenon at all

*White* It might be worth while to ask Drs Young and Li whether either of them has succeeded in further fractionating an alkaline extract of beef pituitary tissue and obtaining a so called ACTH like protein The reason I ask the question is that it was our impression many years ago that in the case of the beef pituitary one starts first with a gland that does not have a great deal relatively speaking of ACTH and secondly that alkaline as compared to acid extraction is relatively inefficient for getting out what ACTH is present I wonder whether one can really isolate from such a crude alkaline extract something that resembles a 20 000 molecular weight protein of ACTH or anything else in the way of a purified preparation

*Young* We have not tried that As I say the material is so lacking in ascorbic acid reducing activity that we have not considered it but it might be well to look into it as a source of material which is AW active

*Li* Dr White brought out a very interesting point We agree that the adrenal weight activity is good in our 20 000 molecular




FIGURE 22 Average percentage change in body weight, adrenal weight, and total adrenal cholesterol in male rats from time of operation (unilateral adrenalectomy) to time of sacrifice as influenced by a normal diet and diets containing large amounts of pantothenic or ascorbic acids.



the alterations in ascorbic acid and adrenal glands other than in the rat? Certainly, in the guinea pig we have considerable difficulty in establishing the relationship of ascorbic acid to the activity, particularly if the animal happens to be deprived of vitamin C. Nevertheless under those circumstances we do know that the adrenal is active.

*Young* I entirely agree with you, Dr. Long. If the Sayers test is assumed to indicate something whatever it is in the rat we are interested to know whether under those conditions it is also responsible for the adrenal weight increasing effect.

*Long* I should like to extend that further. I think it has been purely a matter of chemical convenience that ascorbic acid was selected as the method of assay. One can present a much better argument for following the changes in the adrenal cholesterol as being much more closely related to the actual formation and release of the hormone and yet there is practically no work being done on the association of adrenal weight changes with changes in the adrenal cholesterol. In fact I can point to many examples where the ascorbic acid change can be dissociated from the adrenal cholesterol. I shall refer again to the situation in the guinea pig and there are other circumstances too. Recently we have been simultaneously determining the eosinophil count, adrenal cholesterol and adrenal ascorbic acid. Without any difficulty whatever I can present to this group an idea supported by experimental data that there is a factor in the pituitary that lowers adrenal cholesterol and does not lower adrenal ascorbic acid or any other combination you may wish to consider. However the whole emphasis here seems to be placed on the ascorbic acid as the infallible indicator. It may be extremely useful as an assay method and I grant the convenience in doing it in the rat but do we know that the adrenal ascorbic acid in other species does change in response to ACTH? We have done a few experiments in which we have performed a unilateral adrenalectomy on cats and on rabbits spacing the removal of the two glands two or three hours or more apart. We have not done a great many of them but certainly in contrast to the rat changes in ascorbic acid after unilateral adrenalectomy in larger animals are small within an hour or two compared to the 50 per cent drop obtained in the rat. It is hard to believe that the adrenal-pituitary system has not been activated to a very high degree when a laparotomy is done in these other animals.

*Rall* May I present some work we have done along this same line in the normal rat rather than in the hypophysectomized rat?

studies with adrenal slices that any of these various preparations actually produces a different kind of steroid?

**Dorfman** We have started to study that point. We have used various ACTH preparations a highly purified preparation from Dr Astwood and two crude preparations in an *in vitro* adrenal slice system. Our experience indicates that there is a correlation between ascorbic acid depleting activity and the quantity of hydrocortisone produced.

**Young** We have not done a great deal on the question of adrenal cholesterol but the possible working hypothesis we have had what we have called the AW factor may be concerned with the deposition of cholesterol in the gland and not with production of steroids from it.

**Ingle** There are grounds for questioning the reliability of these tests done from one laboratory to another even when the same standards and the same general procedures are employed. During the past two years I have seen many data on assays from different laboratories. Preparations which I have received from Dr Li from Dr Astwood from Armour and from Merck have all been re-assayed in the Department of Endocrinology at the Upjohn Company and it was rather rare to find agreement between them. Moreover there were two separate groups at Upjohn's doing these assays and each group learned from the other. They were using the same strain of rats and were duplicating the procedures as nearly as possible. During this past year they carried out a study with Dr George Sayers taking several preparations of ACTH and assaying them as unknowns. For a few preparations there was a certain agreement but there was significant disagreement among others. The adrenal weight method has never been a very reliable method from the standpoint of sensitivity. In respect to technique alone there are bases for considerable disagreement.

**Pincus** We have been trying to develop a perfusion method as an assay method and Mr Micchi in our laboratory at the Worcester Foundation has worked on this for several years. As Dr Dorfman has pointed out while there is a correlation between the ascorbic acid depleting activity and the amount of steroid produced we also find that from one day to the next we do not always obtain the same result. On one day the ACTH will give us so many milligrams of steroid per hour and on the next day in similar glands it will give us one fifth or one tenth or three times as much. Was there not an attempt by Haynes (34) to try to develop an *in vitro* assay and did he not also find this great variation?

The left adrenal of the rat was removed, weighed and the cholesterol content determined. At varying intervals of time after unilateral adrenalectomy the right adrenal was removed and the same determinations made. These data are preliminary and are part of a study on the effect of nutritional fractions and stress on adrenal cholesterol. Each point in Figure 22 represents the average of groups of nine or ten rats. The upper section of the figure shows the body weight, the middle section the adrenal weight and the lower section the adrenal cholesterol of rats at intervals varying from six hours to 14 days after unilateral adrenalectomy. Data are presented from animals on (a) a control diet adequate in all the nutritional fractions required by the rat and shown by solid circles, (b) this diet plus 4 mg of pantothenic acid per 10 gm of diet shown by clear circles and (c) the control diet plus 100 mg of ascorbic acid per 10 gm of diet shown by crosses. Following unilateral adrenalectomy there was a sharp drop in the adrenal cholesterol in the rats in all three diet groups. The restoration of cholesterol at 24 hours was greatest in the group on the control diet but from the third day on the group on high pantothenate showed a greater increase in adrenal cholesterol content than the controls. The restoration of adrenal cholesterol in the group receiving ascorbic acid was retarded up to the seventh day but by 14 days in the animals observed up to the present the adrenal cholesterol content was greater than in the other two groups. Interpretation of these data must be postponed until additional animals have been studied. This type of experiment is we think a good index of the response of the adrenal to stress in animals conditioned in various ways. We have published a report on the effects of diets deficient in pantothenic acid on the restoration of adrenal cholesterol following stress (33). In the pantothenate deficient rat both the initial cholesterol concentration and its resynthesis following stress were markedly depressed. We have not yet studied the hypophysectomized animal but hope to do so later.

We also observed animals deficient in pantothenate in which the resynthesis of cholesterol was depressed during the entire period of time following the stress. The absence of pantothenate seems definitely to retard or depress the resynthesis of cholesterol in the normal animal.

*White.* With the new methods for identification of steroids are we not in a position to decide definitely which ACTH does what in terms of producing steroids? In that connection I wonder whether there is any indication through perfusion or incubation

looked for other criteria which we think might be more satisfactory such as mitotic stimulating activity and an adrenal histological factor I think some of the discrepancies that do occur are of a relatively small nature a few hundred per cent and might well be ascribed to differences of this type in the adrenal weight effect

*Astwood* I wonder whether Dr Young would not agree that the main difficulty here is a matter of terminology The adrenal weight factor is really one that restores the adrenal weight to normal in the hypophysectomized rat which is a small weight increase whereas corticotropin is a substance that usually produces a very large increase in adrenal weight This causes a difficulty in the nomenclature

The second point is that many things can change adrenal weight Probably all cells in the body benefit from thyroid hormone it has been shown that cortisone plus androgen will restore the adrenal weight to normal after hypophysectomy just as estrogen will act directly on the ovary Yet we do not speak of estrogen as a gonadotropin or androgen as a corticotropin Perhaps Dr Young will agree to regard the adrenal weight factor as not a specific corticotropin If he would so agree then I think the difficulty would be resolved

*Young* I think the word specific is interesting there I was rather careful to say earlier that I would treat the term ACTH as covering all pituitary substances affecting the adrenal gland and I would not suggest that the substance that we are concerned with was limited in the effects on the gland

*Astwood* You would not regard androgen then as ACTH?

*Young* I referred earlier to an experiment of Winter and Folkers (32) where methylandrostenediol plus cortisone did affect adrenal weight I would have to include these substances if I defined ACTH as an ACTH like substance I should limit my definition to pituitary substances

*Long* Have any of the people working with this factor produced an adrenal larger than normal for example in a normal animal? Can an adrenal two or three times the normal size be produced as can be done with the conventional ACTH?

*Young* In our experience that is very difficult to do I cannot quote an actual experiment at the moment but in the adrenal gland of the normal animal—not the hypophysectomized rat of course—a substantial hypertrophy can be obtained

*Loeb* I should like to say that in the salt depleted rat we obtain hypertrophy of the glomerular zone Whether the actual weight of

*Dorfman* There is a variation. With the adrenal slices we still have difficulties once out of every three trials which is a very serious situation. However if two concentrations of a standard and two of an unknown were run simultaneously I think we could assay ACTH for its ability to produce corticosteroids with perhaps as good a precision as when the ascorbic acid test is used.

*Thorn* We never were able to develop a completely satisfactory assay for adrenal extract. The only thing which saved the situation was the isolation and synthesis of crystalline steroid material.

*Dorfman* I should disagree with that point.

*Ingle* May I make a few comments about this general problem? We have tried to eliminate some of the obvious difficulties by giving hormones in continuous intravenous injections and yet we do not find the answers to such questions as has there been inactivation of the hormone after it has been tested by one method and then put into solution to test by another method? The Merck group have told me that if corticotropin B is diluted beyond a certain point there is inactivation. Even though we deliver the hormone to the blood stream without inactivation we know nothing about differences in rates of inactivation by the body fluids or other factors affecting the efficiency of its action. If in trying to decide whether we have a true discrepancy in ratios of activity of different preparations in various assays we could apply these two criteria simultaneously under the identical conditions it would be more simple to answer these questions. However as far as the adrenal ascorbic acid and adrenal weight tests are concerned one is an acute test and the other requires much longer administration of the hormone. We have used metabolic responses as indices for stimulation of adrenal secretion. This may be more meaningful than either morphologic changes in the gland or ascorbic acid depletion but if we could measure the output of the adrenal steroids from the gland itself this would provide the best possible answer to the question as to whether there is more than one ACTH.

*Young* I should like to make a comment which arises out of a discussion I just now had with Dr. Loeb. I should have perhaps emphasized that an adrenal weight assay is bound to be a somewhat unsatisfactory method because the weight of a gland can be altered by factors such as engorgement of the blood vessels. Dr. Loeb pointed out edema and there are other factors such as the accumulation of cholesterol and so on which will necessarily cause an adrenal weight test to be less specific than say an ascorbic acid reducing test. We have been aware of this and that is why we




FIGURE 23

the gland increases I cannot recall Do you remember whether under those circumstances it is merely a redistribution of cellular activity or cellular hyperplasia in glands?

*Selye* I cannot recall actual weight The increase is not very marked although it can have a definite effect on the glomeruli

*Loeb* I do not think they are very much larger either but I am not sure

*Li* Androgen has corticotropic activity in the hypophysectomized animal only when injected on the day of operation If it is injected into a hypophysectomized rat at seven days postoperatively we obtain neither repair nor increase of adrenal weight

With regard to the point about an index of adrenal activity I think we should not forget that thymus reduction is a very good index of adrenal activity because it measures the functional activity of the adrenal

*Pincus* Has the Speirs method been sufficiently developed for ACTH assays?

*Li* Dr Pincus that is a very touchy question For two or three years Drs William O Reinhardt and Gerald F Hungerford have been testing our ACTH preparations for eosinopenic effect in both rats and mice Up until a year ago we obtained consistently good eosinopenic effect with some of our ACTH fractions but last summer when we purified ACTH further the eosinopenic effect in the hypophysectomized animal completely disappeared Now no matter how large a dose we inject we do not obtain this When cortisone is injected however an eosinopenic effect is produced When I mentioned it to Dr R S Speirs he thought the explanation might be that epinephrine is important for releasing the steroid through adrenal stimulation and he is at present testing one of our ACTH fractions

*Thorn* How long did you give the ACTH continuously in the hypophysectomized animal?

*Li* The circulating eosinophil counts were taken either three or six hours after the ACTH injection

*Thorn* How long had the animals been hypophysectomized?

*Li* The injections in the hypophysectomized rat were given once daily postoperatively That has been our standard procedure for a number of years and we always obtain good results But this time nothing happened The point is that when the ACTH is purified to this extent we no longer obtain any eosinopenic effect in hypophysectomized rats

pletely eliminated by adrenalectomy. Indeed this effect cannot even be restored in the adrenalectomized animal by treatment with either cortisone or DCA. Of course if such large amounts of DCA are given that it in itself causes nephrosclerosis then there will be renal damage but simultaneous treatment with STH fails to aggravate this further.

The effect of STH upon the kidney may be related to an adrenal stimulating factor of some kind (The interrupted arrow is labeled by a question mark in the figure.) In any event it is only this action of STH which could be considered to be adrenal mediated. The pressor effect of large doses of STH which is manifest particularly in animals sensitized by unilateral nephrectomy and a high NaCl intake is likewise dependent upon the integrity of the adrenal cortex and quite possibly upon that of the kidney also.

In discussions of this kind we have to keep in mind that the mineralo-corticoid like actions which we obtained with impure pituitary extracts and subsequently with partially purified STH preparations (including the most purified ones furnished by Dr. Li) simulate the mineralo-corticoid effects of DCA only in the sense outlined above. These effects are of two entirely different kinds: (a) the action upon connective tissue in general which is demonstrable even in the absence of adrenocortical tissue and (b) the effect upon the kidney which is dependent upon the presence of adrenocortical tissue. I do not see how any single corticotropic factor could explain this complex picture.

**EDITOR'S NOTE.** Dr. Selye would like to add the following comment to his remarks at the conference:

In recent experiments with the granuloma pouch it was possible to demonstrate the production during systemic stress of some antiphlogistic factor which is of adrenal origin but which conditions the effect of cortisone as regards inhibition of inflammation. In adrenalectomized rats bearing a standard granuloma pouch systemic stress (e.g. that produced by forced immobilization or a topical irritation arthritis of great intensity) has no effect upon the formation of exudate or granuloma. Conversely under similar conditions in intact rats the resulting alarm reaction simultaneously with adrenocortical enlargement inhibits inflammatory phenomena in the pouch. If adrenalectomized animals are maintained with DCA systemic stress still remains ineffective; however if they are maintained with small doses of cortisone or hydrocortisone which in themselves cause no inhibition of inflammation systemic stress completely prevents exudation and diminishes granuloma formation just as in intact animals. Obviously the antiphlogistic effect of corticoids is greatly enhanced by some extra-adrenal manifestations of systemic stress. This conditioning for antiphlogistic activity is reminiscent of



*Selye* Because we have discussed the adrenal weight factor which may have something to do with mineralo corticoid effects it might be instructive to review the manner in which our experimental arrangement differed from those which have been mentioned in this discussion

Figure 23 is a simple schematic drawing which summarizes what we have seen in our experiments Let me point out at once however that what I say about STH refers only to the purest preparation now available and not necessarily to the pure hormone itself We used Dr Li's highly purified growth hormone The latter may still be impure and the various findings may not have reflected the effects of a single compound but until we have positive evidence of this I shall continue to use the designation STH for the growth hormone preparations now available

The connective tissue cell at the bottom of the figure may be situated in subcutaneous tissue or in a joint or in any other location The effect of STH is exerted directly upon it Thus the stimulation of connective tissue and the augmentation of its reactivity to local irritants is a direct effect of STH which does not have to be mediated through the adrenal cortex It is similar to the effect produced by DCA and in this sense I consider it a mineralo corticoid like effect although it is not inhibited by adrenalectomy and hence cannot be interpreted as a result of adrenal stimulation

This effect of STH is also related to mineralo corticoids in that if subthreshold doses of DCA are given their effect is further augmented by STH due to some synergism between the two hormones On the contrary, if the adrenal cortex is implicated in any way it is in an inhibitory capacity Animals treated with large doses of STH tend to discharge some ACTH from their own pituitary and the resulting glucocorticoid production has an inhibitory effect upon the connective tissue

Therefore in those experiments in which we gave STH to adrenalectomized rats the connective tissue proliferation and the augmentation of the inflammatory potential were even greater than in intact animals because the inhibitory effect of an antiphlogistic corticoid discharge was eliminated The stimulating effect on ACTH secretion of STH is indicated in the drawing by the arrow which reverts to the pituitary The other effect of this hormone is exerted upon the kidney Here it produces nephrosclerosis similar to that obtainable with DCA treatment It is this last mentioned action of STH which is completely abolished by adrenalectomy

The possibility of producing nephrosclerosis with STH is com

**Bauer** On the other hand it brings up the question of the sterility of your STH preparations. Without bacteriologic studies of these joints one cannot rule out infection. In the case of the rats in your experiments there are at least two possible sources of infection: (a) the material injected and (b) the presence of *Streptobacillus moniliformis* in the rat colony. In the case of the latter there may result an infectious arthritis due to the *Streptobacillus moniliformis* or its L form. In animals insulted as much as these were it is conceivable there might result a blood stream infection with either the *Streptobacillus moniliformis* or its L form. The base would be greatly strengthened if bacteriological studies ruled out the possibility of *Streptobacillus moniliformis* infections and showed that the STH was sterile.

**Selye** If there is anyone who believes that in an STH treated animal the production of arthritis is due to the development of an infection at the site of formalin administration rather than to the formalin itself, he should certainly perform such sterility tests. Personally I am quite satisfied that formalin itself suffices to produce inflammation without invoking any such accidental infection.

However be this as it may, the STH preparation which we used did cause an increase in the ability of the connective tissue to respond with inflammation upon local irritation. This was so not only in the topical irritation arthritis test but also in the granuloma pouch test. The enhancing effect upon inflammation, whether it is caused by formalin, croton oil or even incidental infection, does not depend upon the presence of the adrenals. In the adrenalectomized animal the inflammatory potential can still be increased by giving STH or decreased by giving cortisone, and that is the point I wish to emphasize. Furthermore, there is a proportionality between the dose of cortisone necessary for inhibition and the amount of STH required to prevent the inhibition. All this is completely independent of the adrenal and has been demonstrated in bilaterally adrenalectomized rats.

If there is some factor of infection in all this, its existence would first have to be proved. In any case, the balance or antagonism between the proinflammatory STH and the antiinflammatory cortisone is demonstrable even after ablation of the adrenal, while the effect of STH upon the kidney is dependent upon the presence of the suprarenal glands.

**Bauer** I do not think there is any doubt that an increase in ground substance in the tissues will be obtained.

that previously demonstrated in our laboratory for the blood sugar increase or the thymolytic action of these steroids. All of these effects of glucocorticoids are augmented in adrenalectomized animals by systemic stressors.

**Bauer** Do you obtain a connective tissue effect with Dr Li's preparation?

**Selye** Yes. In fact Dr Li (35) published a paper in *Science* on essentially the same topic. He also found that in adrenalectomized animals the extract does have an effect upon the joints and causes a type of chronic arthritis. So this action could certainly not be mediated through the adrenal, and could not be explained on the basis of any among the corticotropic factors which we have discussed here.

**Long** What is the effect on the connective tissue Dr Selye?

**Selye** First it causes a proliferation of connective tissue cells and fibers especially in the joint regions and secondly it augments the inflammatory response caused by local irritation of joints with some chemical agents for example formalin.

**Bauer** I think you and Dr Li are speaking of two different things. You are talking about an inflammatory process of synovial tissues while he is thinking of a degenerative lesion which takes place in cartilage which is more akin to degenerative joint disease or what is sometimes called osteoarthritis.

**Selye** But both seem to be dependent on STH.

**Bauer** The latter is a growth hormone effect. We have no good evidence that it affects the formation of the matrix. Would you agree with that Dr Li?

**Li** Yes. I think it is probably the osteoarthritic type but we have no way of knowing at the moment.

**Bauer** Did you say the most marked effect is in the case of cartilage particularly in the young growing animal whereas the situation is quite different in the adult animal?

**Li** It is quite true that growth hormone has been demonstrated to increase the collagen content of the connective tissue.

**Bauer** If it is growth hormone effect the acromegalic should have rheumatoid arthritis yet we have known of no such case.

**Selye** I have not studied arthritis in acromegalics. Under the conditions of the complex derangement prevailing in acromegaly apparently STH produces the so called acromegalic type of arthritis rather than the rheumatoid type. I was merely describing our experiments on rats.

procedures If the same animal is now treated with STH the pressure can go up to 150 or even 200 mm of Hg and this is accompanied by kidney lesions

Li What are the sensitizing procedures used in connection with the high salt diet?

Selye One per cent sodium chloride solution instead of drinking water and a unilateral nephrectomy

Li You do not give a normal animal a normal diet? Do you get any hypertension?

Selye Not with the doses of growth hormone that we have given Also coming back to the importance of sensitizing procedures an increased blood pressure with nephrosclerosis perarteritis nodosa and death may be obtained by giving an overdose of DCA even in the absence of such sensitization I should like to call attention to the results of Dr Green (36) who has shown that approximately 200  $\mu$ g of desoxycorticosterone per day suffices in a normal non-sensitized animal to produce nephrosclerosis and hypertension In fact this treatment does not even have to continue until death because even a temporary DCA overdose will cause so called meta-corticoid self-perpetuating hypertension and nephrosclerosis

Two hundred  $\mu$ g of desoxycorticosterone would correspond in a sodium potassium test to approximately 2  $\mu$ g of electrocortin I think it is a matter of opinion whether this should be considered a very unreasonable high dose that could not be endogenously produced under any conditions

Long We have given many adrenalectomized rats DCA pellets and I do not think it would apply in that case

Loeb In what period of time?

Selye In about two months of treatment The pellet was gradually absorbed a fact which could be checked by inspection of the implantation site (36 37 38)

Long I should not speak for Dr Thorn but I believe that adrenalectomized humans have been maintained with DCA pellets in amounts sufficient to maintain body weight for a long time and without any evidence of nephrosclerosis

Bauer How would you account for the results Dr Li and his co-workers have reported of experiments where growth hormone was administered for as long as 400 days with no higher incidence in nephrosclerosis than would be found in the control rats?

Selye These animals of Doctor Lis were not sensitized in any way and he administered much smaller quantities of STH than we did

*Selye* Maybe that is what sensitizes for inflammation in these regions

*Bauer* Such increased activity does not result in an inflammatory reaction Yet the photomicrographs of the joints you published showed practically nothing but polys in the exudate a finding that should always lead one to suspect a specific infectious process

*Long* Dr Selye did you say STH releases ACTH?

*Selye* Yes That is to say we obtain a rather pronounced adrenal enlargement with Dr Liss STH preparation in intact animals but practically none after hypophysectomy We assume that this corticotrophic effect of STH is dependent upon the release of endogenous ACTH

*Long* Did you obtain an enlargement of the cortex?

*Selye* Yes If the animal is highly overdosed with STH this may be a nonspecific stress effect but the point is difficult to prove

*Long* You also said it had a pressor effect I believe

*Selye* Yes

*Long* So animals treated with growth hormone do have an increase in blood pressure

*Selye* Yes if they are sustainably sensitized by unilateral nephrectomy and a high salt diet

Incidentally the sensitization as such is another point worthy of comment Dr Bauer has mentioned in some of his writings that sensitization by high salt diet unilateral nephrectomy or castration are drastic procedures not likely to have any equivalent in clinical medicine Hence he expressed his doubts concerning the clinical implications that could be drawn from such animal work

Let me point out therefore that all these sensitizing procedures are necessary only if we wish to obtain nephrosclerosis and hypertension with the minimum amount of hormone during the shortest possible time Sensitization is merely a convenient experimental procedure However lesions such as nephrosclerosis and hypertension can be obtained with hormones even without sensitization

*Long* What increase in pressure do you obtain over and above what would be produced by other procedures?

*Selye* The other procedures do not cause any

*Long* But the blood pressure of the hypophysectomized rat is somewhat depressed to start with

*L* Much depressed

*Selye* This was not done in hypophysectomized rats but the pressure of a normal animal amounts to about 130 mm of Hg when determined with our technique despite all the sensitizing

*Long* In 1945 Reiss and his colleagues (39) reported that the gonadotropic hormones increased cholesterol in the gland whereas ACTH decreased it. I believe he obtained some increase in the adrenal size.

*L:* With pregnant mare serum also.

*Young* I think we differentiated from those particular preparations.

*Bloch* King (40) has reported some marked increase of cholesterol synthesis in vitamin C deficiency.

*Long* We observed that too in the guinea pig. In 1940 Dr Collip reported (41) the pituitary effect on the adrenal medulla particularly the proliferation of dark cells. It is a very interesting fact that if this is an adrenal medulla which is immune from anterior lobe influences, it is almost doubled in size, that is an over all 60 per cent increase in weight by growth hormone. Has any other portion of the chromatin tissue been influenced, for example the sympathetic ganglion?

*L:* We did not examine other areas.

*Pincus* Is that not just about proportional to the increase in body weight, or is it greater?

*L:* The medulla was enlarged disproportionately, it was so huge that the cortex was practically pushed out.

*Young* We found an effect on the medulla, but nothing comparable with the adrenal weight we have observed.

*Selye* I did not find any medullary changes. Of course I did not treat my animals very long, and there may be differences in the rats we used. In any event I have not seen any adrenal medullary enlargement above that corresponding to the growth increment of the animal as a whole.

*L:* This was a long term, high dose experiment, carried out for a period of up to 400 days in three series — two hypophysectomized and one normal.

*Long* I recall that the effect on the brain and the spinal cord was very slight. The growth hormone apparently does not make the brain twice the size. If I remember your figures correctly, the effect on the nervous system is very small.

*L:* Yes.

*Long* This effect on the medulla is an extremely interesting one, since it is apparently not related to any stimulation of the central nervous system.

*Astwood* Some years ago we did that experiment in a different way. We had a sample of horse pituitary powder which would in a small dose restore the adrenal weight in hypophysectomized rats, but a dose 50 times larger did not increase the weight further.

*Young* Rinfret (22) used horse powder, however we did not.

*Astwood* I am sure the phenomenon you have described is absolutely reproducible.

*Young* It is the significance of it that is the question. You would regard it as a nonspecific effect of pituitary material?

*Astwood* Yes. I would not call it a corticotropin.

*Young* I hope for a revised definition of ACTH when I obtain pituitary substances which will affect the adrenal. It would be included within that general category, but it is a question of how specific this physiological effect is for the adrenal or whether it has a significant action.

*Astwood* I am sure that any phenomenon associated with mitosis is physiologically important.

*Thorn* In measuring the summation of the androgen effect and the weight-increasing effect, could you increase the total weight above normal with the use of the two preparations in combination?

*Young* We have not yet performed that experiment or really tried to go above normal in the hypophysectomized animal with our AW preparations. My attitude is that of a biochemist who is interested in anything that could have physiological action and an attempt to isolate, no matter what that substance is, seems to me the first step in trying to understand what function it may have in the animal economy. I have no idea what the AW factor does. As I say, our working hypothesis has been that it might conceivably be a substance concerned with the deposition of cholesterol in the adrenal gland and it has an effect which seems not to correlate with the ascorbic acid reducing effect. At the moment I hesitate to interpret it in terms of physiological action, but I think it would be of interest to know what the substance is.

*Rall* When you did these studies on the mitotic effect of this substance, did you examine any other tissues such as the liver to see whether it also was responding?

*Young* We did not examine the liver in those actual experiments, but in some others we looked at the islands of Langerhans which particularly interested us. In a number of other glands we found some effect, but nothing very striking.

*Pincus* One of the best ways of increasing adrenal cholesterol is to administer glucose to a rat.

**Long** The question is is the increase in the size of the medulla greater than the increase in body size?

**Li** Yes only in very high dose normal mice. In two instances we found that the medulla was increased in size in short term experiments but not in the hypophysectomized animals.

**Rall** Has there ever been any growth promoting assay of the activity of the type of pituitary tumor that is observed in acromegaly in the human?

**Li** There was one case some years ago Dr L. W. Kinsell sent us some blood from an acromegalic patient and we detected growth hormone in the blood.

**Rall** I have a case of acromegaly whom we have observed since 1931. He came in originally with xanthomatosis and a tremendously high cholesterol. He is also a diabetic but it is difficult to know just how severe his diabetes is because he insists on taking 100 units of insulin a day regardless of what anyone says to him.

**Young** Dr Li how do you estimate your growth hormone?

**Li** We use the tibia test for growth promoting activity and about 5  $\mu$ g may be observed of growth hormone. One can detect growth hormone even in the blood plasma (0.1  $\mu$ g per ml) of the normal adult subject but in the acromegalic patient the content is much higher (20  $\mu$ g per ml) according to this biological test.

**Young** I do not think this is necessarily relevant to the present discussion but perhaps I might mention that Dr P. J. Randle in the Department of Biochemistry at the University of Cambridge has recently been estimating insulin in the plasma of various types of patients including acromegalics and has observed a diabetic acromegalic woman who as estimated by the rat diaphragm method seems to have about 15 times the normal amount of insulin in her blood. I do not know whether anybody else has made an observation comparable to that. The problem is that the plasma from this patient did not produce a fall in blood sugar in the diabetic hypophysectomized rat. Our method was based on that of Groen (43). One complication is if growth hormone is added to normal plasma and tested by this method an increased insulin like action in the plasma is obtained.

**Li** *In vitro*?

**Young** Yes.

**Dorfman** What is the relative sensitivity between the tests *in vitro* and on the alloxan diabetic rat?

**Young** The alloxan diabetic hypophysectomized rat is about two or three times more sensitive but the amount of insulin activity — I



*Li* In experiments with mice carried out in collaboration with Dr William R Lyons of the Department of Anatomy University of California a high dose of growth hormone caused a body weight increase after 40 days of from 20 to about 60-odd gm and the medullas were enlarged as well

*Astwood* Dr Collip's factor affecting the adrenal medulla was effective by mouth

*White* In view of Dr Selye's statement that his hypertensive effect is adrenal mediated he has examined the same situation in adrenal demedullated animals to determine whether there is a non-adrenal cortical effect in relation to some of these activities Is this medullary action real and has anyone done epinephrine assays of these hypertrophied adrenals?

*Selye* I have not performed any such experiments on adrenal demedullated animals Let me call attention to the fact however that my experiments do not even prove that the effect is necessarily adrenal mediated They tell us only that the action of STH upon the kidney does not occur in the absence of the adrenals It is possible that some adrenal factor may be present although the STH does not actually increase the secretion of this adrenal factor

*Long* Do you think we could produce an experimental pheochromocytoma by prolonged treatment with growth hormone?

*Selye* Are pheochromocytomas really common in acromegaly?

*Bauer* I do not know but I am sure of one thing the acromegalic may have adenomas in other endocrine glands

*Loeb* There is a syndrome of adenomatosis of the endocrine gland which may involve the pituitary parathyroid and islands of Langerhans but I think probably that is not the same as ordinary acromegaly because changes in the parathyroid and islands of Langerhans are not those seen with isolated tumors in those structures

*Bauer* There were postmortem findings in the series of acromegalics reported by Cushing and Davidoff (42)

*Selye* Is hypertension not more common in the acromegalic than in the general population?

*Astwood* It is The commonest cause of death in the disease is hypertensive cardiovascular disease

*Bauer* They have cardiomegaly as part of the visceromegaly

*Thorn* Could we review once more the evidence which suggests that the growth of the adrenal medulla is greater than the increase of other viscera?

*Long* The question is is the increase in the size of the medulla greater than the increase in body size?

*Li* Yes only in very high dose normal mice. In two instances we found that the medulla was increased in size in short term experiments but not in the hypophysectomized animals.

*Rall* Has there ever been any growth promoting assay of the activity of the type of pituitary tumor that is observed in acromegaly in the human?

*Li* There was one case some years ago Dr L W Kinsell sent us some blood from an acromegalic patient and we detected growth hormone in the blood.

*Rall* I have a case of acromegaly whom we have observed since 1931. He came in originally with xanthomatosis and a tremendously high cholesterol. He is also a diabetic but it is difficult to know just how severe his diabetes is because he insists on taking 100 units of insulin a day regardless of what anyone says to him.

*Young* Dr Li, how do you estimate your growth hormone?

*Li* We use the tibia test for growth promoting activity and about 5  $\mu$ g may be observed if growth hormone. One can detect growth hormone even in the blood plasma (0.1  $\mu$ g per ml) of the normal adult subject but in the acromegalic patient the content is much higher (20  $\mu$ g per ml) according to this biological test.

*Young* I do not think this is necessarily relevant to the present discussion but perhaps I might mention that Dr P J Randle in the Department of Biochemistry at the University of Cambridge has recently been estimating insulin in the plasma of various types of patients including acromegalics and has observed a diabetic acromegalic woman who as estimated by the rat diaphragm method seems to have about 15 times the normal amount of insulin in her blood. I do not know whether anybody else has made an observation comparable to that. The problem is that the plasma from this patient did not produce a fall in blood sugar in the diabetic hypophysectomized rat. Our method was based on that of Groen (48). One complication is if growth hormone is added to normal plasma and tested by this method an increased insulin like action in the plasma is obtained.

*Li* In vitro?

*Young* Yes.

*Dorfman* What is the relative sensitivity between the tests in vitro and on the alloxan diabetic rat?

*Young* The alloxan diabetic hypophysectomized rat is about two or three times more sensitive but the amount of insulin activity — I

must not say insulin—in the plasma of the woman patient I mentioned was of the order of a quarter of a unit per millimeter which seems very high. One possible explanation might be that there is a large amount of glucagon in the blood of this woman and that is what we are setting out to estimate next.

Astwood Drs V W Westermeyer and M S Raben (44) have studied the effect of a pituitary extract on the lowering of the blood sugar. A so called corticotropic fraction was given to fed or fasted mice and either at one hour or at three hours the blood sugar was determined.




FIGURE 24 Log dose-response curve of the one hour effect of the oxycel purified pituitary extract on the blood sugar concentration of intact unfasted mice. Each point is the mean of the number of determinations indicated. The ordinate shows the per cent change in blood sugar; the uninjected control value is shown in the left lower corner. The bars extending from each point represent the standard errors of the means. Reprinted by permission from Westermeyer V W and Raben M S. Fall in blood sugar from anterior pituitary extract. *Endocrinology* 44:173 (1954).

Figure 24 shows the change of blood sugar in one hour. The dosage given on the bottom scale shows that with 3 to 100  $\mu$ g there was a proportionate fall in blood sugar. In un.injected animals it did not change during this one hour period. Above 100  $\mu$ g there was no further drop and the animals did not become hypoglycemic to the extent of convulsions.

The strange thing about this is that while this fraction caused the drop in blood sugar it was anti-insulin at the same time. Five units of insulin to the mouse caused convulsions and death but 5 units of insulin given with 100  $\mu$ g of the extract seemed to have no effect whatever. In other words the blood sugar fell about the amount that it would have fallen with the pituitary extract alone.

White: What is the material on the bottom line?

Astwood: It is a corticotropin concentrate made with oxycellulose. Normal mice were used and it works whether the adrenals are present or not.

L1: Is the same effect obtained with adrenalectomized mice?

Astwood: Yes.

L1: Is the injection subcutaneous?

Astwood: It is either subcutaneous or intraperitoneal.

Long: It is very reminiscent of the effects of crude pituitary extracts and of some more highly purified growth promoting preparations.

Astwood: Something of the order of 500  $\mu$ g of some growth hormone preparations and not others will produce a rather inconstant effect.

Rall: By inconstant effect do you mean an inconstant decrease?

Astwood: Yes, sometimes it will work and sometimes not. Whatever factor it is, it is much more greatly concentrated in this case than in the usual growth hormone preparations.

Rall: We had a hypophysectomized patient in whom the effect of an Armour growth hormone preparation was studied. This patient had an idiosyncrasy about eating and it was difficult to induce her to eat properly. The growth hormone was given twice daily for several days and the blood sugars were done in the morning and also during the day. We found a consistent decrease in blood sugar over a period of three days, probably because the patient would not eat. I do not know about the purity of the preparation used.

Astwood: We have not been able to separate this type of activity from corticotropin. Recently we used modifications of the method of Dixon, Moore, Stack, Dunne and Young (45) which largely

must not say insulin -- in the plasma of the woman patient I mentioned was of the order of a quarter of a unit per millimeter which seems very high. One possible explanation might be that there is a large amount of glucagon in the blood of this woman and that is what we are setting out to estimate next.

*Astutod* Drs V W Westermeyer and M S Raben (44) have studied the effect of a pituitary extract on the lowering of the blood sugar. A so called corticotropic fraction was given to fed or fasted mice and either at one hour or at three hours the blood sugar was determined.




FIGURE 24 Log dose-response curve of the one hour effect of the oxcel purified pituitary extract on the blood sugar concentration of intact unfasted mice. Each point is the mean of the number of determinations indicated. The ordinate shows the per cent change in blood sugar; the uninjected control value is shown in the left lower corner. The bars extending from each point represent the standard errors of the means. Reprinted by permission from Westermeyer V W and Raben M S. Fall in blood sugar from anterior pituitary extract. *Endocrinology* 54:173 (1954).

a larger drop in the treated. When maintained with cortisone the effect was a little greater but in neither case was it quite so large as in the intact animal.

Long: Did cortisone reduce the blood sugar in these animals?

Astwood: No. Both the controls and pituitary treated animals received cortisone.

Li: Are you postulating this as a new principle, Dr. Astwood?

Astwood: I do not know. I think it is probably just a concentrate of the factor which had been studied previously in growth hormone preparations.

Li: Do you think that the growth hormone is contaminated with this material?

Astwood: That may be or there may be overlapping activities. It is difficult to say.

White: Have you assayed this for growth hormone activity?

Astwood: Yes, there is no growth hormone activity in hypophysectomized rats.

Long: What about the fat metabolism factor?

Astwood: It is the same extract that has most of the fat mobilizing factor. This effect and the fat mobilizing effect whatever it is are very efficiently concentrated in this fraction in Figure 26. These are Dr. I. N. Rosenberg's data (46).

The second curve from the right labeled "anterior pituitary" is a dose response curve of whole pig pituitary. The crude corticotropin constitutes about one eighth the weight of the whole pituitary and the activity is roughly four times as great. The oxycel purified corticotropin is perhaps 40 times more active still. You will notice that the assay is poor but nonetheless one can estimate that about one half of the active principle is concentrated in this corticotropin fraction which amounts to about 0.2 per cent of the weight of the pituitary powder. In other words the factor has been concentrated about 250 fold. The problem is whether any of these effects is attributable to corticotropin itself or whether it means that we still have a gross mixture of hormones.

Rall: How are you testing for the fat mobilizing effect?

Astwood: We use the original method of Campbell (47) measuring the amount of fat in the liver after 3 or 7 hours. They have shown that the increased fat in the liver accounted for about 1/5th of the fat that left the depots.

Rall: Do you take a sample of the liver before and after administration of the hormone?

separates intermedia but this activity goes along with the corticotropin fraction

Long Does this produce any change in the amino nitrogen of the blood?

Astwood We have not tested that It does produce the glycostatic effect however as Dr John Otto\* has shown

Pincus Does it work in alloxan diabetic animals?

Astwood I am not sure about that

Conn Is the adrenalectomized animal no more sensitive to the hypoglycemic effect than the intact one?

Astwood Apparently not The effect is not quite as great in the adrenalectomized animal but it is present It seems to be a bit better if the animal is maintained with cortisone but not significantly so

On the left in Figure 25 the adrenalectomized animals were maintained with saline There was some drop in the controls and




FIGURE 25 Fall in blood sugar in adrenalectomized mice The change in blood sugar at one hour after injection with 100  $\mu$ g of the oxycel purified material is compared with un.injected controls using unfasted mice adrenalectomized three days earlier The left pair of graphs summarizes an experiment using mice given 1 per cent NaCl in the drinking water the results on the right were obtained with animals receiving 25 mg cortisone subcutaneously immediately after operation and saline as well Reprinted by permission from Westminster V W and Paben M S Fall in blood sugar from anterior pituitary extract *Endocrinology* 54:173 (1954)

*Astwood* No the controls are other animals. It is a very variable phenomenon because so many things affect liver fat.

*White* This also happens in the absence of the adrenals?

*Astwood* Only if the animals are maintained with cortisone.

*Pincus* Did you study adrenal fat?

*Astwood* No only cholesterol but Dr Charles H. Best and J. Campbell showed that there was an increase in kidney fat. This same extract also causes a drop in respiratory quotient and an increase in oxygen consumption which corresponds very closely with what Drs. O'Donovan and Collip (48) described years ago as the specific metabolic principle.

*Bauer* What is the change in respiratory quotient (R.Q.)?

*Astwood* It goes down at the same time the total oxygen consumption rises and that perhaps would agree with fat mobilization.

*Long* Did you obtain a ketosis?

*Astwood* Yes. All of these effects at one time or another have been attributed to growth hormone but now this fraction contains them all in a much more highly concentrated form.

*Rall* We have been doing something similar in rats. Prior to administering the growth hormone we removed part of the liver in order to study the effect of the growth hormone on the restoration of liver tissue. The liver nitrogen, lipid and glycogen were determined in each rat before and two weeks after growth hormone therapy. At the time of sacrifice the adrenals were assayed for both ascorbic acid and cholesterol. Total protein, albumin and globulin were determined in the blood. An Armour growth hormone preparation was used. Control animals were studied at the same time. At sacrifice the liver nitrogen was reduced in both the control and growth hormone treated rats. The glycogen values in the liver were also reduced. The lipid content of the liver was elevated in both groups. We felt that the dose of growth hormone should be increased in order to exaggerate any differences that might be present. Could Armour's growth hormone be purified by treatment with oxycellulose?

*Astwood* Dr. Rosenberg (46) found Armour's growth hormone to be less than 1/20 as active as this fraction. Treatment with large amounts of oxycellulose did not remove any of the activity which leaves open the question of a different substance in growth hormone or perhaps an inherent property of growth hormone.

*White* There is a point which I think arises in such a situation and that is to what extent in an animal with a pituitary the






FIGURE 26 Relation between dose of pituitary extract and the per cent of hepatic lipid seven hours after injection in normal mice. Comparing the minimal doses required to cause an increase in lipid content from the control value of 69 per cent to a value of 10 per cent it may be noted that oxycel purified corticotropin is about 30 times as active as the crude which in turn is four times as active as the anterior pituitary powder. The oxycel unadsorbed fraction from which growth hormone may be obtained is of very low potency. Reprinted by permission from Rosenberg, I. N. Adipoklastic activity of oxycel purified corticotropin in *Proc Soc Exper Biol & Med* 70: 111 (1953).

*Young* So highly purified ACTH ■ in effect reducing the blood sugar in the adrenalectomized rat

*Astwood* Yes

*Thorn* If the dose ■ increased does the level of blood glucose change with this material?

*Astwood* The larger dose does not produce a greater effect it still produces a 60 per cent fall

*Ingle* Did you say that this preparation also affects the metabolic rate and respiratory quotient?

*Astwood* Yes

*Conn* How low does the R Q go?

*Astwood* To about 0.7 It has been done in mice rats guinea pigs and dogs

*Pincus* You did not mention what the ACTH activity was Could you state it in International units?

*Astwood* Most of the work was done with the type of preparation that you have assayed and the assay has been anywhere from 40 to 100 units depending on whose laboratory it was We found it to be about 80 units material which had been further fractionated by the methods developed in Dr Young's laboratory contained about three times that or 240 units

The Armour Laboratories report that oxycellulose corticotropin contains about 40 I U per mg or about half of what we had thought Now comparing material prepared by the Cambridge procedure we obtain about three times that It is impossible by our method of assay to compare with the international standard

*Long* If we continue injecting the fed animal with a highly purified ACTH preparation will not the blood sugar rise produce the so-called diabetogenic effect?

*Astwood* Yes with the adrenals present

*Long* But the initial effect is a fall?

*Astwood* Yes

*Young* With the adrenalectomized mouse?

*Astwood* We have not done that with the adrenalectomized mouse but mice given one injection a day for eight days will still show this drop one hour after an injection

*Rall* I wonder whether the continued administration of this material to the normal animal would eventually cause an increase in blood sugar Do you think it is the persistent administration of the hormone that causes the changes in the adrenal gland?

*Astwood* Presumably it is the adrenal effect

administration of growth hormone may result in some degree of compensatory secretion of an ACTH like factor

*Long* This preparation is glycostatic in a hypophysectomized rat

*White* I was speaking here about the fact that Dr Astwood was unable to remove this factor from his growth hormone by oxycellulose treatment

*Li* Some years ago we did some studies on hypophysectomized rats in order to examine the effect of growth hormone on liver fat. We did obtain an increase in liver fat produced by growth hormone. Our results appeared to agree with Dr Astwood's using oxycellulose or other means we were unable to remove the fat mobilizing property of growth hormone. As far as a corticotropin our purest ACTH preparation was concerned when it was administered to adrenalectomized animals it did not cause fat mobilization. Only in mice with intact adrenals did we obtain the fat mobilizing effect with this preparation.

*Astwood* What was the biggest dose you tried?

*Li* We used 0.25 mg of our preparation assaying approximately 200 USP units per mg.

*Astwood* What was the time interval?

*Li* We used an interval of six hours. We followed Rosenbergs procedure of extraction (46) including the time as well as the 1936 procedure of Best and Campbell (49) and had the same results each time.

*Astwood* Did you conclude that a separate substance was responsible for this?

*Li* We concluded that ACTH possesses an intrinsic fat mobilizing activity as does growth hormone. The dose response plotted against the degree of fat mobilization with growth hormone is a very flat curve. In the case of ACTH it is a very steep one.

*Astwood* I misunderstood you. I thought you said you did not obtain fat mobilization.

*Li* In the absence of the adrenal we obtain no fat mobilization but with the adrenals intact there is fat mobilization with ACTH.

*Young* But you do regard this preparation as one of the best preparations of ACTH that is available? You have had all these other effects.

*Loeb* That is determined on the basis of an ascorbic acid depressant. I assume

*Pincus* It had a very depressing effect.

Astwood I think that is correct

Young What is the difference between the diabetogenic and hyperglycemic factors?

Astwood By diabetogenic factor I mean the factor which produces permanent diabetes in dogs—the Young factor if you will

Young Then hyperglycemic might or might not be the same

Astwood For example is the factor which alleviates the insulin sensitivity of the hypophysectomized dog the same as the factor which produces permanent diabetes when given for a long period of time? It is very difficult to determine

Young What do you include under glycotropic?

Astwood That, I believe is your own term for the substance which inhibits insulin

Young When you mentioned the factor that relieves the hypophysectomized dog were you thinking of maintaining the blood sugar?

Astwood Yes

Young So the first three factors in Table VII are not clearly differentiated in fact they could all be the same?

Astwood Yes these are poorly differentiated effects

Rall You were saying that this corticotropic hormone has a hypoglycemic effect?

Astwood Yes

Long And a hyperglycemic effect also?

Astwood I did not say it had a hyperglycemic effect. However, I know that if you stimulate the adrenals enough the blood sugar will rise

Loeb Isn't this an ACTH compound that stimulates the adrenal?

Astwood By stimulating the adrenal one can certainly raise the blood sugar but the substance labeled hyperglycemic factor is one that has been referred to in the literature for a long time and is not related to ACTH

Loeb I ask again whether ACTH does not have we will say indirectly by the adrenal a hyperglycemic effect

Astwood Yes I would agree

Long I think what Dr Astwood is saying is that the factors that are present in this extract are effective in the absence of the adrenal but that if the adrenal is present we also obtain all the metabolic effects that are associated with the release of adrenal steroid. Do you accept that Dr Astwood?

Astwood Yes

TABLE VII

A Partial List of Metabolic Factors, or Effects,  
Obtained from Pituitary Extracts

Diabetogenic factor  
Hyperglycemic factor  
Glycotropic factor  
Glycostatic factor  
Hexokinase inhibitor  
Adipokinin  
Specific metabolic principle  
Lowering of respiratory quotient  
Stimulation of insulin secretion  
Stimulation of pancreatic alpha cells

Table VII gives a list of some of the metabolic effects from pituitary extracts that have been described in times past. However, this is only a partial list. The ones that have been associated with the growth hormone in publications are the diabetogenic, hyperglycemic, glycotropic, and glycostatic factors, the hexokinase inhibitor, the adipokinin, the specific metabolic principle, a factor lowering the respiratory quotient, one stimulating insulin secretion, and one the pancreatic alpha cells. Those and others, have been ascribed to the growth hormone. The ones that we now find to be highly concentrated in the oxycellulose absorbed material are glycotropic and glycostatic factors, adipokinin, specific metabolic principle with lowering of the respiratory quotient, and in addition a lowering of the blood sugar.

*Ralli:* Did you say the hexokinase inhibitor was associated with the corticotropic factor?

*Astwood:* No.

*Loeb:* You are not including the hyperglycemic factor in ACTH activity?

*Astwood:* No. That usually referred to as hyperglycemia which was not mediated by the adrenal.

*Long:* But it is present in preparations rich in ACTH.

*Astwood* Yes it would certainly seem reasonable that a single substance could mobilize fat and promote its burning to cause a lowering of the respiratory quotient and an increased oxygen consumption and perhaps spare glucose so it could have an apparent glycostatic effect. I do not know about the glycotropic and hypoglycemic effects they are difficult to determine.

*Bauer* You do not think the latter would in any way be concerned with fat metabolism?

*Astwood* This one substance might be very intimately connected with fat metabolism and do all of those things.

*Long* Have you observed these effects in subjects other than the mouse and the rat? In the human for example?

*Astwood* The respiratory experiments have been done in rats guinea pigs and dogs.

*Young* Is there any particular reason why the hypoglycemic effect is missing from the list in Table VII?

*Astwood* It is an old table we did not know about it.

*Loeb* You would put the hypoglycemic factor definitely into the ACTH group but Dr. La says you find the same in growth. Is that correct?

*Astwood* That was shown by Milman and Russell (50) several years ago but the dose was very different it takes many times as much growth hormone to have these effects.

*Rall* When you remove the pituitary freeze and lyophilize it and then put it on the oxycellulose column how many times do you have to elute it before this substance is obtained? Where does it come off the column?

*Astwood* The oxycellulose is not used in a column it is used batchwise. The minimal amount of oxycellulose is stirred with the crude extract for 24 hours then one elutes with hydrochloric acid yielding the oxycel fraction.

*Long* I would be extremely interested to know if this lowered the nitrogen excretion in rats particularly the crude B alpha extract. If it does then we might have an explanation of the hypoglycemic effect when the proportion of proteins in the metabolic mixture is reduced. We might very well have a depression of the blood sugar which is merely a reflection of the diversion of the gluconeogenetic material. Dr. Harrison and I (51) studied this a good many years ago. All one has to do is simply fast the animal select one control day and on the second or third day give the preparation one obtains from a 25 to 30 per cent drop in the nitrogen excretion.

*Loeb* You are separating the fact of growth hormone and ACTH on the presence or absence of the adrenal in terms of hyperglycemic activity

*Astwood* Yes

*Thorn* Then possibly to be consistent the study ought to be carried out in the absence of the thyroid and in the absence of the islet cells

*Bauer* But in the absence of the adrenal there would be the glycotropic and glycostatic factors and the adipokinin and the lowering of the blood sugar also Is that correct?

*Astwood* Yes

*Ralli* And a decrease in the respiratory quotient

*Astwood* And the effects described by O'Donovan and Collip (48)

*Long* The lowering of the respiratory quotient is in the absence of the adrenal?

*Astwood* Yes Dr Rosenberg (46) showed that

*Ralli* Then this should be labeled corticotropic hormone effects in the absence of the adrenal; to make it quite clear

*Long* As I understand it this preparation has no growth promoting activity therefore you exclude the growth hormone preparation as being responsible for these extra adrenal effects

*Bauer* There might be some overlapping

*Astwood* Yes The usual growth hormone preparations though active are very weak when compared with the corticotropic fraction

*Long* As the preparations become richer and richer in ACTH and yet still contain growth hormone we are forced to use the hypophysectomized and adrenalectomized animal for the assay of growth hormone otherwise the ACTH may completely mask its effect

*Astwood* That has been done

*Ralli* Has this hormone factor no adrenal ascorbic acid effect?

*Astwood* Oh yes it is highly active

*Ralli* Do you attempt to explain the effects of this hormone in the absence of the adrenal?

*Astwood* It is unknown whether they are due to one or many substances in that particular extract

*Long* Would you hazard a guess as to whether we now have to go back to six hormones in the pituitary? There are obviously some close interrelations between a hyperglycemic factor and that which lowers the respiratory quotient

Young Dr Astwood this material is oxycellulose absorbed followed by elution Have you also obtained effects from material that has been put through amberlite IRC-50?

Astwood Only in a preliminary way. We have not good quantitative data but from columns such as those used in our laboratory all the data we have so far show that the metabolic effects go along with the corticotropic activity and not with the intermedin.

Young Do you find your activity in any one peak in the columns or is it spread over a number of peaks?

Astwood We obtain two main peaks of corticotropic activity and both contain adipokinetic activity. We agree with you that there is a large first peak which contains intermedin.

Young We originally prepared crude corticotropin by the method which Dr Astwood and his colleagues developed but more recently we have gone back to the Lyons acid acetone method obtaining what is in effect a crude prolactin preparation.

We then put it through oxycellulose absorption precisely by the method that Dr Astwood has developed and ran the extracts which assayed about 30 IU. I believe you obtained 40 IU.

Then we ran this through a column of amberlite IRC 50 by the method we published (52) and obtained four peaks of activity. In Figure 27 is the main peak which we call  $A_1$ , then  $A_2$ ,  $A_3$ , and  $A_4$ . We find that the material in these peaks runs something like 50 IU per mg. We have done a little better than that but we cannot get up to the 100 at least not consistently. The original glands have been extracted by a number of different methods. We have not yet investigated these peaks for different physiological activities but have been anxious to know whether each one would behave as a single substance on rechromatography or when other treatments were used.

When peak  $A_1$  is again put through a column of amberlite IRC 50 it comes out at the same place as it should do if it were behaving as a single substance. We have also subjected a material to chromatography by a system Hess and Carpenter (53) have used and again find it behaving as a single substance. We have done some paper electrophoresis and also can obtain no evidence of separation of this peak into more than one substance likewise the peak  $A_2$  will consistently rechromatograph and also peak  $A_3$ .

We have observed more recently that if one treats peak  $A_1$  with ammonia or with any alkaline medium around pH 11 or 12 it is converted into material that is indistinguishable in our hands from peak  $A_2$  so that some change has occurred in the alkaline medium.



This occurred also in the adrenalectomized animal given the crude extract

*Thorn* Did these changes occur in the nonprotein R Q value?

*Long* One has to do the urea nitrogen

*Thorn* We have to be very careful in studying the lowering of respiratory quotient in an adrenalectomized animal. It is important to know the exact time at which it is measured. If an adrenalectomized animal responds as a patient with Addison's disease then we know that these individuals will maintain a relatively high R Q for a short period of fasting but that a break may suddenly occur. At this point the respiratory quotient falls to quite low values. If we should happen to give hormone to the fasting adrenalectomized animal at or about the time the spontaneous fall in R Q might have occurred we would not be certain of whether the material administered was responsible for the fall in R Q or whether this was a natural occurrence.

*Long* That is why I asked whether a larger animal would be used. I do not think the fasted dog would show these rapid fluctuations. They are fed anyway.

*Astwood* Most of the R Q's were done in the fed animal and some with continuous infusion of glucose. We have arranged a mechanical device for measuring oxygen consumption and CO<sub>2</sub> production and can obtain an almost continuous measurement of these two. The animal may be arranged in a chamber with a cannula placed intravenously, subcutaneously or intraperitoneally and after obtaining a base line of oxygen consumption and CO<sub>2</sub> production injections may be carried out without disturbance. Thus the time course of these effects may be easily followed.

*Long* I have no doubt it all that these effects can be produced by pituitary extracts; they have all been well substantiated. The interesting thing is that we now have this activity in a much more highly purified state.

You said 3  $\mu$ g of the oxycellulose preparation would produce a measurable effect on the blood glucose. How much of that is ACTH 50 per cent? Five per cent? It is an extraordinarily active hormone.

*Astwood* I do not know. I failed to mention that if one grinds up beef pituitary glands all the ACTH virtually disappears as Dr Sayers has also shown. The Parke Davis and Company thyrotropic hormone preparation is made from fresh beef and sheep glands and next to this preparation it is the most potent so far as adipokinetic activity is concerned; it has no corticotropic activity.

which is responsible for a shift in position on the columns in keeping with a change in isoelectric point. However, one cannot say for certain what the isoelectric points are.

I asked about the activity of the various types of biological response that Dr. Astwood has been dealing with in these various peaks because I wondered whether one had a spread of activity in other tests such as we have found with ACTH. We certainly did not obtain one main peak as Hays and White (54) and I think some other workers found. Dr. Astwood, you detected two main fractions but did you not find anything corresponding to our  $A_2$  and  $A_3$ ?

**Astwood:** In general we obtained just two corticotropic peaks. We have noticed without deliberately trying to treat with alkali that on rechromatographing these peaks the slower peak seems to turn into the faster one.

**Young:** How did you desalt your peaks before the rechromatographing?

**Astwood:** Either by precipitating with picric acid and regenerating or else by using coarse Dowex 50 resin in the acid cycle.

**Young:** We were, I think, misled for a time by using a desalting method which involves ammonia and ammonia treatment under the conditions we were using causes the partial transformation of peak  $A_1$  to  $A_2$  but if one uses a method for desalting which we now have developed involving shaking up with phenol and precipitation of the active material from the phenol by addition of ether one can obtain consistent  $A_1$  activity out of the  $A_1$  peak without any transformation to  $A_2$ .

**L1:** What solvent do you use for this resolution?

**Astwood:** Bicarbonate buffer 0.1 Molar pH 9.

**L1:** And this is a sort of elution analysis or pH change?

**Astwood:** We have followed the method used in Dr. Young's laboratory.

**Young:** Your pH is 5 we have used pH 6.6 or 6.8 and we seem to obtain a fairly good differentiation. One wonders if there is one ACTH in the gland which is being divided into a number of fractions here or whether all of these things are pre-existing. The impression one gets from publications from the Armour Laboratories is that there is just one corticotropin A.

**Astwood:** I still rather like the idea based upon physiological considerations that there are separate substances giving rise to these several effects. Apparently the intact animal has a way of regulating the adrenal cortex separately from the regulation of these




FIGURE 27 Chromatography of an oxycellulose concentrate of an acid acetone extract of pig pituitary tissue on amberlite XE 64 at pH 6.70

**Li:** Yes. The amino acid content accounts for over 95 per cent of the peptide nitrogen.

**Astwood:** Would you hazard a guess as to the size of the material after pepsin?

**Li:** It would be difficult to say, but I think it should be smaller than 4500.

For the peptic digestion of the unhydrolyzed product we use an entirely different system. The peak in the middle we call B<sub>1</sub> and B<sub>2</sub>. The B<sub>1</sub> and B<sub>2</sub> are both active biologically, but B<sub>2</sub> can be converted to B<sub>1</sub> very easily, and we obtain only a single B<sub>1</sub>. The D fraction sodium hydroxide treated has a pH of about 12 and peak A comes out about the same.

**Ingle:** I might tell a little story about a biological effect which we once thought was an inherent property of ACTH. We had developed the work test for the bioassay of adrenocortical hormones. Whereas a normal rat can work very well for periods of several days, the adrenalectomized rat goes into collapse within a few hours time. We found that if we gave a sufficient amount of adrenocortical extract to the adrenalectomized rat by continuous intravenous injection it would work as well as a normal rat. The untreated hypophysectomized rat also works very poorly, but its work performance is improved by treatment with either adrenocortical extract or by corticotropin. Using commercial preparations of corticotropin given by continuous intravenous injection we were able to make the hypophysectomized rat work just as well as the normal rat.

We assumed that cortical extract should also restore the performance of the hypophysectomized animal to normal, but instead the recovery was only from 60 to 65 per cent of normal value. Corticotropin was doing something that cortical extract would not do. We found this to be true of three commercial preparations of corticotropin and of several other experimental preparations obtained from Drs. Astwood and Li of this conference and from Mr. John Nelson in the Upjohn Laboratories. There was a marked discrepancy between the apparent effect of corticotropin in the work test and in the Sayers test, and we suspected that these activities were not parallel.

The studies were then extended to the adrenalectomized hypophysectomized animal. Again, treating the animal with adrenocortical extract partially restored work performance. When we added corticotropin work performance was restored to normal even though the adrenals were not present. During the past year we have

other phenomena so that if these other metabolic effects have physiological significance one would prefer to attribute them to some substance other than the one affecting the adrenal cortex

**Li** We have recently been able to obtain an adrenocorticotrophic hormone from an unhydrolyzed ACTH concentrate of sheep pituitary glands (55) which behaves as a pure peptide in various physicochemical and biological tests and is different chemically from the preparations reported by the Armour and Merck groups. There are three steps in our procedure. First from a solution of Fraction E (56) in 50 per cent dioxane at pH 9.3-9.4 the inactive material is precipitated out. The supernatant is then submitted to zone electrophoresis on starch. The active fraction obtained thereby is then chromatographed on amberlite XC 97 resin which is similar to IRC 50. From this column is obtained an active fraction which is further purified by being submitted to countercurrent distribution in a 2 butanol per 0.1 per cent trichloroacetic acid system. Those tubes whose contents follow the theoretical distribution curve for a partition coefficient of 0.41 yield a product which behaves as a single substance as judged by various additional criteria of purity such as (a) zone electrophoresis on starch in various buffers at different pHs (b) elution analysis on XC 97 resin columns (c) end group analysis (d) chemical composition and (e) biological assay. Since this product possesses physicochemical characteristics which differ from the unhydrolyzed preparation corticotropin A of Armour we propose to designate it as a corticotropin. The molar ratio of the amino-acids in a corticotropin is as follows: alanine 3, arginine 3, aspartic acid 2, glutamic acid 5, glycine 3, histidine 1, leucine 1, lysine 4, methionine 1, phenylalanine 3, proline 4, serine 3, tryptophan 1, tyrosine 2 and valine 3. The minimum molecular weight of a corticotropin is approximately 4500. The iso electric point has been estimated to be located at pH 7.0.

**Long** What is the biological activity?

**Li** Between 150 and 200. We are not really sure one day we get 150 and another day 200.

**Astwood** To which of Dr. Youngs' peaks would your peak correspond?

**Li** It is difficult to say because I do not know Dr. Youngs' solvent system.

**Astwood** But the order of emergence would be the same.

**Mason** When you add up all those amino acids do they add up to 100 per cent?

*Ingle* The volume is 20 ml of solution to a 200 gm rat in a 24 hour period

*Astwood* Is there anything to be observed in these rats that would suggest how this effect is being brought about?

*Ingle* No We have not attempted to carry out any of the metabolic studies on these animals When Dr Marthe Vogt of the University of Edinburgh visited my laboratory she called my attention to a peculiar difference between the animals that received this principle and those that did not The rat if it is anesthetized over a long period of time such as 24 hours or so is likely to extrude a pigment from the eyes which is related chemically to hemoglobin it does not represent blood itself She noted that the animals receiving this pituitary fraction had much more pigment about their eyes and that is true I have no idea why

*Astwood* That is of interest because I believe the secretion of that material in the eye is brought about by cholinergic drugs We have isolated one pure substance from the corticotropic concentrate We have had it in crystalline form for some three years as a picrate and it was only recently that we accumulated enough to find out what it is It turned out to be spermine much to our disappointment because spermine crystals were described by Lewenhoeck (57) nearly 300 years ago It was not a new discovery

*Long* And widely distributed in the body

*Astwood* Yes

*Bauer* That is right Dr Rene Dubos of the Rockefeller Institute found that to be true

*Selye* We use a procedure in which rats are forcefully immobilized in order to produce stress This invariably causes chromodacryorrhea which is I think the correct designation for this condition We have also seen it in forcefully immobilized adrenalectomized rats

*Long* We certainly do not seem to have solved the question that was posed to us by Professor Young as to whether ACTH is a single substance or a mixture of hormones I suppose the only thing we can say is that certain preparations of ACTH are most certainly a mixture of hormones Whether there has yet been prepared a substance that represents the real tropic hormones of the adrenal cortex is undecided Do you agree Dr Astwood?

*Astwood* Yes

*Long* How about you Dr Li do you think you have free ACTH now?

used Merck's corticotropin B Armour's corticotropin A and the pure preparation of corticotropin that Dr Li has just described to you. These purified preparations do not have this extra adrenal effect unless relatively large doses are administered. Dr Li has a fraction which is active in as little as  $1 \mu\text{g}$  per rat per day. This fraction does not have any significant amount of corticotropic activity.

We have tested the other purified pituitary hormones. They do not have this effect nor does intermedin. So we appear to be dealing with a principle that has not been identified. It is possible that we are dealing with a mixture of known principles but this does not seem probable. It is possible that we are dealing with a principle which somebody else has measured by another criterion for example one of the criteria which Dr Astwood has been discussing. Whatever it is our data do not seem to be explicable in terms of the principle which causes depletion of adrenal ascorbic acid.

*Long:* It is an extra adrenal factor.

*Ingle:* Yes.

*Li:* This factor that Dr Ingle mentioned also has had no effect on adrenal size.

*Astwood:* Where did it emerge on the column in the fractionation that you just described?

*Li:* It is the first peak derived from the AE 97 column using the pepsin digest of purified ACTH.

*Astwood:* With the intermedin?

*Li:* Yes that fraction is quite a mixture.

*Mason:* How do you know it is not intermedin?

*Li:* I think Dr Ingle tested not only our own highly purified intermedin but also another preparation.

*Ingle:* Yes one which we obtained from Armour.

*Mason:* That intermedin I believe has a little ACTH activity in it.

*Ingle:* Yes but very little. It is a fraction of a unit per milligram. One other point should be made clear. In order to demonstrate this effect one must first treat the animal with adrenocortical extract or with one of the 11 oxysteroids. An optimum amount of adrenal hormone gives partial replacement. By adding this factor there is full replacement.

*Bauer:* Do they receive glucose all the time?

*Ingle:* They do not receive glucose. There is 0.9 per cent salt in the solution.

*Bauer:* And that amount would be how much salt per day per rat?

**Long** Because ACTH has often been given by continuous drip hypoglycemia might well have been reported if it were a fairly frequent occurrence. Have you observed it Dr Conn?

**Conn** I have never seen any hypoglycemic phase preceding the hyperglycemic phase with ordinary ACTH in man. Some of the things that Dr Astwood has mentioned is characteristic of this potent fraction reminds one of that peculiar disease that Dr R D Lawrence has described (59). He calls this lipo atrophic diabetes. It is characterized by tremendous oxygen consumption without thrototoxicosis, hyperglycemia and hyperlipemia with great insulin resistance, no ketosis, almost complete loss of subcutaneous and depot fat and gradual enlargement of the liver with ultimate hepatic cirrhosis. Whatever this disease is Lawrence described two such cases. Removal of the thyroid lowered the oxygen consumption only slightly. Without any thyroid there was still a very high oxygen consumption.

**Bauer** We have seen a case very much like that. It turned out to be hemochromatosis with involvement of the myocardium. The autopsy findings explained a lot of things observed during life. I wish the two reported cases had been autopsied then we would know for sure what they had.

**Conn** One was autopsied and revealed fatty infiltration of the liver and cirrhosis. The fat depots as well as the subcutaneous fat were all gone.

**Bauer** There is another situation which should be considered and that is the end stage of dermatomyositis. It can give a clinical picture of the type you described including a fatty liver. I do not think we know what disease Lawrence reported.

**Young** In Dr Lawrence's case the basic metabolic rate went up to 130 at one stage. I think it is one of the highest that ever has been described.

**Bauer** He also mentioned a couple of cases of dermatomyositis.

**Conn** Have you speculated on where that blood sugar has gone? Because the R Q is down it can be oxidized but cannot be converted to fat. It could go into the liver as glycogen. Was there any increase in liver glycogen?

**Astwood** This is all quite recent. Dr V W Westermeyer\* has experiments going at the moment to try to answer these questions but he does not know as yet.

**Long** As I suggested before it may have some effect on the protein metabolism.

\*Personal communication



*Li* As a matter of fact we have had a corticotropin for about a year and we have been trying to prove that it is pure. If it is then I believe that we shall have solved this problem.

*Long* Does this have a hypoglycemic action?

*Li* We have not yet tried it. However we feel that this material controls fat mobilizing activity. A pure hormone could have more than one effect, both cortisone and oxytocin have. Insulin also has more than one biological property.

*Loeb* In the case of insulin I think one has to say whether one is talking about the primary direct effect or a secondary series of changes.

*Li* The fat mobilizing fraction has to be tested in the presence of the adrenal. No fat mobilizing effect occurs in the absence of the adrenals.

*Loeb* All I am trying to say is that it is possible the fat mobilization is secondary to a change which is taking place, we will say in the utilization of glucose?

*Li* Yes.

*Ingle* If one gives a sufficient amount of cortisone fat can be mobilized in the liver. Dr. Louis Levin (58) has shown that one cannot account for all of the fat mobilizing effect of pituitary extracts in terms of adrenal mediation.

*Long* Dr. Kendall didn't you point out some time ago that compounds A and B had more fat mobilizing activity than E and F?

*Kendall* I think that may be because the animals that had E did not live long. A and B had very little effect on the animal except to suppress growth, whereas E produced loss of weight and lesions in the muscles and killed a large number of animals. But with A and B there was very little else that happened, they ceased to grow and fat was deposited where protein should have been.

*Thorn* Has anyone ever observed any improvement in a patient with Addison's disease given ACTH or any striking metabolic change other than the retention of water?

*Loeb* We tried it in a desultory way but nothing happened.

*Long* I should like to ask if anyone has observed a hypoglycemic effect in man given an ACTH preparation, whether intravenously or any other way.

*Astwood* Dr. M. S. Riben\* did one experiment in an untreated Addisonian giving I think 5 mg. of this preparation intravenously and there was no significant change in the blood sugar. This needs to be studied further, however.

\*Personal communication

## REFERENCES

- 1 STACK DUNNE M P and YOUNG F G The properties of ACTH *J Endocrinol* 7 1x11 (1951)
- 2 TALBOT N H WOOD M S CAMPBELL A M CHRISTO E and ZYGMUNTOWICZ A S Concerning the probability that there are at least two adrenocorticotrophic hormones in the human being *Proc Second Clin ACTH Conf* Vol I J R Mote Editor Philadelphia Blakiston Co 1951 (p 20)
- 3 WINTER C A HOLLINGS H L and STEBBINS R B The effect of androgenic hormones upon the adrenal atrophy produced by cortisone injections and upon the anti inflammatory action of cortisone *Endocrinology* 52 123 (1953)
- 4 ZIZINE L Action comparative de doses variees de testosterone sur l'atrophie surrenalienne produite par la cortisone *Compt rend Soc biol* 147 26 (1953)
- 5 COLLIP J B Properties of anterior lobe extracts *Cold Spring Harbor Symp Quant Biol* 5 210 (1937)
- 6 JOHNSON S and HOGBERG H Observations on the connexion between intermedin and adrenocorticotrophic hormone *Nature* 169 286 (1952)
- 7 SULMAN F G Chromatophototropic effect of adrenocorticotropin A new method for standardization of ACTH *Quart Israel Vet M A* 9 31 (1952)
- 8 ——— Mechanism of the chromatophototropic effect of ACTH *J Endocrinol* 8 275 (1952)
- 9 POPENOE E A PIERCE J G DU VIGNEAUD V and VAN DYKE H B Oxytocic activity of purified vasopressin *Proc Soc Exper Biol & Med* 81 506 (1952)
- 10 SULMAN F G ACTH and the pigment hormone *Lancet* 2 247 (1952)
- 11 JOHNSON H and HOGBERG H The occurrence of the melanophore hormone in serum from human subjects in different pathological conditions and its relation to corticotrophin *Acta endocrinol* 13 325 (1953)
- 12 HUNGERFORD G T REINHARDT W O and LI C H Lack of correlation of eosinopenic and adrenal ascorbic acid depleting activities of various adrenocorticotrophic preparations *Proc Soc Exper Biol & Med* 81 320 (1952)
- 13 VOGT M *The Suprarenal Cortex* J M Yoffey Editor *Proc Fifth Symp Colston Res Soc London* Butterworths Scientific Publications 1953 (p 28)
- 14 DUMM M E RALLI E P and GRAEF I Effect of hypophysectomy in pigmentation and ascorbic acid excretion in black rats *Proc Soc Exper Biol & Med* 79 214 (1952)
- 15 RALLI E P and GRAEF I Stimulating effect of adrenalectomy on hair growth and melanin deposition in black rats fed diets adequate and deficient in filtrate factors of vitamin B with note on effect of diet on post operative survival *Endocrinology* 32 1 (1943)

*Conn* Suppose you assume that you completely stopped the glyconeogenesis then the subsequent disappearance of glucose from the blood must indicate that it has reappeared somewhere as glycogen or has been oxidized That would seem to be the only explanation

*Long* If you stop it coming in that is the natural way

*Thorn* Did you observe hyperventilation in these animals during the initial phase of the infusion? This of course might make a marked difference in the apparent R Q

*Astwood* With large doses in rats and mice, one can see an increase in actual physical activity, and the animals suffer from a high environmental temperature I think it is true though that the increase in metabolism in association with a lowering of R Q can occur without any visible change in physical activity including respiration It has with large doses an anleptic effect When one does the experiment under barbiturate anesthesia the animals tend to wake up

*Young* I should just like to comment on the question of multiple effects of peptide hormones that have been described Perhaps now that synthetic peptide hormones are becoming available there is a chance to test whether there is intrinsic multiple activity

*Long* I know of no effects attributable to the posterior lobe hormones in such small quantities Quite large amounts must be given if there is to be any effect on the blood sugar

*Young* Not with regard to resistance to the intravenous action of the insulin In 1941 an experiment was made (60) in which significant effects were obtained with I think one or two units or less of oxytocin That was in response to intravenously administered insulin In those experiments animals differed one from the other Some showed a response and others did not The animal that showed the response would do so consistently

*Astwood* Some of the effects described by Dr Collip in 1941 (61), were obtained with posterior lobe extracts as well as with anterior if I am not mistaken

*Young* Dr Collip did obtain metabolic effects with intermedin

*Astwood* He later showed that the specific metabolic principle was separable from intermedin

*Ingle* May I ask whether it is clear that the antidiuretic principle of posterior lobe is identical with the pressor principle?

*Young* There is no evidence to the contrary yet that I know of

*Li* The pure and synthetic oxytocin of du Vigneaud has pressor antidiuretic and about 20 per cent oxytocic activity Obviously a pure substance can have more than one biological effect

## REFERENCES

- 1 STACK DUNNE M F and YOUNG F G The properties of ACTH *J Endocrinol* 7 1x1 (1951)
- 2 TALBOT N B WOOD M S CAMPBELL A M CHRISTO E and ZYGMUNTOWICZ A S Concerning the probability that there are at least two adrenocorticotrophic hormones in the human being *Proc Second Clin ACTH Conf* Vol 1 J R Mote Editor Philadelphia Blakiston Co 1951 (p 20)
- 3 WINTER C A HOLLINGS H L and STEBBINS R B The effect of androgenic hormones upon the adrenal atrophy produced by cortisone injections and upon the anti inflammatory action of cortisone *Endocrinology* 52 123 (1953)
- 4 ZIZINI L Action comparative de doses variees de testosterone sur l'atrophie surrenalienne produite par la cortisone *Compt rend Soc biol* 147 26 (1953)
- 5 COLLIP J B Properties of anterior lobe extracts *Cold Spring Harbor Symp Quant Biol* 5 210 (1937)
- 6 JOHNSON S and HOGBERG B Observations on the connexion between intermedin and adrenocorticotrophic hormone *Nature* 169 286 (1952)
- 7 SULMAN F G Chromatophototropic effect of adrenocorticotropin A new method for standardization of ACTH *Quart Israel Vet M A* 9 31 (1952)
- 8 ——— Mechanism of the chromatophototropic effect of ACTH *J Endocrinol* 8 275 (1952)
- 9 POPENOE E A PIERCE J G DU VIGNEAUD V and VAN DYKE H B Oxytocic activity of purified vasopressin *Proc Soc Exper Biol & Med* 81 506 (1952)
- 10 SULMAN F G ACTH and the pigment hormone *Lancet* 2 247 (1952)
- 11 JOHNSON S and HOGBERG B The occurrence of the melanophore hormone in serum from human subjects in different pathological conditions and its relation to corticotrophin *Acta endocrinol* 13 325 (1953)
- 12 HUNGERFORD G F REINHARDT W O and LI C H Lack of correlation of eosinopenic and adrenal ascorbic acid depleting activities of various adrenocorticotrophic preparations *Proc Soc Exper Biol & Med* 81 320 (1952)
- 13 VOCT M *The Suprarenal Cortex* J M Yoffey Editor Proc Fifth Symp Colston Res Soc London Butterworths Scientific Publications 1953 (p 28)
- 14 DUMM M F RALLI E P and GRAEF I Effect of hypophysectomy in pigmentation and ascorbic acid excretion in black rats *Proc Soc Exper Biol & Med* 79 214 (1952)
- 15 RALLI E P and GRAEF I Stimulating effect of adrenalectomy on hair growth and melanin deposition in black rats fed diets adequate and deficient in filtrate factors of vitamin B with note on effect of diet on post operative survival *Endocrinology* 32 1 (1943)

- 16 BUTCHER E O and RICHARDS R A The relation of the adrenals to retarded hair growth in underfed albino rats *J Nutrition* 25 787 (1939)
- 17 BUTCHER E O Accelerated hair growth in the rat after adrenalectomy cannot be attributed to the thyroid *Proc Soc Exper Biol & Med* 48 120 (1941)
- 18 CATER D B and STACK DUNNE M P The histological changes in the adrenal of the hypophysectomised rat after treatment with pituitary preparations *J Path & Bact* 66 119 (1953)
- 19 HIRS C H W STEIN W H and MOORE S Chromatography of proteins Ribonuclease *J Am Chem Soc* 73 1893 (1951)
- 20 DIXON H B F STACK DUNNE M P YOUNG F G and CATER D B Influence of adrenotropic hormone fractions on adrenal repair and on adrenal ascorbic acid *Nature* 168 1084 (1951)
- 21 BRUCE H M and PARKES A S A slow release medium for adrenocorticotrophic hormone *Lancet* 1 71 (1952)
- 22 RINFRET A P GRIFFIN A C and WEXLER B C Equine pituitary corticotrophin and its effect on the rat adrenal *Federation Proc* 12 259 (1953)
- 23 LIDDLE G W RINFRET A P RICHARD J and FORSHAM P H Functional evidence in man for the existence of an adrenal growth factor distinct from ACTH *J Clin Endocrinol* 13 842 (1953)
- 24 BUSH I Discussion of paper on The Growth Hormone and Diabetes *Recent Progr Hormone Research* 8 303 (1953)
- 25 REINHARDT W O GESCHWIND I I and LI C H On evidence suggesting multiplicity of adrenocorticotrophic hormones evaluation of bioassay methods *Acta endocrinol* 8 393 (1951)
- 26 PIERCE J G Countercurrent distribution studies on anterior pituitary growth hormone *Biochem J* 57 16 (1954)
- 27 BRUCE H M PARKES A S and PERRY W L M Assay of ACTH on thymus of nestling rat *Lancet* 1 790 (1952)
- 28 LYONS W R LI C H JOHNSON R E and COLT R D Evidence for progestogen secretion by ACTH stimulated adrenals *Proc Soc Exper Biol & Med* 84 336 (1953)
- 29 PINCUS G HOPKINS T F and HECHTER O An ACTH inactivating factor in mammalian blood *Arch Biochem Biophys* 37 408 (1952)
- 30 FORSHAM P H RENOLD A E and FRAWLEY T F The nature of ACTH resistance *J Clin Endocrinol* 11 757 (1951)
- 31 LIDDLE G W RINFRET A P ISLAND D and FORSHAM P H Factors responsible for the variable effectiveness of ACTH in man *J Clin Investigation* 32 584 (1953)
- 32 WINTER C A BRINK N G and FOLKERS K Adrenal repair and chromatophore expanding activities of corticotropin B *Proc Soc Exper Biol & Med* 82 365 (1953)

- 33 DUMM M E GERSHBERG H BECK F M and RAHLI F P Effect of pantothenate deficiency on synthesis of adrenal cholesterol following stress *Proc Soc Exper Biol & Med* 82 659 (1953)
- 34 HAYNDS R SAVARD K and DORFMAN R I The action of adrenocorticotrophic hormone on beef adrenal slices *J Biol Chem* 207 925 (1954)
- 35 REINHARDT W O and LI C H Experimental production of arthritis in rats by hypophyseal growth hormone *Science* 117, 295 (1953)
- 36 GREEN D M Hypertension A special review *Third Annual Report on Stress* H Selye and A Horava Editors Montreal Acta Inc. 1953
- 37 GREEN D M SAUNDERS F J WAHLGREN N and CRAIG R L Self sustaining post DCA hypertensive cardiovascular disease *Am J Physiol* 170 94 (1952)
- 38 GREEN D M SAUNDERS F J WAHLGREN N McDONOUGH F J and CLAPPIT J M Mechanism of desoxycorticosterone action VII Influence of the pituitary *Am J Physiol* 170 107 (1952)
- 39 CARREYETT R A GOLLA Y M L and REISS M The action of gonadotrophic hormone and of pituitary corticotrophic hormone on the cholesterol content of the adrenals *J Physiol* 104 210 (1945)
- 40 BECKIR R R BUCH H B SALOMON L L VENKITA SUBRAMANIAN T A and KING C G Ascorbic acid deficiency and cholesterol synthesis *J Am Chem Soc* 75 2020 (1953)
- 41 COLLIP J B Demonstration of orally active medullotrophic principle in primary extract of pituitary tissue *Canad MAJ* 42 2 (1940)
- 42 CUSHING H and DAVIDOFF L M The pathological findings in four autopsied cases of acromegaly with a discussion of their significance *Monographs of the Rockefeller Inst for M Res* No 22 (1927)
- 43 GROEN J HAMMINGA C E WILLEBRANDS A F and BLICKMAN J H Evidence for the presence of insulin in blood serum A method for an approximate determination of the insulin content of blood *J Clin Investigation* 31 97 (1952)
- 44 WESTERMEYER V W and RABEN M H Fall in blood sugar from anterior pituitary extract *Endocrinology* 54 173 (1954)
- 45 DIXON H H F MOORE S STACK DUNNE M P and YOUNG F G Chromatography of adrenotropic hormone on ion exchange columns *Nature* 168 1041 (1951)
- 46 ROSENBERG I N Adipokinetic activity of oxycel purified corticotropin *Proc Soc Exper Biol & Med* 82 701 (1953)
- 47 CAMPBELL J A method of assaying the potency of anterior pituitary extracts which increase liver fat *Endocrinology* 23 92 (1938)
- 48 O DONOVAN D K and COLLIP J B The specific metabolic principle of the pituitary and its relation to the melanophore hormone *Endocrinology* 23 718 (1938)

- 49 BEST C H and CAMPBELL J Anterior pituitary extracts and liver fat *J Physiol* 86 190 (1936)
- 50 MILMAN A E and RUSSELL J A Some effects of purified pituitary growth hormone on carbohydrate metabolism in the rat *Endocrinology* 47, 114 (1950)
- 51 HARRISON H C and LONG C N H Effects of anterior pituitary extracts in the fasted rat *Endocrinology* 26 971 (1940)
- 52 DIXON H B F STACK DUNNE M P and YOUNG F G The preparation and properties of ACTH *The Suprarenal Cortex* J M Yoffey Editor Proc Fifth Symp Colston Res Soc London Butterworths Scientific Publications 1953 (p 11)
- 53 HESS G P and CARPENTER T H Chromatographic separation of the adrenocorticotrophic hormone on partition columns *J Am Chem Soc* 74 4971 (1951)
- 54 HAYS E E and WHITE W H The chemistry of the corticotrophins *Recent Progr Hormone Research* 10 265 (1954)
- 55 LI C H GESCHWIND I I LEVY A L HARRIS J I DIXON J S PON N G and PORATH J O Isolation and properties of alpha-corticotropin from sheep pituitary glands *Nature* 173 251 (1954)
- 56 LI C H Recent studies on the problems involved in the preparation properties and bioassay of adrenocorticotrophic hormone *Acta endocrinol* 10 255 (1952)
- 57 LEWENHOECK A Observationes D Anthonie Lewenhoeck de Natis e femine genitali Animalculis *Phil Trans* 12 1040 (1678)
- 58 LEVIN L and FARBER R K Symposium recent developments in endocrinology endocrine mechanism controlling mobilization of depot fat *Tr Neu York Acad Sc* 13 260 (1951)
- 59 LAWRENCE R D Human and experimental diabetes *Hormonal Factors in Carbohydrate Metabolism* Ciba Foundation Colloquia on Endocrinology Vol VI London J & A Churchill 1953 (p 245)
- 60 GRIFFITHS M Antagonism between insulin and posterior lobe pituitary extract *J Physiol* 100 112 (1941)
- 61 NEUFELD A H and COLLIP J H Effect of pituitary preparations on glycogen stores of fasted mice *Endocrinology* 28 926 (1941)

# INDEX

## A

- Acetate
  - in cholesterol synthesis 1949 124
  - as precursor of neutral steroid 1953 47
  - radioactive 1953 90
  - radioactivity of compound B after 1953 93
  - in steroidogenesis in isolated perfused adrenal 1951 130 134
- Acid loading with after adrenalectomy 1951 21 77 1953 89 90
- Acromegaly
  - arthritis in 1953 128
  - diabetes mellitus in 1952 158
  - and hypertension 1952 158 1953 134
- ACTH 1950 59 199 1951 116
  - in Addison's disease with diabetes mellitus 1949 145
  - adenohypophyseal discharge of 1949 72
  - administration of 1950 47
  - adrenal activation by in stress 1952 3
  - and adrenal ascorbic acid 1949 64 85 86 1952 65 73 1953 99 127
  - after adrenal atrophy 1950 60
  - adrenal cholesterol after 1953 118 171
  - and adrenal cortical hormone 1949 49 52 72 74
  - after adrenalectomy 1949 173 177 183
  - adrenal gland after 1949 147 154 1950 60
  - in adrenal priming 1952 71
  - and adrenal weight 1950 65 73 1953 100 126
  - in adrenogenital syndrome 1953 78 87 84
  - allergic reaction to 1949 99 100
  - for allergy 1949 92
  - antagonism of to insulin 1949 145
  - antibody formation after 1949 99 100
  - antidiuretic effect of 1950 34 35 38 41
  - and antigen antibody reaction 1949 97
  - antigen response to 1949 99 100
  - and ascorbic acid depleting factor 1949 64 85 86 1952 65 73 1953 99 122
  - for asthma 1949 92
  - in blood
    - after ether anesthesia 1952 91 97
    - oxycellulose method for determination of 1952 95
  - blood activating factor for 1951 85 86

## ACTH—Compound

- blood sugar after 1953 143
- body temperature after 1949 101
- for burns 1950 189 189
- calorigenic action of 1950 186
- and cellular atrophy
  - in brain 1950 83
  - in hypothalamus 1950 83
  - in periventricular nucleus 1950 83
- chemistry of 1950 11 46
- chloruretic effect of 1950 35 38 39
- cholesterol synthesis without 1949 145
- chromatogram of 1953 106
- clinical use of 1951 156 204
- for colitis ulcerative 1949 93
- for collagen diseases 1949 90 97
- composition of 1950 18
- and compound B in rabbit 1953 61
- continuous administration of 1950 42
- cortico d inhibition of discharge of 1950 59
- in corticosteroidogenesis from cholesterol 1951 141 148
- in Cushing's syndrome 1953 71 75
- cystine after urinary 1949 120
- desoxycorticosterone inhibition by 1949 108 1950 52
- and desoxycorticosterone toxicity 1949 69
- destruction of by liver tissue 1950 16
- in diabetes mellitus 1950 38
- with Addison's disease 1949 145
- and diet 1950 76
- different forms of 1951 26 61 67 77 1953 97 159
- in edema in nephrotic syndrome 1951 50 51
- and electroshock 1949 68 69
- enimopenic response to in adrenalectomized rats 1950 76
- and epinephrine 1949 72
- epinephrine in regulation of pituitary secretion of 1949 74 1951 6 71 73
- excretion of C metabolites after 1953 4 49
- extraction of from pituitary 1950 2 30
- fever after 1949 101
- fixing of in adrenal gland 1950 42
- forms of 1952 26 32 64 67 7 1953 97 158
- glucose tolerance after 1950 199
- growth hormone antagonist of 1952 60



## ACTH—Cont'd

- hair growth after
  - hirsutism 1953 89
  - inhibition of 1949 118
- for hay fever 1949 92
- and healing of tissue 1949 91
- hyaluronidase spreading effect after 1950 144
- hydrolysis of with crystalline pepsin 1950 13 21
- for hypoglycemia congenital 1949 94
- hypothalamus in regulation of secretion of 1951 54 87
- and intermedin 1953 98
- intermittent administration of 1950 42
- iodine uptake by thyroid after 1949 104
- ketosteroid excretion after 1951 201 202
- in kidney 1950 43
- La 1 A as standard 1950 22 73 28 31
- for leukemia 1949 94
- lymphatic 1949 94
- liver fat after 1953 139
- liver lipid after 1949 142
- for lupus erythematosus 1949 91
- vs lyophilized anterior pituitary 1950 44
- melanophore expanding activity of 1953 98 99
- metabolic responses to 1949 19
- molecular weight of 1950 18 32 33
- for myasthenia gravis 1949 91
- and nail defects 1949 119
- ox chemical nature of 1950 12 72
- and pantothenate 1950 76
- peptide vs protein 1950 11 41
- in perfusion of isolated adrenal gland 1949 50 52 56 60
- pig chemical nature of 1950 12 14 72
- and premenstruation 1949 106 1950 156
- in pituitary body anterior 1949 184 185
- after dietary deficiency 1949 185
- after stress 1949 185
- pituitary discharge of
  - 17 hydroxycorticosterone in inhibition of 1949 66
  - regulation of 1950 48 58 61 83
  - after stress 1949 61 66
- plurality of forms of 1952 26 32 64 67 72 1953 97 158
- for pneumonia 1950 105
- due to pneumococcus 1949 93
- poly regression after 1949 9
- postoperative 1950 18 188
- protein vs peptide 1950 11 41
- psoriasis after 1949 101 104
- refractoriness to 1950 7 1
- regulation of pituitary discharge of 1950 48 58
- adrenal cortical hormone in 1950 5 69 70
- epinephrine in 1950 53 55 61 83
- hypothalamus in 1950 55 5 67

## ACTH—Cont'd

- response to after cortisone 1949 100
  - schizophrenic response to and stress 1949 157
  - secretion of after emotional stress 1951 55
  - seminal vesicle after 1949 148
  - and sensitivity to tuberculin 1950 109
  - serum cholesterol after 1949 133 145
  - sheep chemical nature of 1950 12 14 22
  - and sodium retention factor from adrenal cortex 1953 23 24
  - and somatotrophic hormone 1952 39 1953 130
  - induced release of 1952 57
  - somatotrophic stimulation of 1953 126
  - stability of in blood 1950 42 43
  - for status asthmaticus 1949 92
  - after stress 1949 72 73
  - sulfur excretion after 1949 170
  - synthesis of
    - vs gonadotrophin synthesis 1949 185
    - during starvation 1949 185
  - in synthesis of compound B
    - from cholesterol 1952 115
    - from progesterone 1952 115 117
  - in synthesis of compound F
    - from cholesterol 1952 115
    - from progesterone 1952 115 117
  - as test for adrenal cortical function 1950 191 193
  - testis after 1949 148
  - thymus response to 1950 14
  - thyroid gland after 1950 185
  - urinary 17 ketosteroids after 1952 121
  - and urinary steroid output 1949 116
  - wound healing after 1949 91 121
- Adaptation diseases of 1949 110 111 1952 82 87
- Addison's disease
- ACTH in with diabetes mellitus 1949 145
  - antidiuretic hormone in 1949 37
  - compound B in 1950 193 195 1951 168
  - corticosterone in 1950 207 203
  - cortisone for 1949 77 73 1950 161 17 206 1951 161 173 1953 60 65
  - with desoxycorticosterone acetate 1950 205 1951 17 175
  - and diabetes mellitus 1951 170 173
  - electroencephalogram after 1949 23
  - hypertension after 1952 154
  - hypoglycemia in 1950 165 168
  - during intercurrent infection 1952 159
  - rate of administration of 1953 59

Addison's disease—*Cont'd*cortisone for—*Cont'd*

- surgery after 1951 168
- desoxycorticosterone for
  - amorphous fraction of 1949 23
  - with cortisone 1950 205 1951 162 165
  - and hypertension 1952 145
  - stiffness after 1949 109
  - work output after 1951 168 169
- and diabetes mellitus
  - ACTH in 1949 145
  - compound II for 1950 201
  - cortisone in 1951 170 173
- electroencephalogram in 1951 167 168
- eosinopenia in 1952 18 19
  - as measure of 11 17 oxysteroids 1950 78
- eosinophils in
  - after cortisone 1953 60 65
  - diurnal variation of 1953 60 65
- fasting hypoglycemia in corticosterone for 1950 204
- glucose in blood in, 1951 165 168
- hormone utilization in 1952 83
- hydrocortisone for 1953 60
- 17 hydroxycorticosteroids in blood in 1951 95
- hydroxysteroid excretion in 1952 121 and hypertension 1952 145
- impaired water tolerance in cortisone for 1950 168 169
- inflammation in 1950 107
- insulin in 1950 166
- 17 ketosteroid excretion in 1950 80
- pigmentation in 1949 106-107 1950 155
- pregnancy in 1952 88
- serum cholesterol in during ACTH administration 1949 136
- tuberculosis in 1950 107
- water excretion in 1951 51
- water load in 1949 37

Adenohypophysis *See* Pituitary body anterior

## Adipokin in pituitary factor 1953 144

## Adrenal cortex

- ACTH as test for function of 1950 191 193
- activation of in stress 1952 13
- in alarm reaction 1952 25
- androgen from 1953 86-89
- ascorbic acid discharge from after epinephrine 1949 75
- and barbiturate anesthesia 1950 57
- cholesterol from 1949 139
- cholesterol synthesis by 1949 129
- after cold exposure 1952 22

Adrenal cortex—*Cont'd*

- corticosteroid secretion by rate of 1951 157
- cortisone induced atrophy of abolished by somatotrophic hormone 1952 52
- desoxycorticosterone from 1949 30
- in diabetes mellitus 1949 26
- and epinephrine 1949 72 1950 52 55 1951 64 71 1952 20 23
- after estrogen 1951 73
- hyperactivity of 1953 66-85
- insufficiency of and diabetes insipidus 1949 37
- after lyophilized anterior pituitary in sensitized rat 1952 74 75
- mineralocorticoid in 1949 110
- mitotic figures of after adrenal ascorbic acid reducing material from pituitary 1953 106
- in pantothenic acid deficiency 1949 160
- qualitatively different effects of 1952 29 95
- secretion from
  - after ACTH 1949 49 52 56 60
  - regulation of 1949 47 88
  - after severe burns 1950 188 189
- sodium retaining factor from 1953 11 25
- somatotrophic hormone stimulation of 1952 52 57
- steroid from
  - biogenesis of 1951 115 154
  - determination of 1951 89 113
  - metabolism of 1953 27 93
- and stress 1950 53
  - mechanical analogy 1952 77 80
- after sympathectomy 1950 53
- thymic involution due to hyperreactivity of 1952 85
- and vitamin 1949 159 189
- weight of and growth hormone 1953 110

## Adrenal cortical cell from fibroblast 1950 153

## Adrenal cortical extract

- after adrenalectomy 1949 165
- and tubular absorption of salt 1951 16-21
- capillary permeability after administration of 1950 107
- and carbohydrate tolerance after hepatectomy 1951 107
- and epinephrine effector cell response to 1950 54
- during exercise 1949 65
- extrarenal effect of 1951 42 45
- and glomerular filtration rate after adrenalectomy 1951 12 16

Adrenal cortical extract—*Cont'd*

- and hyaluronidase spreading effect 1950 116 162
- and inhibition of hair growth 1949 118
- potassium excretion after 1949 34 35
- and tubular absorption of salt, after adrenalectomy 1951 16 21
- urinary excretion of 1950 124
- vascular effect of 1950 106
- Adrenal cortical hormone
  - and ACTH 1949 72 74
  - and allergy 1950 88 113
  - ammonia excretion after 1951 32
  - amorphous fraction of
    - activity of 1947 23
    - vs desoxycorticosterone 1949 23 24
    - and electrolyte metabolism 1949 23 24
    - and liver glycogen deposition 1949 23
    - structure 1949 11
  - and anaphylactic shock 1950 88 101
  - atrophy due to
    - of adrenal gland 1949 11
    - of thymus 1949 11
  - biological activity of as related to chemical structure 1949 11 46
  - in blood
    - arterial 1949 74
    - determination of 1951 89 113
    - venous 1949 74
  - chemical structure of as related to biological activity 1949 11 46
  - cholesterol as precursor of 1947 130 1951 130 137
  - clinical use of 1951 156-204
  - and diabetes mellitus 1952 12 13
  - diabetogenic effect of 1952 12 15
  - epinephrine activity blocked by 1950 65 69
  - after estrogen 1950 128
  - extrarenal effect of 1951 42 44
  - formaldehydogenic 1947 52
  - and hyaluronidase 1949 77 79 105 1950 115 16
  - and hypersensitivity 1950 88 113
  - and hypertension 1952 133 139
  - and hypoglycemia 1950 75
  - and kidney function 1951 11 55
  - macrophage response to 1950 107
  - in malignant hypertension 1950 178
  - in mobilization of foodstuffs 1952 154 155
  - permissive action of 1952 11 78 31 37
  - in hypertension 1952 153 154
  - phagocytosis after 1950 101 107
  - physiologic actions of 195 154 155
  - and pigmentation 1950 155 156
  - in pregnancy 1952 88
  - rate of disappearance of 1950 79
  - in regulation of pituitary ACTH discharge 1950 50 5 57 60 0

Adrenal cortical hormone—*Cont'd*

- secretion of
  - diurnal variation in 1953 59 61
  - proposed mechanism of control of 1949 79
  - rate of 1953 59 61
- sheep chemical nature of 1950 17 14 22
- site of action of in kidney tubule 1951 31 40
- and sodium excretion 1951 55
- and spread of injected India ink 1949 98 105
- after stress 1949 72 78 1950 79
- transformation of 1949 24 27
- urinary
  - after burns 1952 86
  - in stress 1950 79
- utilization of 1953 54
- vascular effect of 1950 106
- See also Cortisone
- Adrenal cortical pituitary system in regulation of pituitary ACTH discharge 1950 48 83
- Adrenalectomy
  - acid loading after 1951 21 27 1053 89 90
  - ACTH after 1949 173 177 183
  - and pantothenic acid 1949 183
  - adrenal cortical extract after 1947 165
  - ammonium chloride loading after 1951 21 27
  - anaphylactic sensitivity after 1950 88 101
  - bilateral
    - congestive heart failure as indication for 1952 146 149
    - for nephrotic syndrome with hypertension 1952 146 147
    - with choline deficiency 1949 108
  - cortisone after 1952 47
  - and desoxycorticosterone acetate 1949 165
  - for diabetes mellitus 1952 151
  - eosinopenia after 1952 18 19 161 167
  - eosinophilia after 1952 161 162
  - fur growth after 1949 167
  - glomerular filtration rate after 1951 12
  - hair growth after 1949 119 167
  - for hypertension 1952 131 161
  - and cortisone as replacement therapy 1950 17 182
  - with inositol deficiency 1949 168
  - kidney function after and sodium loading 1951 30
  - and lymphocytopenia after radiation 1952 163
  - lymphocytosis due to stress after 1952 25
  - in man 1952 151 161
  - and pantothenic acid 1949 162 189

Adrenalectomy—*Cont'd*

- pigmentation after 1949 162
- and desoxycorticosterone 1949 162 181
- for renal hypertension 1952 157
- salt after
  - and growth 1949 21
  - retention of 1949 33 35
  - tubular absorption of 1951 16-21
- and spreading induced by hyaluronidase 1950 118
- stress after 1952 30
- eosinophilia due to 1952 167
- by swimming 1949 174 175
- subtotal
- adrenal cortical regeneration after 1952 149 150
- for Cushing's syndrome with uterine tumor 1951 176
- tubular absorption of salt after 1951 16 21
- tubular excretion of ammonia after 1951 70 27
- for vascular disease hypertensive 1951 151 152
- water excretion after 1951 28
- water tolerance after 1949 156
- work performance after 1949 157 154

## Adrenal gland

- after ACTH 1949 154
- and somatotrophic hormone 1952 39 40
- in stress 1952 31 32
- ACTH weight-increasing effect on 1953 100 126
- in adaptation to stress 1952 160
- androgenic hormone from 1949 147 148 1952 118 120
- in adenogenital syndrome 1953 84 86 87
- ascorbic acid in 1949 159 19 183
- after ACTH 1949 85 86 1953 99 122
- after cold 1949 85 86
- as measure of ACTH activity 1950 49
- as measure of adrenal cortex secretion 1949 86 8
- and steroidogenesis in isolated beef adrenal 1951 119 123
- and steroidogenesis in scurvy guinea pig 1951 125
- after stress 1952 163 164
- after thyroxine 1949 159
- atrophy of
  - ACTH effect on 1950 60
  - due to adrenal cortical hormone 1949 11 16
  - after cortisone 1950 60 1951 158
  - after hypophysectomy 1950 60
- canal of 1953 74 78
- contents of 1953 78

Adrenal gland—*Cont'd*cancer of—*Cont'd*

- steroid production in 1953 74 78
- of cattle hormones in 1949 12
- cholesterol in 1951 122
- ACTH effect on 1953 118 121
- after burns 1953 93
- after cold 1949 85 86
- after hemorrhage 1953 93
- as index of ACTH activity 1950 49
- and steroidogenesis in isolated beef adrenal 1951 119 120
- composition of after hypophysectomy 1952 73
- cortex of See Adrenal cortex
- Adrenal cortical hormone
  - in Cushing's syndrome steroid production by 1953 70 2
- eosinopenia as index of activity of 1952 18 4
- after estrogen 1949 155 1950 128
- fixing of ACTH in 1950 42
- after growth hormone 1949 146
- and hair growth 1949 118 119
- of hamster cholesterol in 1951 122
- of hog hormones in 1949 12
- hormonal transformation by 1949 23
- insufficiency of
  - in rheumatoid arthritis 1951 157 159
- See also Addisons disease
- Adrenal ectomy Cushing's disease
- isolated
  - ACTH in perfusate of 1949 50 53 56 60
  - androgenic steroids from 1951 126-127
  - androstenedione in perfusate of 1949 55
  - ascorbic acid in perfusate of 1949 54 59
  - blood in perfusate of 1949 50 55
  - compound S in perfusate of 1949 55
  - corticosteroidogenesis in 1952 115
  - desoxycorticosterone acetate in perfusate of 1949 53 55 59 60
  - epinephrine in perfusate of 1949 57 58
  - hydroxyprogesterone in perfusate of 1949 55 56
  - plasma in perfusate of 1949 52 55
  - progesterone in perfusate of 1949 55
  - steroidogenesis in 1951 119 154
  - whole blood in perfusate of 1949 50 55
- lipid
  - during alkaline reaction 1950 127
  - after estradiol 1950 127
- lymphocyte level as measure of activation of 1951 67 105
- after major surgery 1950 187 188

Adrenal gland—*Cont'd*

- medulla of *See* Adrenal medulla
- mineralo corticoid secreted by 1952 98 114
- normal steroid production by 1953 68
- output of and epinephrine in arterial blood 1949 57 59
- perfused 1949 50 60
  - corticosteroid output of 1951 116
- priming of with ACTH 1952 71
- in psychosis 1949 107 104
- salt hormone secreted by 1952 98 114
- secretion from 1949 147 151 152
  - with ACTH 1947 147
  - without ACTH 1949 156
- adrenal ascorbic acid as measure of 1949 86 87
- after androstenedione 1949 55
- after ascorbic acid 1949 54 59
- after compound S 1949 55
- after desoxycorticosterone acetate 1949 53 55 59 60
- after epinephrine 1949 57 58 72 84
- after 17 hydroxyprogesterone 1949 55 56
- after progesterone 1949 55
- See also* Adrenal cortical hormone Cortisone
- after somatotrophic hormone 1952 39 40
- after starvation 1949 179
- steroidogenesis in 1953 67 70
  - in adrenogenital syndrome 1953 78 81 86 87
  - in Cushing's syndrome 1953 70 72
- suppression of by cortisone 1951 184
- and thyroid gland activity 1950 184 186
- total extract of 1949 14
- tumor of 1942 119 1953 90 93
- virilism due to malformation of 1952 118 119
- weight of
  - after ACTH 1952 65 73
  - after growth hormone 1953 107 126
  - restoration of after cortisone inhibition 1952 65

## Adrenalin

- adrenal cortical stimulating effect of 1951 64 71
- in adrenal medulla 1949 144
- after insulin 1951 77
- hypothalamic stimulation induced by 1951 85
- lymphopenia due to 1949 75 76
  - after emotional stress 1951 64
- reflex excitability of autonomic system after 1951 84
- and sympatheticoadrenal discharge 1949 73 83
- See also* Epinephrine

## Adrenal medulla

- epinephrine in 1949 144
- after insulin 1951 77
- after growth hormone 1953 133 135
- Adrenal weight factor 1952 65 72 1953 102 126

Adrenocorticotrophic hormone *See* ACTH

## Adrenogenital syndrome 1953 78 84 86 87

## ACTH in 1953 78 87 84

## Adrenosterone 1953 48 50

## metabolism of 1953 38

## Age (of subject) and growth hormone 1952 63

## Alarm reaction 1952 95 86

- adrenal cortex in 1952 25
- and anesthesia 1949 84 85
- and lipid in adrenal gland 1950 127
- thymus involution during 1952 85

## Aldosterone 1953 25

## Alkalosis hypochloremic after desoxy corticosterone 1949 31 32

## Allergy

- ACTH for 1949 92
- after ACTH 1949 99 100
- and adrenal cortical hormone 1950 111 113

## Allopregnanone 1953 111

## Alpha cell pancreatic stimulation of by pituitary extract 1953 144

## Amberlite IRC 50 1953 105

## Ammonia

- tubular exchange of for sodium 1951 18 31 37
- tubular excretion of
  - after adrenal cortical hormone 1951 32
  - after adrenalectomy 1951 20 27
  - after desoxycorticosterone 1951 24 27

## Ammonium chloride loading after adrenalectomy 1951 21 27

## Anaphylaxis

- and adrenal cortical hormone 1950 88 101
- cortisone protection against shock due to 1949 66-67
- and desoxycorticosterone acetate 1950 89
- and histamine 1950 89 93
- leucopenia after 1950 24
- and pyribenzamine 1950 91 95

## Androgen adrenal 1947 147 148 1952 118 120 123 1953 86-89

- from isolated perfused gland 1951 126-12

- Androstane** 1953 28  
**Androstenedione** 1952 124 1953 28 30  
     34 36 38 87  
     in perfusate of isolated adrenal gland  
     1949 55  
**Androsterone** 1949 148 1952 125 1953  
     34 36  
     specific activity of 1953 90 92  
     urinary excretion of after testosterone  
     administration 1953 56 5  
**Anemia hemolytic antigen antibody union**  
     after cortisone in 1950 107 108  
**Anesthesia**  
     and alarm reaction 1949 84 85  
     due to barbiturate pituitary response  
     to 1950 57  
     pentathol and lymphopenia due to  
     cold 1949 76 82 84  
**Anoxia in abolition of salyrgan diuresis**  
     1951 29 30  
**Antibody antigen union** 1950 107 109  
     and ACTH 1949 97  
**Antibody formation of** 1950 157  
**Antidiuretic hormone**  
     in Addison's disease 1949 37  
     changes of in body 1949 37  
     and compound E 1949 36  
     and desoxycorticosterone 1949 36  
**Antigen antibody union**  
     and ACTH 1949 92  
     and antihistamine 1950 107  
     after cortisone 1950 107 109  
**Antihistamine**  
     and antigen antibody union 1950 109  
     hyaluronidase inhibition by 1950 149  
**Antihyaluronidase** 1950 147  
**Antimony trichloride as reagent with**  
     steroids 1949 62 63  
**Anxiety and eosinopenia** 1950 189  
**Arthritis**  
     acromegalic type of 1953 128  
     cortisone for 1949 96  
     and desoxycorticosterone 1949 112  
     formalin 1949 112  
     after growth hormone 1952 59 60  
     due to lyophilized anterior pituitary  
     powder 1949 113  
     rheumatoid  
         adrenal corticosteroid secretion in  
         1952 87  
         adrenal insufficiency in 1951 157  
         159  
         and rheumatism of liver 1951 200  
         compound B for 1950 207 1951  
         187  
         compound E for 1949 13  
**Arthritis—*Cont'd***  
     rheumatoid—*Cont'd*  
         compound F for 1950 108  
         cortisone for 1951 161 181 184  
         and diabetes mellitus 1949 26  
         keloid formation in 1949 121  
         pathogenesis of 1952 84  
         Reichstein's compound S for 1949  
         13 14  
**Ascorbic acid**  
     ACTH in depletion of 1952 65 73  
         1953 98 99  
     adrenal 1949 159 183  
     and ACTH 1949 64 85 86  
     after cold 1949 85 86  
     and dietary ascorbic acid 1949 160  
     discharge of after epinephrine 1949  
     75  
     as index of ACTH activity 1950 49  
     as measure of adrenal cortex secre-  
     tion 1949 86-87  
     and steroidogenesis in isolated beef  
     adrenal 1951 119 123  
     and steroidogenesis in scorbutic  
     guinea pig 1951 125  
     after stress 1951 163 164  
     after thyroxine 1949 159  
     hyaluronidase inhibition by 1950 148  
     in perfusion of isolated adrenal gland  
     1949 54  
**Ascorbic acid factor** 1952 65 72  
**Asthma**  
     ACTH for 1949 92  
     epinephrine in 1950 67 68  
     and schizophrenia, 1949 103  
**Autonomic system reflex excitability of**  
     after adrenalin 1951 84

## B

- Barbiturate anesthesia due to and pitui-**  
     tary response 1950 57  
**Benzedrine action of** 1951 179  
**Bile**  
     as precursor of adrenal cortical hor-  
     mone 1949 130  
     steroid from 1949 44  
**Blood**  
     ACTH in  
         activating factor in 1951 85 86  
         after ether anesthesia 1952 91 92  
         oxycellulose method for determina-  
         tion of 1952 95  
         stability of 1950 42 43  
     adrenal cortical hormone in in preg-  
     nancy 1952 88  
     adrenal cortical steroids in determina-  
     tion of 1951 89 113  
     arterial epinephrine in 1949 57 59  
     compound F in 1951 103 104

Blood—*Cont'd*

- cortisone in 1951 98 102 107
- glucose in
  - in Addison's disease 1951 165 168
  - after ethylenediamine 1952 16
- 17 hydroxycorticosteroid in 1951 95 103
- in Addison's disease 1951 95
- sugar in
  - and abnormal electroencephalogram in Addison's disease 1950 170
  - ACTH effect on 1953 143
  - after adrenalectomy 1949 177 186 187
  - calcium pantothenate effect on 1949 177 186 187
  - pituitary effect on 1953 135 138
  - vitamin C in after cortisone 1949 91
- Blood flow and cell differentiation 1950 153 154

Body temperature after ACTH 1949 101

Bone of rat after treatment with somatotrophic hormone and stilbestrol 1952 41 4

## Brain

- cellular atrophy in after ACTH 1950 83
- cholesterol in 1949 128 129
- edema in 1949 41
- electrolyte in after desoxycorticosterone 1949 39 41
- water in after desoxycorticosterone 1949 39 40

## Burns

- ACTH for 1950 168 189
- adrenal cholesterol after 1953 93
- cortisone for 1950 188 189
- urinary excretion of adrenal cortical hormone after 1952 86

## C

## Cancer

- adrenal 1953 74 79
- metastases of 1953 78
- of prostate bilateral adrenalectomy for 1952 149

Capillary permeability of after adrenal cortical extract 1950 106

Carbohydrate tolerance to after adrenal cortical extract and hepatectomy 1951 10

Carboxymethylcellulose as cortisone suspending agent 1950 103

Cardiovascular disease hypertensive Smithwick classification of 1952 137

Cattle hormones in adrenal gland of 1949 12

## Cell

- differentiation of 1950 150 154
- in hypothalamus 1950 75

Element substance of connective tissue 1950 115 116

Chemotaxis in differentiation of cell type 1950 153

Child compound E dosage for 1949 28

## Chloride

- balance in Addison's disease 1950 172 175
- in brain after desoxycorticosterone 1949 41
- kidney excretion of
  - after ACTH 1950 195 197
  - after compound B 1950 194 197 200
  - after compound E 1950 199
- in plasma in Addison's disease after cortisone and desoxycorticosterone 1951 167 165
- retention of after ACTH 1950 35 38 39
- in sweat after cortisone 1949 27

Cholesterol 1953 12

## Cholestenone

- conversion of to dihydrocholesterol 1949 131
- in corticosteroidogenesis 1951 138 139
- as steroid precursor 1952 115

## Cholesterol

- adrenal 1949 119
- ACTH effect on 1953 118 111
- after burns 1953 93
- after cold 1949 83 86
- in hamster 1951 17
- after hemorrhage 1953 13
- as index of ACTH activity 1950 49
- and steroidogenesis in isolated beef adrenal 1951 119 120
- biosynthesis of 1949 124 113 1251 150 154
- catabolism of 1949 131
- as precursor
  - of adrenal cortical hormone 1949 130 1951 130 137
  - of compound B 1952 115
  - of compound F 1952 115
  - of neutral steroids 1953 47
  - of urinary steroid metabolite 1951 90

## radioactive

- compound F after 1953 93
- in steroidogenesis in isolated perfused adrenal 1951 140 138
- in verum
  - after ACTH 1949 133 145
  - in Addison's disease during ACTH administration 1949 136
  - and cirrhosis of liver 1949 110
  - after compound E 1949 137 138

- Cholesterol—Cont'd**  
in serum—*Cont'd*  
in Cushing's syndrome during ACTH administration 1949 136  
synthesis of without ACTH 1949 145
- Cholesterol chloride** 1949 125
- Choline deficiency of** with adrenalectomy 1949 168
- Chondroitin sulfuric acid** 1950 116
- Chromatography paper of ACTH peptide mixture** 1950 14 17
- Cirrhosis of liver**  
and hypertension 1952 147  
and rheumatoid arthritis 1951 200  
erum cholesterol in 1949 140
- Cold**  
and adrenal cholesterol 1949 85 86  
and adrenal cortical activity after 1957 7  
and glycosuria 1952 16  
lymphopenia due to 1949 76
- Colitis ulcerative**  
ACTH for 1949 93  
chronic cortisone for 1949 18 93
- Collagen disease**  
ACTH for 1949 90 97  
cortisone for 1949 90 97
- Compound A**  
activity of vs compound E 1949 13 16  
in a adrenal gland  
of cattle 1949 17  
of hog 1949 12  
chemical structure of 1949 11  
hyaluronidase spreading effect after 1950 125 127 129 130 134  
and membrane permeability after hyaluronidase 1949 97 99  
as precursor of compound E 1949 12 13
- Compound B**  
after ACTH in rabbits 1953 64  
for Addison's disease 1950 197 205 1951 168  
and diabetes mellitus 1950 201  
in a adrenal gland  
of cattle 1949 17  
of hog 1949 12  
for arthritis rheumatoid 1950 206 1951 187  
chemical structure of 1949 11  
cholesterol as precursor of 1952 115  
cholestenone as precursor of in isolated perfused adrenal gland 1952 115  
glucose tolerance after 1950 199  
urinary excretion of  
glucuronide after 1950 196 198 199 201  
urinary ketosteroid feces 1950 199 200
- Compound B—Cont'd**  
kidney excretion of—*Cont'd*  
nitrogen after 1950 196 198 201  
11 oxysterooids after 1950 199 200  
uric acid after 1950 196 198 201  
metabolic effects of 1950 193 207  
physiological properties of 1950 205  
as precursor of compound F 1949 12 13  
progesterone as precursor of 1952 115 117  
radioactivity of  
after radioactive acetate administration 1953 93  
after radioactive cholesterol administration 1953 93  
*See also* Corticosterone
- Compound C** chemical structure of 1949 11
- Compound E** 1950 199  
activity of  
vs compound A 1949 13 16  
vs compound F 1949 11 13  
in adrenal gland  
of cattle 1949 12  
of hog 1949 12  
and antidiuretic hormone 1949 36  
for arthritis rheumatoid 1949 13  
chemical structure 1949 11  
cholestenone as precursor of in isolated perfused adrenal gland 1952 115  
and cholesterol 1949 137 138  
compound A as precursor of 1949 12 13  
dosage of for child 1949 28  
glucose tolerance after 1952 199  
hyaluronidase spreading effect after 1949 97 99 1950 125 127 129 130 134  
and hypotivcem 1949 40  
inhibition of by hyaluronidase 1950 142  
17 ketosteroids after 1957 122 123  
local anti-inflammatory effect of 1951 207  
and membrane permeability after hyaluronidase 1949 97 99 1950 125 127 129 130 134  
physiological properties of 1950 205  
preparation of suspension of 1949 41 45  
and salt retention 1949 71  
and serum cholesterol 1949 137 138  
sodium retention after 1949 31 1952 110 113  
substitutes in 1949 14  
*See also* Cortisone
- Compound F**  
activity  
vs free 1951 106 199



Compound F—*Cont'd*acetate—*Cont'd*

metabolic effects of 1951 200 201  
204

activity of vs compound E 1949  
11 13

in adrenal gland  
of cattle 1949 12

of hog 1949 12

for arthritis rheumatoid 1950 108

in blood 1951 103 104

in fever 1952 III

chemical structure of 1949 11

cholesterol as precursor of 1952 115

compound II as precursor of 1947  
12 13

compound S as precursor of in per-  
fusate of isolated adrenal gland  
1949 55 56

vs cortisone 1951 200

cortisone transformation to 1952 125  
and desoxycorticosterone acetate in  
pneumoderma 1952 51

electrolyte metabolism after 1951 196

free vs acetate 1951 106 198

glucose tolerance after 1951 196

hyaluronidase spreading effect after  
1950 125 127 129 130 134

inhibition of by hyaluronidase 1950  
142

intramuscular

■ oral 1951 112 113

urinary 17 ketosteroids after 1952  
120

urinary steroid excretion after 1951  
189

17 ketosteroids after 1952 120 122 124

local anti-inflammatory effect of 1951  
203

oral

vs intramuscular 1951 112 113

urinary 17 ketosteroids after 1952  
120

urinary steroidal excretion after  
1951 188 190

progesterone as precursor of 1952  
115 11

sodium retention after 1952 110 113  
*See also* Hydroxycorticosterone

## Compound N 1952 111

Compound III and urinary 17 ketosteroid  
1952 127

## Compound S

17 ketosteroids after 1952 10 127  
13

metabolic effects of 1951 149 150

oral

urinary 17 ketosteroids after 1952  
170

urinary steroidal excretion after  
1951 189 193 191

Compound S—*Cont'd*

in perfusate of isolated adrenal gland  
1949 55

as precursor of compound F 1949 55  
for rheumatoid arthritis 1949 13 14

*See also* Desoxycorticosterone

## Compound V, 1952 111

Conjugation of adrenal cortical steroid  
1949 42 43

Connective tissue 1950 107

cement substance of 1950 115 116

disease of 1950 149 150

and somatotrophic hormone 1953 126  
128 129

## Coprostanol 1953 42

Corpus luteum cholesterol pregnenolone  
reaction in 1951 142

## Corticoid

ACTH secretion blocked by 1940 59

antiphlogistic 1952 32

after systemic stress 1953 177

cortisone transformation into 1949 28

after electroshock 1953 63

11 hydroxylated 1952 99 100

permissive actions of 1952 11 28  
31 37

prophlogistic 1952 31 32

selective fixation of 1952 43

## Corticosteroid

excretion of rate of 1951 157

output of in schizophrenia 1952 87

from perfused cow adrenal 1951 115  
116

after ACTH 1951 115 119

after stress 1952 81

tissue fixation of 1953 56

urinary in rheumatoid arthritis 1952 87

*See also* Compound B

## Corticosteroidogenesis 1952 114 118

from cholesterol 1952 130 134

## Corticosterone

acetate in synthesis of 1951 130 134

from ACTH perfused cow adrenal  
1951 117 118

in Addison's disease 1950 20 203

in adrenal gland secretion 1949 151

anti-insulin effect of 1950 202 203

cholesterol in synthesis of 1951 130  
134

from desoxycorticosterone 1949 53 55  
59 60

in isolated perfused adrenal gland  
1951 126

for fast acting hypoglycemia in Addison's  
disease 1950 61

oral 1950 207

urinary steroid excretion after 1951  
191

*See also* Compound B

## Corticotrophin See ACTH

## Cortisone 1949 14

for acquired hemolytic icterus 1951  
184 183

for Addison's disease 1949 12 23  
1950 164 177 206 1951 161 173  
1953 60 63

with desoxycorticosterone acetate  
1950 205 1951 167 165

and diabetes mellitus 1951 10 13

electrocardiogram after 1950 172

electroencephalogram after 1949  
23 1950 112

hypertension after 1952 145

hypoglycemia in 1950 163 169

during intercurrent infection 1952  
139

rate of administration of 1953 59

surgery after 1951 168

adrenal atrophy after 1950 60 1951  
158

after adrenalectomy 1952 147

for Cushing's disease 1952 133 134

for hypertension 1950 177 1952  
133 139

adrenal gland suppression by 1951 184

in adrenal venous blood 1953 108

for adrenal virilism 1950 182 184  
1952 118

age difference in response to 1949 20

antigen anti body union after 1950  
107 109

antiprolipostic action of 1950 98 101

for arthritis 1949 96

the matoid 1951 161 181 184

after bilateral adrenalectomy for hyper-  
tension 1950 177

in blood 1951 98 102 107

half life of 1953 51 53 53

blood vitamin C after 1949 91

for burns 1950 188 189

calorigenic action of 1950 186

castrated rat after 1951 169

cerebral effect of 1951 168 169

and chloride in sweat 1949 7

for colitis ulcerosa 1949 18 93

for collagen diseases 1949 90 22

vs compound F 1951 200

Cushing's disease due to 1952 157

and 6-dehydrocortisone as impurity  
1949 14

for dermatomycosis 1949 18

vs desoxycorticosterone 1950 89 101  
109 112 1951 178

in electrolyte excretion 1951 35 39

in nephrectomized rats with high  
sodium intake 1949 27

with desoxycorticosterone acetate for  
Addison's disease 1950 205 1951  
16 165

## Cortisone—Cont'd

and desoxycorticosterone antagonism  
1949 111 1951 49

and desoxycorticosterone synergism  
1949 111

and electrolyte balance in Addison's  
disease 1950 172

and electrocardiogram in Addison's dis-  
ease 1950 177

and electroencephalogram in Addison's  
disease 1949 23 1950 172

electrolyte excretion after 1951 35 39

eosinophil response to 1949 96

in hepatitis 1952 125

and estrogen 1951 13

excretion of 1953 43

in Addison's disease 1953 60

diurnal variation in 1953 60

excretion of C<sub>19</sub> metabolites after 1953  
47 49 58 59

and glomerular filtration rate 1951 38  
39

and hair growth 1949 118 122

half life of in blood stream 1953 51  
52 53

and healing of tissue 1949 91

after hepatectomy 1951 107

hypertensive effect of 1952 145

for infectious disease acute 1950 104  
105

and inflammation 1950 98 101 1953  
52

injected vs oral 1950 108

11 ketosteroids from 1953 30 31

17 ketosteroid excretion after 1949 121

leucocyte response to in inflammation  
1950 105

for leukemia lymphatic 1949 94

local anti-inflammatory effect of 1951  
205

for lupus erythematosus 1949 18

vs ut 1951 185

and lyophilized anterior pituitary 1950  
44 45

and membrane permeability after hvalur-  
onidase 1949 97 99

metabolic responses to 1949 19

metabolism of 1953 29 30 31 40 41

oral 1950 175 177

vs parenteral 1950 108 1951 202 203

for periarthritis nodosa 1951 185 186

permissive action of 1952 145

and pigmentation 1949 106

plasma concentration after 1951 42

potassium excretion after 1951 42

as protection against anaphylactic shock  
1949 66 67

and protein dietary 1949 101

and proteinuria 1949 101 102

psychosis after 1949 107

rate of disappearance of 1950 79

Cortisone—*Cont'd*

- requirement of in Addison's disease during intercurrent infection 1952 159
- response to ACTH after 1949 100
- for rheumatoid arthritis 1951 161 181 184
- for rheumatoid spondylitis 1951 184
- as salt retaining hormone 1950 174
- seminal vesicle after 1949 148
- and sodium in sweat 1949 27
- and somatotrophic hormone 1950 45
- antagonism 1952 53 76
- for spondylitis rheumatoid 1951 184
- and spread of injected India ink 1949 27
- in surgery
  - for Cushing's syndrome 1951 173 176 179 180
  - for pituitary tumor 1951 177
- suspending agent for 1950 103
- and sweat electrolytes 1949 27
- testes after 1949 148
- thyroid gland after 1950 185
- tissue fixation of 1953 56
- topical action of 1952 126
- transformation of
  - to compound F 1952 125
  - to corticoid 1949 28
- tubular absorption of sodium after 1951 18
- urinary steroidal excretion after 1951 121
- vim and vigor effect of in Addison's disease 1951 165 16
- water excretion after
  - in Addison's disease 1951 31
  - and adrenalectomy 1951 78*See also Compound E*

Crooke's changes 1953 73 4 85

## Cushing's disease

- ACTH in 1953 71 73
- adrenal steroidogenesis in 1953 71
- adrenocortical production in 1953 0 77
- C<sub>19</sub> steroids in 1953 70 72
- C<sub>21</sub> steroids in 1953 0 2
- due to cortisone 1952 15
- cortisone requirement after adrenalectomy for 1952 134 134
- cortisone in surgery in 1951 131 179 180
- desoxy corticosterone for 1950 15
- with diabetes mellitus urine in 1953 73 74
- hydrocortisone in 1953 71 77
- hypertension in 1952 157
- kidney component in 1952 157 158
- myxedema in 1950 71
- and pheochromocytoma 1951 79

Cushing's disease—*Cont'd*

- serum cholesterol in during ACTH 1949 136
- Cystine urinary after ACTH 1949 10

## D

- Dehydrocortisone and cortisone 1949 14 15
- Dehydroepiandrosterone 1949 130 131 149 1753 28 30 36
- in adrenal cancer 1953 76
- differential in vivo metabolism of 1953 36
- Dehydroisandrosterone specific activity of 1953 90 9
- Dehidropregesterone metabolism of 1953 29
- Dermatomyositis cortisone for 1949 18
- Desoxycorticosterone 1949 13 27
- action of 1949 23 71
- for Addison's disease
  - amorpheus fraction of 1949 23
- stiffness after 1949 109
- from adrenal cortex 1949 30
- as adrenal hormone 1949 110
- for adrenal insufficiency 1953 18
- 16 alpha 1953 19
- vs amorphous fraction of adrenal cortical hormone 1949 23 24
- and antidiuretic hormone 1949 36
- and arthritis 1949 11
- formalin 1949 112
- chemical structure of 1949 11
- chloride in brain after administration of 1949 41
- and corticoid antagonism 1949 111
- and corticoid synergism 1949 111
- corticosterone from in isolated perfused adrenal gland 1941 176
- vs cortisone 1951 49 178
- in electrolyte excretion 1951 35 39
- in nephrectomized rats with high sodium intake 1949 2
- for Cushing's disease 1950 175
- differential in vivo metabolism of 1953 37
- and electrolyte
  - in Addison's disease 1950 17
  - in human 1949 39 41
  - excretion 1951 35 39
  - and electrolyte 1949 68 69
  - and glycogen level 1953 74 75
- hair growth inhibition after 1949 118
- and hypertension in Addison's disease 1952 145
- hypochloremic alkalosis after 1949 31 32
- kidney after 1949 12
- renal membrane permeability after hypernatremia 1949 97 99

**Desoxycorticosterone—Cont'd**

- metabolism of 1953 29
- as natural mineralocorticoid 1952 98
- overdosage with 1951 159
- in panhypopituitarism 1949 156
- physiological properties of 1950 205
- and pigmentation after adrenalectomy 1949 181
- pituitary inhibition by 1949 68
- plasma concentration after 1951 42
- and potassium
  - in brain 1949 39 40
  - excretion 1949 34 35 1951 42
  - in serum 1952 104
- as precursor of corticosterone 1949 51 55 59 60
- and serum potassium 1952 104
- and sodium
  - dietary 1949 111 113
  - excretion after pituitary 1951 28 29
  - retention in Addison's disease 1950 39 41
- and spread of injected fluid sink 1949 97
- and sweat electrolytes 1949 27
- toxicity in effect of ACTH on 1949 69
- transformation of 1949 24 1951 106
- and water
  - in brain 1949 39 40
  - excretion 1949 36
  - retention in Addison's disease 1950 39 41

- Desoxycorticosterone acetate 1953 31**
  - with ACTH 1949 108 1950 59 110 112
  - for Addison's disease
    - with cortisone 1951 162
    - work output after 1951 168 169
  - after adrenalectomy 1949 165
  - and anaphylactic shock 1950 89
  - castrated rat after 1951 169
  - and compound F in porus derma 1952 51
  - with cortisone 1949 89 101 109 112
  - with cortisone for Addison's disease 1950 205
  - for Cushing's disease 1950 173
  - and glomerular filtration rate after adrenalectomy 1951 12 14
  - and hyaluronidase spreading effect 1950 141 116 162
  - hypertension due to overdosage with 1951 16 3
  - and insulin sensitivity 1949 68
  - and lymphoid antipituitary 1952 35
  - effect of 1952 99
  - and water 1949 116 117
  - hypertension due to 1952 36 37
  - physiological effect a protection against effect of 1952 33 35

**Desoxycorticosterone acetate—Cont'd**

- in perfusion of isolated adrenal gland 1949 33 35 39
- and pigmentation 1949 106
- in protection of adrenalized rat from water intoxication 1952 103 104
- and somatotrophic hormone 1952 61
- and water excretion after adrenalectomy 1951 28
- Desoxycorticosterone metabolism of 1953 29**
- Diabetes insipidus 1949 36**
  - and ACTH 1950 38
  - and adrenal cortical insufficiency 1949 37
- Diabetes mellicus**
  - in acromegaly 1952 158
  - and Addison's disease
    - ACTH in 1949 145
    - compound B for 1950 201
    - cortisone in 1951 170 173
  - adrenal cortex in 1949 26
  - and adrenal cortical hormone 1952 12 15
  - adrenalectomy for 1952 151
  - and arthritis rheumatoid 1949 26
  - with Cushing's syndrome 1953 73 74
  - exacerbation of
    - by estrogen 1952 12
    - by ethylenediamine 1952 13 14
  - infection during 1952 16 17
  - and rheumatic fever 1949 26
  - and rheumatoid arthritis 1949 26
  - and thyroid hormone 1952 16
- Diabetogenic factor in pituitary extract 1953 144 145**
- Dibenzamine 1950 33**
- Dicumaryl hyaluronidase inhibition by 1950 149**
- Diet and ACTH 1950 76**
- Dihydrocholesterol conversion of cholesterol to 1949 131**
- Dihydroxyacetone 1949 124**
- Diseases of adaptation 1949 110 111 1952 82 87**
- Diuresis**
  - in nephrotic syndrome after ACTH 1951 50 51
  - salyrgan anoxia in abolition of 1951 29 30

**E**

- Edema in brain 1949 41**
- Effector cell**
  - and adrenal cortical hormone 1950 54
  - and epinephrine 1950 54
- Electrocardiogram in Addison's disease 1950 172**
- Eleutherocton 1953 11 25**

**Electroencephalogram**

- in Addison's disease 1950 169 172
- 184 1951 167 168
- after cortisone 1949 23
- in water intoxication 1952 104

**Electrolyte**

- balance in Addison's disease 1950 172 175
- after cortisone and desoxycorticosterone acetate 1951 162 163
- in brain after desoxycorticosterone 1949 39 41
- excretion of
  - after ACTH 1950 195 197
  - after compound H 1950 194 197 200
  - after compound E 1950 195
  - after cortisone 1951 33 39
  - after desoxycorticosterone 1951 35 39
- metabolism of
  - and amorphous fraction of adrenal cortical hormone 1949 23 24
  - after compound F 1951 196
  - in panhypopituitarism 1949 155
- in plasma
  - after ACTH 1949 69
  - after desoxycorticosterone acetate 1949 67
- in sweat after desoxycorticosterone 1949 27

**Electroshock**

- and ACTH 1949 68 69 102 104
- corticoid after 1953 63
- and desoxycorticosterone 1949 68 69
- 1 ketosteroids after 1953 63
- for psychosis after ACTH 1949 102

**Eosinopenia**

- ACTH effect on in adrenalectomized rats 1950 76
- in Addison's disease 1952 18 19
- after adrenalectomy 1952 18 19 161 162
- and anxiety 1950 189
- after cortisone in hepatitis 1952 125
- and epinephrine 1950 64
- after hypophysectomy 1950 61
- extra adrenal 1952 18 19
- due to globulin, 1952 24 26 27
- as index
  - of ACTH activity 1950 49
  - of adrenal activation 1952 18 4
- postoperative 1950 187
- after stress
  - emotional 1950 189 191
  - physical 1950 187 190

**Eosinopenic factor from hypothalamus**  
1950 62**Eosinophil**

- in Addison's disease 1953 60 63
- circulating after major surgery 1950 186 188

**Eosinophil—Cont'd**

- diurnal variations in 1953 60 63
- after laparotomy 1950 72 74
- level of
  - in Addison's disease after cortisone 1953 60 63
  - after cortisone 1949 96
  - after epinephrine 1951 66 1952 23

**Eosinophilia after adrenalectomy** 1952 161 162**Epinephrine**

- and ACTH discharge 1949 72 74
- and adrenal cortical extract 1950 34
- adrenal cortical hormone inhibition of activity of 1950 65 69
- and adrenal cortical response 1949 7 1950 53 55 1951 64 71 1952 20 22
- in adrenal medulla after insulin 1951 77
- in arterial blood and adrenal gland output 1949 57 59
- and ascorbic acid discharge from adrenal cortex 1949 75
- in asthma 1950 67 68
- and eosinopenia 1950 64
- after hypophysectomy 1950 61
- after laparotomy 1950 7 74
- and eosinophil 1951 66 1952 23
- and hypoglycemia 1950 75
- in perfusate of isolated adrenal gland 1949 57 59
- in regulation of pituitary response 1950 57 55 61 83 1951 67 71 73
- secretion of 1947 75
- after mammillary body stimulation 1951 77
- See also Adrenalin

**Epithelium definition of** 1950 153**Estradiol**

- hyaluronidase spreading effect after 1950 127
- and lipid in adrenal gland 1950 127

**Estrogen**

- adrenal cortical hormone after 1950 129
- adrenal gland after 1949 155 1950 128 1951 73
- and cortisone 1952 13
- diabetes mellitus exacerbation due to 1952 12
- hair growth inhibition after 1949 118

**Ether ACTH in blood after anesthesia**  
with 1952 91 92**Ethylenediamine**

- and blood glucose 1952 16
- d zebotogenic effect of 1952 13 14

**Ethroholane** 1953 28 34 36

- specific activity of 1953 90 92

**Etiocholanolone—Cont'd**

urinary excretion of after testosterone administration, 1953 36 37

Etiocholanolone 1952 123

**F**

Fasting ACTH synthesis during 1949 185

**Fat, in liver**

ACTH effect on 1953 139 147  
growth hormone effect on 1953 141 142

**Feces**

cortisone excretion in 1953 43  
testosterone excretion in 1953 43

Femur of rat, after treatment with somatotrophic hormone and stilbestrol 1952 41 42

**Fever**

after ACTH 1949 101  
compound F in blood in 1952 88

**Fibroblast**

adrenal cortical cell from 19 0 153  
phagocytic like activity of 1950 107  
steroid hormones from 1950 151

Fur growth of after adrenalectomy 1949 162

**G**

General adaptation syndrome 1952 82

Globulin eosinopenia due to 195 24 26-27

**Glomerular filtration rate**

and adrenal cortical hormone 1951 12 14  
after adrenalectomy  
and desoxycorticosterone acetate 1951 12 14  
and sodium loading 1951 30  
and cortisone desoxycorticosterone antagonism 1951 38 39  
and desoxycorticosterone acetate 1951 12 14  
and desoxycorticosterone cortisone antagonist 1951 38 39

Glomerulosa as site of production of steroid hormone 195 105

**Glucocorticoid 1949 110 1952 37**

and membrane permeability 1949 11  
and mineralocorticoid antagonism 1949 111 112 113  
and mineralocorticoid synergism 1949 111  
necessity 195 112

**Glucose**

in blood  
in Addison's disease 1951 165 168

**Glucose—Cont'd****in blood—Cont'd**

after ethylenediamine 1952 16  
excretion of after ethylenediamine 1952 16  
kidney excretion of after compound B 1950 196 198 201  
tolerance for  
after ACTH 1950 199  
after compound B 1950 199  
after compound E, 1950 199  
after compound F 1951 196

**Glycogen**

deposition of  
by compound E, 1949 15  
by 6-dehydrocortisone 1949 15  
in liver and amorphous fraction of adrenal cortical hormone 1949 23  
after desoxycorticosterone 1953 24 25

Glycostatic factor in pituitary extract 1953 144

**Glycosuria**

due to cortisone and growth hormone 1952 58 59  
during exposure to cold 1952 16  
due to growth hormone and cortisone 1952 58 59

Glycotrophic factor in pituitary factor 1953 144 145

Glycyrrhetic acid 1952 99

Glycyrrhizic acid 1952 99

Gonadotrophin, effect of on isolated ovary 1949 61

Granuloma pouch 1952 47 52

inflammation in  
cortisone for 1953 52  
hydrocortisone for 1953 52 54 55

Growth hormone 1950 44-45

ACTH as antagonist of 1952 60  
adrenal gland after 1949 146  
medulla 1953 133  
weight of 1953 102 110  
and age of subject 1952 63  
arthritis after 1952 59 60  
dabetogenic activity of 1953 110  
in granuloma pouch 1952 50  
liver fat after 1953 141 142  
lipid after 1949 142  
nephrosclerotic effect of 1952 74  
nitrogen balance after 1952 61 62  
and tumor formation 1952 59  
and vitamin B deficiency 1952 13  
See also Somatotrophic hormone

**Guinea pig**

insensitivity of to growth hormone 1952 61  
sco butic adrenal steroidogenesis in 1951 125

## H

- Hair growth of 1949 118 119 122  
 after ACTH for adrenal cortical insufficiency 1953 89  
 after adrenalectomy 1949 167  
 in area of pneumoderma with hydrocortisone 1952 50 51
- Hamster adrenal cholesterol in 1951 172
- Hay fever ACTH for 1949 97
- Healing of tissue  
 after ACTH 1949 91  
 after cortisone 1949 91
- Heart after temporary overdosage with desoxycorticosterone acetate and lyophilized anterior pituitary 1952 35 36
- Heart disease hypertensive and schizophrenia 1949 103
- Heart failure congestive as indication for bilateral adrenalectomy 1952 146 149
- Hemorrhage adrenal cholesterol after 1953 93
- Heparin hyaluronidase inhibition by 1950 148
- Hepatectomy  
 and adrenal cortical effect on carbohydrate tolerance 1951 107  
 cortisone after 1951 10
- Hepatitis  
 eosinopenia after cortisone in 1952 125  
 and urinary 1 ketosteroids 1952 120
- Hexokinase inhibitor in pituitary extract 1953 144
- Histamine and anaphylactic shock 1950 89 93
- Hog hormones in adrenal gland of 1949 12
- Hormone modification of 1949 24 28
- Humidity environmental and spreading effect of hyaluronidase 1950 120
- Hyaluronic acid 1950 116  
 hyaluronidase in hydrolysis of with lipoadrenal extract 1950 140 147
- Hyaluronidase 1950 116  
 and adrenal cortical hormone 1949 97 99 105 1950 115 167  
 hyaluronic acid hydrolysis by with lipoadrenal extract 1950 140 141  
 inhibition of  
 by adrenal steroids 1950 140 141  
 by compound E 1950 147  
 by compound F 1950 142  
 and membrane permeability 1949 99 105 1950 116-16  
 in skin 1950 146
- Hyaluronidase—Cont'd  
 spreading effect of 1949 97 99 105 1950 116 162  
 after ACTH 1950 144  
 after adrenal cortical extract, 1950 116 162  
 antihistamine inhibition of 1950 149  
 ascorbic acid inhibition of 1950 148  
 after C11 oxysteroid 1950 133  
 after compound A 1950 125 127 129 130 134  
 after compound E 125 127 129 130 134  
 dicumaryl inhibition of 1950 148  
 and environmental temperature and humidity 1950 120  
 after estradiol benzoate 1950 127  
 heparin inhibition of 1950 148  
 after pregnenolone 1950 177  
 and pressure of bleb 1950 158 160  
 after progesterone 1950 127  
 salicylate inhibition of 1950 148  
 after testosterone 1950 177 135  
 vitamin P inhibition of 1950 148  
 and volume of bleb 1950 158 160  
 synovial 1950 146
- Hydrocortisone  
 for Addison's disease 1953 60  
 for arthritis induced by growth hormone 1952 60  
 in Cushing's syndrome 1953 71  
 in granuloma pouch 1952 48 52  
 for inflammation 1953 52 54 55  
 metabolism of 1953 29 40 41  
 in pneumoderma 1952 42 43  
 in regulation of pituitary adrenal system 1953 68 72  
 in synovial fluid disappearance of 1953 46  
 topical effect of 1952 48 49 176
- Hydrogen  
 tubular exchange of for sodium 1951 18 31 37  
 tubular excretion of 1951 18
- Hydroxyandrostenedione 11 beta 1953 88
- Hydroxycorticoid conversion of to 1 keto steroids in stress 1953 65
- Hydroxycorticosteroid in blood 1951 95 105
- Hydroxycorticosterone 17  
 acetate in synthesis of 1951 130 134  
 from ACTH perfused cow adrenal 1951 11 118  
 in adrenal gland secretions 1949 151  
 in adrenal vein plasma 1952 117  
 cholesterol in synthesis of 1951 130 138  
 hair growth inhibition after 1949 118  
 from 17 hydroxyprogesterone 1951 139

**Hydroxycorticosterone—Cont'd**

- in inhibition of pituitary discharge of ACTH 1949 66
- pituitary inhibition by 1949 66 68
- in pregnancy 1952 98
- See also Compound E

**Hydroxy group in adrenal cortical steroid** 1949 41 42**Hydroxypregesterone**

- 11 progesterone as precursor of 1949 13
- 17
  - in adrenal virilism 1952 119
  - as androgen 1952 119
  - 17 hydroxycorticosterone from 1951 139
  - in perfusate of isolated adrenal gland 1949 33 36
  - and urinary ketosteroids in adrenal virilism 1952 118
- 17a differential inhibition of 1955 8

**Hydroxysteroid**

- in Addison's disease 1952 121
- low excretion of with high 17 keto steroid excretion 1953 62

**Hyperglycemia and abnormal electroencephalogram in Addison's disease** 1950 10**Hyperglycemic factor in pituitary extract** 1953 144 145**Hypersensitivity and adrenal cortical hormone** 1950 88 113**Hypertension**

- and acromegaly 195 158 1953 154
- after ACTH 1947 93
- and Addison's disease 1952 145
- and adrenal cortical hormone 1952 134 139
- adrenalectomy for 195 131 161
- cortisone after 1950 177 1952 133 139
- and urrhosis of bile 1952 142
- after cortisone 1949 93
- in Addison's disease 1952 145
- cortisone after adrenalectomy for 1950 1 1952 133 139
- in Cushing's disease 1952 15
- kidney symptom at 1952 15 158
- and deoxycorticosterone in Addison's disease 1952 145
- due to deoxycorticosterone overdosage 1951 152
- hypophysectomy for 1950 144
- major inhibitory adrenal cortex hormone in 1950 18
- in it is 1952 37 143
- in it is adrenal virilism 1952 143
- with pheochromocytoma bilateral after phentolamine 1950 146 147

**Hypertension—Cont'd**

- post deoxycorticosterone 1952 37
- renal adrenalectomy for 1952 15
- and salt retention 195 142
- Smithwick classification of 1952 137 138
- after temporary deoxycorticosterone overdosage 1952 16 37
- urinary steroid excretion in 1952 144

**Hypohyemia**

- in Addison's disease cortisone for 190 163 168
- adrenal cortical hormone response to 1950 75
- in adrenogenital syndrome 1953 81
- and compound E 1949 40
- congenital ACTH for 1949 94
- epinephrine response to 1950 75
- fasting corticosterone for in Addison's disease 1950 704

**Hypophysectomy**

- adrenal atrophy after 1950 60
- adrenal gland after 1950 73
- and eosinopenia due to epinephrine 1949 61
- for hypertension 1951 144
- and pantothenic acid 1949 176 177
- as protection against effects of deoxycorticosterone overdosage 1952 53 55
- sodium metabolism after 1953 1 18
- stress after 1952 30

**Hypophysis See Pituitary body****Hypotension postural after adrenalectomy for hypertension** 1952 135**Hypothalamus**

- adrenal stimulation of 1951 85
- cells in 1950 75
- cellular atrophy after ACTH 1950 84
- eosinopenic factor from 1949 62
- hormonal effect of 1950 76 77
- in regulation of ACTH secretion 1951 14 87

**I****Icterus acquired hemolytic cortisone for** 1951 184 185**India ink spread of**

- after adrenal cortical extract 1949 99
- 195 1950 116 167
- after compound A 1949 97
- after cortisone 1949 9
- after deoxycorticosterone 1949 9
- after hyaluronidase 1949 97 1950 116 162

**Infection**

- in diabetic animals 1952 16 1
- intercurrent and cortisone requirement in Addison's disease 1952 159

**Inflammation**

- in Addison's disease 1950 107



Inflammation—*Cont'd*

- and cortisone 1950 98 101 1953 52
- and hydrocortisone 1953 52

## Inositol deficiency of with adrenalectomy 1949 168

## Insulin

- in Addison's disease 1950 166
- antagonism of to ACTH 1949 145
- epinephrine in adrenal medulla after 1951 77
- sensitivity to in demedullated rats 1949 68
- stimulation of secretion of by pituitary extract 1953 144

## Intermedin and ACTH 1953 98

## Intradermal salt test as index of corticoid activity 1950 145

## Involution thymic 1952 85

## Iodine thyroid uptake of after ACTH 1949 104

## Isovaleric acid 1949 128

## J

## Joint

- disappearance of radiocortisone in fluid in 1953 44 46
- diseased
  - compound F in 1952 175
  - cortison in 1952 175

## K

## Keloid 1949 121 172

- after desoxy corticosterone 1949 122

## Ketoprogesterone 11:1 metabolism of 1953 29

## Ketosteroid 17 1951 188

- in Addison's disease 1950 80
- as androgen 1952 123
- after compound E 1952 122
- after compound F 1952 122
- from compound F 1952 123
- after compound S 1952 122
- conversion of 1 hydroxycorticoids to in stress 1953 65
- from cortisone 1953 30 31
- diurnal variations in 1953 66
- after electroshock 1953 65
- excretion of
  - after ACTH 1951 201 02 1952 121
  - in adrenal virilism 1952 118
  - after compound B 1950 199 200
  - after compound F 1951 188 190 193 1952 120
  - after compound S 1952 110
  - after cortisone 1949 121
  - after intramuscular administration of steroid 1951 187 196

Ketosteroid—*Cont'd*excretion of—*Cont'd*

- in liver disease 1952 120
- with low 17 hydroxysteroid excretion 1953 67
- after oral administration of steroids 1951 187 196
- in schizophrenia 1949 103
- after stress 1952 81

## Kidney

- after ACTH 1950 43
- and somatotrophic hormone 1952 39
- ammonia excretion by 1951 18 27
- after adrenalectomy 1951 20 27
- after desoxycorticosterone acetate 1951 74 27
- after cortisone and desoxycorticosterone acetate 1950 110-112
- electrolyte excretion by
  - after ACTH 1950 195 197
  - after compound B 1950 194 197 00
  - after compound E 1950 195

## function of

- and adrenal cortical hormone 1951 11 52
- after adrenalectomy and sodium load ing 1951 30
- glucose excretion by after compound B 1950 196 198 201
- isolated function of 1951 43
- nitrogen excretion by after compound B 1950 196 198 01
- nuclear inclusion bodies in after ACTH and lyophilized anterior pituitary 1950 102
- osmotic work of in sodium excretion 1949 38
- plasma flow of
  - after adrenalectomy 1951 12 16
  - after adrenalectomy and sodium load ing 1951 30
  - after somatotrophic hormone 1952 39
- steroids from 1949 43
- after temporary overdosage with desoxy corticosterone acetate and lyophilized anterior pituitary 1952 35 36
- uric acid excretion by after compound B 1950 196 198 201

## L

- La 1 A as standard 1950 2 23 28 31
- Laparotomy eosinophil response to 1950 2 74
- Leucocyte cortisone effect on in inflammation 1950 105
- Leucopenia after anaphylaxis 1950 94
- Leukemia lymphatic
  - ACTH for 1949 94
  - ritone for 1949 94

- Lipid**  
 in adrenal gland  
   during alarm reaction, 1950 127  
   after estradiol 1950 127  
 in liver  
   after ACTH, 1949 142  
   after growth hormone 1949 14
- Lipoadrenal extract and hyaluronic acid**  
 hydrolysis by hyaluronidase 1950  
 140-141
- Lis growth hormone preparation** 1951  
 127-130
- Liver** 1951 187  
 ACTH destruction by 1950 46  
 cholesterol synthesis by 1949 128  
 cirrhosis of  
   and hypertension 1952 142  
   and rheumatoid arthritis 1951 200  
   serum cholesterol in 1949 140  
 disease of  
   urinary excretion of steroids in 1953  
   63  
   and urinary 17 ketosteroids 1952  
   120  
 enzymes of  
   in metabolism of compound E 1951  
   43-44  
   in metabolism of cortisone 1953  
   43-44  
 fat in after growth hormone 1953  
 141-142  
 glycogen deposition in and amorphous  
 fraction of adrenal cortical hor-  
 mone 1949 23
- Lupus erythematosus**  
 ACTH for 1949 91  
 cortisone for 1949 18  
 disseminated  
   cortisone for 1951 185  
   keloid formation in 1949 11
- Lymphocyte**  
 antibody from 1950 152  
 circulating 1949 183  
 level of as measure of adrenal activa-  
 tion 1951 67-103  
 from spleen perfused with adrenal ex-  
 tract 1949 20
- Lymphocytopenia** *See* Lymphopenia
- Lymphocytosis** due to stress after adrena-  
 lectomy 1952 25
- Lymphopenia**, 1952 75  
 due to adrenalin 1949 75-76  
 due to cold 1949 6  
 effect of emotional stress adrenalin effect  
 on 1951 64  
 index of ACTH activity 1950 49  
 after radiation 1952 163  
 due to stress 1949 5-76  
 emotional 1951 55
- Macrophage and adrenal cortical hor-  
 mone** 1950 107
- Mammary body** 1951 76-77
- Melanophore ACTH effect on** 1953 98  
 99
- Membrane permeability of** 1950 116-  
 167  
   corticoid effect on 1949 111-117  
   after hyaluronidase 1949 97-99 105
- Mesenchymal disease** 1950 149-150
- Methylandroscenediol** 195 65
- Methylene blue hyaluronidase spreading  
 effect with** 1950 144-146
- Mexican yam as starting material for syn-  
 thesis of cortisone** 1949 17
- Micellophagosis** 1950 10
- Mineralo-corticoid** 1949 110 1952 31-32  
 adrenal 1952 98-114  
 different from desoxycorticosterone  
 1952 100  
 and gluco-corticoid  
   antagonism 1949 111  
   synergism 1949 111  
 hypertension due to 1952 143  
 and membrane permeability 1949 112  
 site of production of 1952 103  
 urinary 1952 107
- Mitotic figure of adrenal cortical cells  
 after adrenal ascorbic acid reducing ma-  
 terial** 1953 103-104  
 after growth hormone 1953 103
- Mucose anaphylactic shock in** 1950 88  
 101
- Myasthenia gravis ACTH for** 1949 94
- Myxedema in Cushing's syndrome** 1950  
 71

## N

- Nail defect in after ACTH** 1949 119
- Neoplastic disease**  
 ACTH for 1949 94  
 cortisone for 1949 94
- Nephrosclerosis due to desoxycorticoste-  
 rone overdosage** 1951 159
- Nephrotic syndrome**  
 diuresis in after ACTH 1951 30-31  
 with hypertension on bilateral adrenalect-  
 omy for 1951 146-147
- Neutropenia, splenic** 1951 184
- Nitrogenous membrane as indicator of  
 hypothalamic activity** 1951 85
- Nitrogen**  
 balance after growth hormone 1952  
 62  
 kidney excretion of after compound B  
 1950 196-198 201

## O

- Ovary isolated effect of gonadotrophins on 1949 61
- Oxycellulose method for measurement of blood ACTH 1952 95
- Oxysteroid  
Addison's disease as measure of osino phil fall in 1950 78  
antiallergic action of 1950 95  
hyaluronidase spreading effect after 1950 133  
kidney excretion of after compound III 1950 199 200  
site of action of 1950 103 104

## P

- Pancreas stimulation of alpha cells of by pituitary extract 1953 144
- Panhypopituitarism  
desoxycorticosterone in 1949 156  
electrolyte metabolism in 1949 155
- Pantothenate  
and ACTH 1950 76  
and blood sugar 1949 177 186 187  
dietary  
and water excretion after adrenalectomy and cortisone 1951 28  
and water excretion after adrenalectomy and desoxycorticosterone acetate 1951 28
- Pantothenic acid  
adrenal cortex in deficiency of 1949 160  
and adrenalectomy 1949 167 189  
dietary and work performance of adrenalectomized rat 1949 152 154  
and hypophysectomy 1949 176 177  
sensitivity to as function of age 1949 187  
and survival after adrenalectomy 1949 162 180
- Pentothal and lymphopenia due to cold 1949 76 III 84
- Pepsin crystalline hydrolysis of ACTH with 1950 13 21
- Periarteritis nodosa  
cortisone for 1951 185 186  
due to desoxycorticosterone overdosage 1951 159
- Periventricular nucleus cellular atrophy in after ACTH 1950 83
- Permeability  
capillary after adrenal cortical extract 1950 106  
of membrane 1950 116 162  
corticoid effect on 1949 111 112
- Phagocytosis after adrenal cortical hormone 1950 104 107

Pheochromocytoma and Cushing's syndrome 1951 8

## Pigmentation

- and ACTH 1949 106 1950 156  
in Addison's disease 1949 106-107 1950 155  
and adrenal cortical function 1950 155 156  
after adrenalectomy 1949 162  
and desoxycorticosterone 1949 162 181  
and sodium chloride 1949 165 181  
and cortisone 1949 106  
and desoxycorticosterone acetate 1949 106

## Pitressin

- antidiuretic activity of after sodium thioglycollate treatment 1950 33 37  
sodium excretion after and desoxy corticosterone 1941 28 29

Pituitary adenocortical system in regulation of pituitary ACTH discharge 1950 48 83

## Pituitary body

- and blood sugar 1953 135 138  
gonadotrophin synthesis in vs ACTH synthesis 1949 185  
inhibition of  
by desoxycorticosterone 1949 III  
by 17 hydroxycorticosterone 1949 66 68  
metabolic factors in extract of 1953 144  
tumor of cortisone in surgery for 1951 177

## Pituitary body anterior

- ACTH in 1949 184 185 1950 44  
after dietary deficiency 1947 185  
and gonadotrophin synthesis 1949 185  
after stress on 1949 184 185  
ACTH discharge from 1949 7 184 185  
and adrenal cortical secretion 1949 77 83  
regulation of 1950 48 83  
after stress 1947 64 66  
and barbiturate anesthesia 1950 56 57  
and epinephrine 1950 57 58 67  
hydrocortisone in 1953 68 72  
lyophilized  
adrenal cortex after in sensitized rat 1952 74 75  
and cortisone 1950 44 45  
min ralocorticoid action of 1950 44  
nephrotoxic action of 1950 44 45  
powder of 1949 113 116  
thymus response to 1950 44  
transient overdosage with 1952 35 36

**Pituitary body anterior—Cont'd**

- number of hormones from 1951 71 73 78 79
- regulation of ACTH discharge from 1950 43 83
- adrenal cortical hormone in, 1949 72 83 1950 30 37 37 69 0
- epinephrine in 1950 52 53 61 83
- hypothalamus in 1950 55 57 62
- in regulation of mineralo corticoid 1952 106

**Pituitary body posterior**

- extracts of 1950 33 34
- hormone from See Antidiuretic hormone Pitressin

**Plasma**

- concentration of
  - after cortisone 1951 47
  - after desoxycorticosterone 1951 42
- electrolyte in
  - after ACTH 1949 69
  - after desoxycorticosterone acetate 1949 69
- kidney flow of after adrenalectomy 1951 12 16
- potassium in
  - after ACTH 1949 69
  - after desoxycorticosterone acetate 1949 69
- sodium in
  - after ACTH 1949 69
  - after desoxycorticosterone; acetate 1949 69

**Pneumoderma, with hydrocortisone deposit** 195 42 43 126**Pneumonia ACTH for** 1949 93 1950 105**Polyp regression of after ACTH** 1949 9**Potassium**

- in brain after desoxycorticosterone 1949 39 40
- excretion of
  - after ACTH 1950 195 19
  - after compound III 1950 194 197 200
  - after compound II 1950 195
  - after cortisone 1951 47
  - after desoxycorticosterone 1949 34 35 1951 4
- in plasma
  - after ACTH 1949 69
  - in Addison's disease after cortisone and desoxycorticosterone acetate 1951 165 164
  - after desoxycorticosterone acetate 1949 69
- in serum
  - in corticoid patients with kidney damage 1952 104
  - after desoxycorticosterone 1952 104

**Potassium—Cont'd**

- tubular absorption of after cortisone 1951 19
- tubular exchange of for sodium 1951 19 31 37

**Pregnancy**

- in Addison's disease 1952 88
- cortical hormone in 1952 88
- pregnanediol in, 1953 51
- progesterone in 1953 51
- urinary pregnanediol in 1953 51

**Pregnane** 1953 28**Pregnanediol urinary in pregnancy** 1953 51**Pregnenolone in corticosteroidogenesis** 1951 138 139 143 146**Pregnenolone**

- in adrenal cancer 1953 6-77
- hyaluronidase spreading effect after 1950 127

**Progesterone** 1953 31

- in corticosteroidogenesis 1951 138 139
- hyaluronidase spreading effect after 1950 127
- metabolism of 1953 29 50
- in perfusate of isolated adrenal gland 1949 35 1957 115 117
- as precursor of compound B in presence of ACTH 1952 115 117
- as precursor of compound F in presence of ACTH 1952 115 117
- as precursor of 11 hydroxyprogesterone 1949 55
- in pregnancy 1953 51
- in rabbit 1953 51

**Progestogen** 1953 111**Prostate cancer of bilateral adrenalectomy for** 195 148**Protein diet and cortisone** 1949 101**Proteinuria and cortisone** 1949 101 107**Psychosis**

- after ACTH 1949 101 104
- adrenal gland in 1949 107 104
- after cortisone 1949 102

**Pyribenzamine in anaphylactic shock** 1950 91 95**II****Radiation, lymphocytopenia after** 1952 163**Radiocholestenone** 1952 115**Radiocholesterol** 1952 115**Radio cortisone disappearance of from synovial fluid** 1953 44-46**Radio progesterone** 1952 115**Radio sodium, disappearance of from synovial fluid** 1953 44-46

- Rat**  
 adrenalectomized  
   and cortisone 1949 20  
   and salt 1949 21  
 castrated  
   and cortisone 1951 163  
   and desoxycorticosterone acetate 1951 169  
 diabetic infection in 1952 16 17  
 Reflex pathway for epinephrine secretion in regulation of pituitary ACTH discharge 1950 63 72 74  
 Reichstein's compound S 1949 13  
   as precursor of compound F 1949 55  
*See also* Compound S Desoxycorticosterone
- Respiratory quotient** lowering of by pituitary extract 1953 144
- Retinopathy** hypertensive after bilateral adrenalectomy 1952 149
- Rheumatic fever** and diabetes mellitus 1949 6
- Rutin** hyaluronidase inhibition of 1950 148
- S**
- Salicylate**  
 and hyaluronidase inhibition 1950 148  
 and spreading factor inhibition 1949 105
- Salt**  
 diurnal variation in excretion of in adrenal insufficiency 1953 61  
 and growth in adrenalectomized animal 1949 21  
 and pigmentation 1949 163 181  
 retention of  
   after adrenalectomy 1949 33 35  
   and compound E 1949 21  
   and hypertension 1952 142  
 tubular absorption of  
   after adrenalectomy 1951 16 21  
   after adrenal insufficiency 1951 16 21
- Salt hormone** adrenal 1952 98 114
- Salt test** intradermal as index of corticoid activity 1950 145
- Salyrgan** abolition of diuresis due to by anoxia 1951 29 30
- Sarmentogenin** as starting material for synthesis of cortisone 1949 17
- Schizophrenia**  
 ACTH in, 1949 87 107  
   with stress 1949 157  
 and asthma 1949 103  
 and heart disease hypertensive 1949 103  
 total corticosteroid in 1952 87  
 urinary ketosteroids in 1949 103
- Seminal vesicle**  
 after ACTH 1949 148  
 after cortisone 1949 148  
 cholesterol in  
   in Addison's disease during ACTH 1949 136  
   in cirrhosis of liver 1949 140  
   after compound E 1949 137 138  
   in Cushing's syndrome during ACTH 1949 136  
 potassium in  
   after corticoids in patients with kidney damage 1952 104  
   after desoxycorticosterone 1952 104
- Sex (of subject)** and cortisone side effects 1951 183
- Shock** anaphylactic  
 and adrenal cortical hormone 1950 88 101  
 cortisone protection in 1949 66 67  
 and desoxycorticosterone 1950 89  
 and histamine 1950 89 95  
 and pyribenzamine 1950 91 95
- Skin** detached by pneumoderma hydro cortisone deposit in 1952 42 43
- Smithwick classification**, of hypertensive disease 1952 137 138
- Sodium**  
 balance in Addison's disease 1950 172 175  
 dietary and desoxycorticosterone 1949 111 113  
 excretion of  
   after ACTH 1950 195 177  
   after adrenal cortical hormone 1951 35  
   after compound B 1950 194 177 200  
   after compound E 1950 195  
   after cortisone 1951 35 39  
   after desoxycorticosterone 1951 45 39  
   osmotic work required for 1949 38  
 labeled disappearance of from synovial fluid 1953 44 46  
 metabolism of after hypophysectomy 1952 17 18  
 mineralo corticoid for retention of 1952 99 128  
 in plasma  
   after ACTH 1949 69  
   in Addison's disease after cortisone and desoxycorticosterone 1951 162 165  
   after desoxycorticosterone acetate 1949 69  
 retention of  
   after ACTH 1950 38 39 1953 3 24  
   adrenal factor for 1953 11 75  
   after compound E 1949 31 1952 110 113

Sodium—*Cont'd*retention of—*Cont'd*

- after compound F 1952 110 113
- after desoxycorticosterone in Addison's disease 1950 39 41
- mineralocorticoid test 1952 98 118
- in sweat after cortisone 1949 27
- tubular absorption of
  - after adrenal insufficiency 1951 16-21
  - after cortisone 1951 18
- tubular exchange of 1951 18 31 32

## Sodium carboxymethyl cellulose as cortisone suspending agent, 1950 103

## Sodium chloride

- and pigmentation 1949 165 181
- See also Salt

## Sodium thioglycollate and antidiuretic activity of pressin 1950 35 3

## Somatotrophic hormone

- and ACTH 1952 39 5 1953 126 130
- adrenal cortical stimulation by 1952 52 57
- bone after treatment with 1952 41
- connective tissue after 1953 126 128 129
- corticotrophic effect of 1952 53
- and cortisone 1950 43
- as antagonist 1952 53 76
- glycosuria due to 1952 58 59
- and deoxycorticosterone acetate 1952 61
- guinea pig sensitivity to 1952 61
- kidney after 1953 12
- mineralocorticoid activity of 1950 43
- selective conditioning of by tibestrol 1952 41
- and tibestrol 1952 41
- See also Growth hormone

## Somatotropin, highly purified anterior pituitary 1950 44 45

## Spinal cord cholesterolin 1949 129

## Spleen

- lymphocytes from after adrenal extract perfusion 1949 0
- perfusion of with adrenal extract 1949 20

## Spontaneous human cortisone fever 1951 184

## Spreading factor 1949 9 99 105

- See also Mylon disease

## Squalene 1951 153

## Starvation

- ACTH synthesis during 1949 185
- in prolonged after 1949 179

## Sulfathiazole, ACTH for 1949 9

## Steroid

- in Addison's disease during pregnancy 1952 89
- in adrenal cancer 1953 75 78
- adrenal cortical
  - biogenesis of 1951 115 154
  - in blood 1951 89 113
  - conjugation of 1949 42-43
  - hydroxy groups in, 1949 41 42
  - metabolism of 1953 7 93
  - normal production of 1953 68
  - production of in adrenal cancer 1953 74 9
  - production of in adrenogenital syndrome 1953 78 81
  - production of in Cushing's syndrome 1953 70-72
- in adrenal steroidogenesis 1953 27 36 72
- in adrenogenital syndrome 1953 78 79 86-87
- androgenic from isolated perfused adrenal gland 1951 126-127
- antimony trichloride as reagent with 1949 62 63
- from bile 1949 44
- cholestenone as precursor of 1952 115
- C<sub>19</sub> 1953 2 37 67 77 578
- conversion of C<sub>19</sub> to 1953 31 32
- in Cushing's syndrome 1953 70-72
- excretion of after ACTH 1953 47 49
- excretion of after cortisone 1953 47 49 58 59
- C<sub>21</sub> 1953 29 30 579
- conversion of to C<sub>19</sub> 1953 31 32
- in Cushing's syndrome 1953 70-72
- excretion of
  - after compound F 1951 188 190
  - after compound S 1951 188 193 194
  - after corticosterone 1951 191
  - after cortisone 1951 191
  - in hypertension 1952 144
  - in liver disease 1953 65
- from fibroblast 1950 151
- from maldehydogenic
  - in adrenal perfusate after ACTH 1951 116
  - after compound F 1951 188 189
  - after compound S 1951 188 193
- from kidney 1949 43
- metabolism of 1953 7 93
- neutral
  - acetate as precursor of 1953 47
  - cholesterol as precursor of 1953 42
  - reduction of R<sub>1</sub> ring A nucleus of 1953 2
- synthesis of 1952 114 118
- urinary
  - acetate as precursor of 1953 90
  - after ACTH administration 1949 61-63

Steroid—*Contd*

cholesterol as precursor of 1953 90  
after stress 1952 81

Steroidogenesis in adrenogenital syndrome 1953 881 86 87

## Sulbesterol

bone after treatment with 1952 41  
and somatotrophic hormone 1952 41

## Stress

ACTH response to 1949 72 73 1950 49

in urine 1950 79

and adrenal ascorbic acid 1952 163 164  
and adrenal cortical activation 1949

72 78 1950 52 83 1952 13

adrenal cortical hormone after 1949  
72 78 1950 79

after adrenalectomy 1952 30

adrenal gland in adaptation to 1952 160

corticosteroid after 1952 81

definition of 1952 9

## emotional

eosinopenia after 1950 189 191

lymphopenia after 1951 51

eosinophilia due to after adrenalectomy 1952 162

glucocorticoid in 1952 112

17 hydroxycorticoid conversion to 17 ketosteroids in 1953 65

after hypophysectomy 1952 30

17 ketosteroid after 1952 81 1953 65

lymphocytosis due to after adrenalectomy 1952 25

lymphopenia due to 1949 75 6 1951 55

nonspecific 1952 19 29

physical eosinopenia after 1950 189 190

pituitary adrenocortical system response to 1950 48 83

pituitary discharge of ACTH after 1949 64 66

by swimming after adrenalectomy 1949 174 175

sympatheticoadrenal system in 1949 73 85

urinary steroid pattern after 1952 81

*Scrophanthus stermensis* a starting material for synthesis of cortisone 1949 17

## Sugar in blood

and abnormal electroencephalogram in Addison's disease 1950 170

ACTH effect on 1953 143

after adrenalectomy 1949 177 186 18

after calcium panthothenate on 1949 177 186 187

pituitary effect on 1953 135 138

Sulfur excretion of after ACTH 1949 120

## Surgery

after cortisone for Addison's disease 1951 168

in Cushing's syndrome 1951 1 3 176 179 180

for pituitary tumor cortisone in 1951 177

## Sweat

chloride in after cortisone 1949 27

electrolytes in after desoxycorticosterone 1949 27

sodium in after cortisone 1949 27

Sympathectomy adrenal cortical response after 1950 33

Sympatheticoadrenal system in stress 1949 73 85

## Synovial fluid

cortisone in 1953 44 46

hydrocortisone in 1953 46

## T

## Temperature environmental

and inhibition of spreading factor 1949 105

and spreading effect of hyaluronidase 1950 120

Testes after cortisone 1949 148

Testosterone 1953 78 30

androstosterone excretion after 1954 36 57

etiocoline excretion after 1953 56 5

excretion of 1953 43

hyaluronidase spreading effect after 1950 127

Tetraethylammonium bromide 1950 33

Thiamine dietary with adrenalectomy and pantothenic acid deficiency 1949 168

Thioglycollate and antidiuretic activity of pitressin 1950 35 37

## Thymus

after administration of lyophilized anterior pituitary 1950 44

involution of 1952 85

due to hypercorticism 1952 89 90

weight of after adrenal weight increasing material from pituitary 1953 108

## Thyroid gland

after ACTH 1950 185

and adrenal gland activity of 1950 184 186

after cortisone 1950 185

les created and response to ACTH 1950 73

iodine uptake by after ACTH 1949 104

Thyroid hormone and diabetes mellitus 1952 16

Thyrotropin adrenal steroid effect on 1950 71

Thyroxin dietary and adrenal ascorbic acid 1949 139

## Tissue

ACTH and healing of 1949 91  
corticosteroid fixation by 1953 56  
spreading factor in 1949 97 99 105  
1950 116 162

Tuber cinereum histamine like substance in 1951 72

Tuberculin sensitivity to 1950 109

Tuberculosis in Addison's disease 1950 107

## Tubule of kidney

acid base regulation in 1951 20  
base conserving mechanism in 1951 18  
potassium absorption in after cortisone 1951 19  
salt absorption in after adrenalectomy 1949 33 35  
odium absorption in  
in adrenal insufficiency 1951 16 21  
after cortisone 1951 18

## Tumor

adrenal 1952 119 1953 90 93  
after long term injection of growth hormone 1957 39  
pituitary cortisone in surgery for 1951 177

Tween 80 as cortisone suspending agent 1950 103

## U

Uric acid kidney excretion of after compound B 1950 196 198 201

## Urine

adrenal cortical extract in after intravenous administration 1950 124  
cortisone excretion in 1953 43  
flow of after desoxycorticosterone 1949 36  
ketosteroid fractions of in schizophrenia 1949 103  
mineralo corticoids in 1952 107  
testosterone excretion in 1953 43

## V

Vascular disease hypertensive after ACTH 1949 93

Vascular disease hypertensive—*Cont'd*  
adrenalectomy for 1952 151 157  
after cortisone 1949 93

Virilism adrenal 1952 118 119

Vitamin and adrenal cortex 1949 139 189

Vitamin B and growth hormone 1952 13

Vitamin C in blood after cortisone 1949 91

Vitamin P compound hyaluronidase inhibition by 1950 148

## W

## Water

in brain after desoxycorticosterone 1949 39 40

## excretion of

in Addison's disease 1951 51  
after adrenalectomy 1951 28  
after desoxycorticosterone 1949 36  
diurnal variation in in adrenal insufficiency 1953 61

impaired tolerance for in Addison's disease 1950 168 169

## intoxication due to

desoxycorticosterone acetate in protection of adrenalectomized rat from 1952 103 104

electroencephalogram after 1952 104  
loading with in Addison's disease 1949 3

## retention of

after ACTH 1950 34 35 38 39  
in Addison's disease 1950 39 41  
after desoxycorticosterone in Addison's disease 1950 39 41

## Wound healing of

after ACTH 1949 91 121  
after cortisone 1949 91  
in Addison's disease 1951 169

## Y

Yam Mercan as starting material for synthesis of cortisone 1949 17

## Z

Zona glomerulosa as site of production of salt hormone 1952 105





